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ABSTRACT 
Genetic and Dietary Effects on Physical Properties, Assembly  
and Secretion of apoB-containing Lipoproteins. (August 2003) 
Limin Wang, M.D, Taishan Medical College; 
M.S., Shanghai Medical University 
Chair of Advisory Committee: Dr. Rosemary L. Walzem 
 
The physical properties (i.e., mass, particle diameter and composition) of 
apolipoprotein B (apoB)-containing lipoproteins (apoB-LP) are a major determinant 
of atherosclerotic cardiovascular disease (ASCVD) risk. The objective of this research 
was to investigate how nascent apoB-LP physical properties affect circulating 
lipoprotein profiles and risk of disease. Relationships between apoB-LP physical 
properties and arterial plaque formation in four genotypes of mice with apoB isoform 
specific clearance defects were investigated. Multivariate statistical analysis found 
that arterial lesions were most closely related to genetic background and apoB 
concentration related to delayed clearance rate. For defining the dietary effects on 
circulating lipoprotein profiles, the physical properties of lipoproteins in hamsters fed 
high-carbohydrate diets containing either 60% fructose or 60% cornstarch for 2 wk 
were studied. Fructose increased very low-density lipoprotein (VLDL) particle 
diameter and decreased low-density lipoprotein (LDL) particle diameter. Elevations in 
all high-density lipoprotein (HDL) fractions were observed in the fructose-fed group. 
Further investigation was made of whether changes to the physical properties in 
 iv 
 
 
circulating lipoproteins resulted from changes to nascent particles in the assembly and 
secretion processes. Intermediate particles used for lipoprotein assembly were isolated 
from rough endoplasmic reticulum of hamster liver, and nascent VLDL were isolated 
from plasma after Triton WR-1339 injection of hamsters. A large, TG-rich apoB-
deficient particle and a small, lipid-poor apoB-containing particle were isolated in 
each dietary setting. The diameter of first-step particles was larger in fructose feeding, 
which indicated that apoB degradation decreases and provides the basis for apoB 
oversecretion. Fructose feeding significantly increased the concentrations recovered 
from liver for these two particles and for nascent particles compared with chow or 
starch feeding. Collectively, these results demonstrate: 1) genetic factors can dictate 
metabolism, and metabolic conditions can critically affect the physical properties and 
further atherogenicity of apoB-LP; 2) changes in physical properties of circulating 
apoB-LP are derived from changes to the nascent particles; and 3) dietary factors can 
influence the assembly, secretion, and metabolism of apoB-LP. The findings of the 
research may provide a metabolic basis for the recognition of new targets that could 
regulate apoB-LP metabolism to prevent and treat ASCVD. 
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CHAPTER I 
INTRODUCTION 
Pathogenesis of Atherosclerosis 
Atherosclerotic cardiovascular disease (ASCVD) is a broad term for common, 
chronic pathological changes in blood vessels associated with the heart and brain. 
Atherosclerosis is an irregular thickening of the inner wall of the artery that reduces the 
size of the arterial lumen and compromises its functionality. The lesions of 
atherosclerosis occur principally in large- and medium-sized elastic and muscular 
arteries. Arteries are composed of three concentric layers termed the intima, the media 
and the adventitia. The innermost intimal layer consists of a sheet of endothelial cells 
that adhere tightly to the internal elastic lamia, a feltwork of collagens, glycoproteins and 
laminin. Internal elastic lamia functions as supporter of endothelial cells and separates 
endothelial cells from subendothelial space. The media consists exclusively of smooth 
muscle cells and extracellular matrix material. This layer provides the structure 
necessary for arterial wall to cope with the high pressure emulating from each 
contraction of the heart. The adventitia comprises a loosely woven connective tissue 
layer that contains nutrient arteries (Gordon, 1999). The main processes believed to be 
involved in the genesis of atherosclerotic lesions are: 1) formation of a fatty steak (Ross, 
1999) (Fig. 1.1). The earliest visible lesion of atherosclerosis, the fatty streak, is a 
discrete marginated lesion comprised of lipid-laden monocytes, macrophages and T 
This dissertation follows the style and format of the Journal of Nutrition. 
 2
 
 
Figure 1.1   Fatty streak formation in atherosclerosis. Fatty streaks initially consist 
of lipid-laden monocytes and macrophages (foam cells) together with T lymphocytes. 
Later they are joined by various numbers of smooth muscle cells. The steps involved in 
this process include smooth muscle cell migration, foam cell formation, T cell activation, 
platelet adherence and aggregation, and the adherence and migration of leukocytes 
(Ross, 1999). 
 3
lymphocytes in the arterial wall. Expression of monocyte chemo-attractant and adhesion 
molecules on the endothelium is of central importance in recruiting 
circulatingmonocytes into the intima. The monocytes migrate into the subendothelial 
space where they differentiate into macrophages capable of engulfing large amounts of 
cholesterol and cholesteryl ester via the scavenger receptor pathway. The main source of 
foam cell lipid is chemically modified low-density lipoproteins (LDL), because unlike 
the LDL receptor, the scavenger receptor is not subject to feedback regulation by cellular 
cholesterol content. Macrophages may engulf large amounts of LDL-derived lipid. 
Lipid-laden macrophages appear to be filled with bubbles at low resolution 
magnification, hence the name foam cells. Collections of foam cells beneath an intact 
endothelium constitute a fatty streak; 2) formation of fibrous cap (Ross, 1999) (Fig. 1.2). 
As fatty streaks progress, proliferation of smooth muscle cells of the arterial wall leads 
to vessel thickening. In addition, the elaboration of connective tissue matrix by smooth 
muscle cells can produce a fibrous cap. The fibrous cap is characterized by the 
appearance of smooth muscle cells and extra-cellular lipid in the intima of the arterial 
wall; 3) Formation of fibrous plaque (Ross, 1999) (Fig. 1.3). With continued cell 
proliferation, necrosis, lipid accumulation, and connective tissue formation, the lesions 
increase in size until they become fibrous plaque with a dense fibrous cap. These plaques 
narrow arterial diameter and cause irregularities in the surface of the vessel thus altering 
blood flow. As lesions grow, the interior surfaces of the arteries become roughened. 
Eventually, some plaques rupture, breaking through the cell lining the interior surface of  
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Figure 1.2   Formation of a fibrous cap of atherosclerosis. As fatty streaks 
progress to intermediate and advanced lesions, they tend to form a fibrous cap 
that walls off the lesion from the lumen. The fibrous cap covers a mixture of 
leukocytes, lipid and debris, which may form a necrotic core (Ross, 1999). 
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Figure 1.3   Fibrous plaques in atherosclerosis. Rupture of the fibrous cap or 
ulceration of the fibrous plaque can rapidly lead to thrombosis and usually occurs 
at sites of thinning of the fibrous cap that covers the advanced lesion (Ross, 
1999). 
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Figure 1.4   Endothelial dysfunction in atherosclerosis. The earliest changes 
that precede the formation of lesions of atherosclerosis take place in the 
endothelium. These changes include increased endothelial permeability to 
lipoproteins and other plasma constituents, leukocyte migration, endothelial 
adhesion and leukocytes adhesion (Ross, 1999). 
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the arteries. The rough surface attracts platelets to adhere and propagate to form platelet 
plaques (thrombus), which can cause sufficient stenosis or thrombosis, to impede blood 
supply and acutely obstruct arteries in the heart, brain or extremities, causing ischemia 
and tissue damage or death. 
Although lesion progression is well documented and many of the processes of 
atherogenesis are known, the initial cellular and molecular mechanisms in 
atherosclerosis remain equivocal. Three hypotheses regarding the initial steps leading to 
the development of this complex, multifactorial, autoimmune inflammatory disease are 
currently being tested (Ross, 1999). The "response to injury" hypothesis, originally 
developed by Ross (1993), proposes that the initial event in atherosclerosis is injury to 
endothelial and smooth muscle cells of the arterial wall (Fig. 1.4). The earliest change 
that precedes the formation of visible atherosclerosis is endothelial dysfunction 
including increased endothelial permeability to lipoproteins and other plasma 
constituents. Enhanced arterial permeability is mediated by toxic chemicals and agents, 
which are released from macrophages and lymphocytes. (Ross, 1999; Newby, 2000; 
Newby and Zaltsman, 2000). The "oxidation" hypothesis states that oxidative 
modification of LDL could produce the relevant factors that are injurious to arterial 
endothelium and ultimately to smooth muscle cells (Henriksen et al., 1981a; Steinberg 
and Witztum, 1999). According to this hypothesis, LDL particles retained in the intima 
by proteoglycans undergo oxidative modification by pathways that require reactive 
intermediates such as superoxide (O2-) and hydrogen peroxide (H2O2). The oxidized  
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Figure 1.5   The response-to-retention model of early atherogenesis. (A) Mild to moderate 
hyperlipidemia causes lesion development only in specific sites, which are particularly lesion-
prone by stimulating local synthesis of apoB-retentive molecules (B). Predisposing stimuli in the 
absence of abundant atherogenic lipoproteins are insufficient to cause atherogenesis. 
Predisposing stimuli in the presence of abundant atherogenic lipoproteins result in lipoprotein 
retention (C). Once significant retention has occurred, a cascade of early responses, including 
lipoprotein oxidation and cellular chemotaxis, leads to lesion development (D). ECs, endothelial 
cells; PGs, proteoglycans; IEL, internal elastic lamina; SMCs, smooth muscle cells; and LPs, 
lipoproteins (Williams and Tabas, 1995). 
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LDL particles can deliver various lipid oxides and hydroperoxides to target cells. These 
compounds variably act as cytotoxins, monocyte chemoattractants, stimulators of 
cholesteryl ester accumulation by macrophage, and inhibitors of macrophage movement 
(Steinberg et al., 1989b). The "response-to-retention" hypothesis, proposed by (Williams 
and Tabas, 1995) emphasizes that retention by and accumulation of apolipoprotein B 
(apoB)-containing lipoproteins (apoB-LP) within the subendothelial space of the artery 
wall provides the relevant oxidizing environment to create atherogenic species of 
lipoproteins (Williams and Tabas, 1998; Wood et al., 1998) (Fig. 1.5). According to the 
"response to retention" hypothesis, the atherogenicity of apoB-LP depends on four 
factors: 1) the plasma concentration of the atherogenic apoB-LP; 2) the difference 
between the arterial wall influx and efflux of apoB-LP; 3) modification of the retained 
apoB-LP and 4) inflammatory response to the modified retained apoB-LP. How are the 
atherogenic apoB-LP formed? Walzem et al. (1995) proposed that aged apoB-LP are 
more susceptible to oxidation and so more atherogenic. These hypotheses are not 
mutually exclusive, and the last hypothesis includes major components of the first two. 
There is ample recent evidence from epidemiological studies, as well as experiments in 
vivo and in vitro, to support the "response to retention" hypothesis as a very early step in 
the pathobiology of ASCVD. Convincing evidence indicates that specific changes in the 
physical properties of apoB-LP constitute a metabolic profile that is closely associated 
with the incidence of ASCVD (Walzem et al., 1995; Williams and Tabas, 1995; Wood et 
al., 1998).  
 10
apoB-containing Lipoprotein Heterogeneity and ASCVD 
As early as 1950, Gofman et al. (1950) revealed the heterogeneous nature of the 
complexes in plasma that were responsible for lipid transport and also reported that 
many people who suffered from atherosclerosis had blood cholesterol concentrations in 
the normal range (< 240 mg/dL). This was the first time lipoprotein heterogeneity was 
reported to be as a major determinant of atherosclerotic risk. More recently, significant 
atherogenic potential was related to elevated concentrations of specific apoB-LP 
(Young, 1990; Walzem et al.; 1995; Packard and Shepherd, 1997). ApoB-containing 
lipoprotein heterogeneity is now believed to reflect dietary and genetic influences that 
affect lipoprotein metabolism and ASCVD risk. Lipoproteins can be heterogeneous with 
regards to composition, diameter, and atherogenicity (Krauss, 1994; Krauss, 1997, 
Millar et al., 1998, Demant and Packard, 1998; Kwiterovich, 2002).  
Structure and function of plasma lipoproteins 
Plasma lipoproteins are spheroidal particles that contain a hydrophobic nonpolar 
lipid core of triacylglycerol (TG) and cholesteryl ester (CE) that is surrounded by a more 
polar, amphipathic coat of apolipoprotein, phospholipid and unesterified (free) 
cholesterol (Mayes, 2000) (Fig. 1.6). The diameter and density of the lipoprotein 
particles are determined by the relative mass amounts of core-lipid: protein ratio. Plasma 
lipoproteins are typically classified into two major families based on apolipoprotein 
type: apoB-containing lipoproteins and apoAI-containing lipoproteins (Kwiterovich, 
2002a). The apoBs are structural proteins and integral constituents of apoB-LP; a family 
 11
 
 
 
 
Figure 1.6   General structure of plasma lipoprotein (Mayes, 2000). 
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                                                 TABLE 1.1 
 
                         Characterization of apoB-containing lipoproteins 
 
Lipoprotein 
classes 
Diameter  
(nm) 
Hydrated 
Density 
(g/mL)
Major 
lipids 
Major 
apoproteins 
Subclasses 
CM 90–1000 <0.95 TG apoB48, 
apoCI, 
apoCII, 
apoCIII, 
apoE 
 
VLDL 30–90 095-1.006 TG apoB100, 
apoCI, 
apoCII, 
apoCIII, 
apoE 
VLDL1 
VLDL2 
IDL 28–35 1.006-
1.019 
TG 
Cholesterol 
apoB100, 
apoCI, 
apoCII, 
apoCIII, 
apoE 
IDL1 
IDL2 
LDL 20–26 1.019-
1.063 
Cholesterol apoB100 LDL1-4 
 
Lp(a) 30 1.040-
1.090 
Cholesterol apo(a), 
apoB100 
Lp(a)5 
Lp(a)1           
 (Kwiterovich, 2002b) 
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of lipoproteins that include the TG-rich chylomicrons (CM) and very low-density 
lipoproteins (VLDL) and their remnants, intermediate-density lipoproteins (IDL), LDL 
and lipoproteins (a) (Lp (a)) (Table 1.1). VLDL, LDL and IDL are transitional particle 
components of a continuous metabolic cascade in which TG is lost in a series of small 
lipolytic steps. There is only one apoB molecule per apoB-LP particle. Because of the 
nature of lipid/protein interactions between apoB and particle lipid, apoB is incapable of 
exchanging among lipoprotein particles. Mammals exhibit two isoforms of these high-
molecular weight hydrophobic apolipoproteins: apolipoprotein B100 (apoB100) and 
apolipoprotein B48 (apoB48). ApoB100 represents the full length protein, which 
contains 4536 amino acids, and the apoB48 (2152 amino acids) isoform is a truncated 
version of apoB100, constituting 48% of the amino terminal residues of apoB100, hence 
the name "B48." In human and other mammals, CM are secreted from the intestine and 
particles that contain apoB48 as their structural base. CM serve as the transport vehicles 
for exogenous (dietary) lipid. Chylomicrons contain 88% of their weight as TG, and as a 
result are the least dense (0.98 g/mL < d < 1.006 g/mL) type of lipoprotein. 
Triacylglycerol is the major dietary fat that is transported from the intestine into the 
bloodstream.  
Very low-density lipoproteins are primarily synthesized in the liver from which they 
transport fat of endogenous (hepatic) origin. VLDL particles contain about 56% of their 
weight as TG. VLDL also contain apoB100, the primary structural component, as well 
as apolipoproteins E and C (apoE, apoC). LDL particles are the metabolic end products 
of VLDL metabolism. Low-density lipoproteins are what remain after VLDL particles 
 14
have lost most of their TG and all of apoE and apoC. Thus, apoB100 is the major 
apolipoprotein in LDL and contains the domain required for interaction of this 
lipoprotein species with the LDL receptor (Betteridge et al., 1999). The major function 
of LDL is to deliver cholesterol to cells. Each LDL particle contains 58% of its weight 
being contributed by CE and unesterified cholesterol. Finally, apoB100 contains an 
unpaired cysteine residue at position 3426 that can participate in formation of 
lipoprotein(a) (Lp (a)) (Callow et al., 1994). Lp (a) is composed of two components: 
LDL and apolipoprotein(a) (apo(a)). Lp (a), unlike LDL, is not a metabolic product of a 
TG-rich, apoB-LP (Krempler et al., 1979).   
apoB48 is essential for CM formation in the small intestine of all mammalians and 
VLDL formation in liver of some mammals. Functional differences in apoB isoform 
actions during metabolism arise from a lack of some domains in apoB48 that are 
contained in the carboxyl terminal of apoB100. Chylomicrons and CM remnants are 
cleared by LDL receptor-related proteins (LRP) and VLDL receptors by virtue of apoE, 
rather than apoB as is the case for LDL receptors (Spillane et al., 1995). apoB48 is the 
product of apoB mRNA editing, and as such represents a unique post-transcriptional 
modification (Davidson et al., 1995). A site-specific C-to-U editing reaction produces a 
UAA stop codon and translational termination of intestinal apoB mRNA at residue 2152. 
This C-to-U conversion, a site-specific hydrolytic deamination, is mediated by a 
multicomponent enzyme complex containing apobec-1 and other factors (Harris et al., 
1993). apoB mRNA editing occurs in the small intestines of all mammals and in the 
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livers of mice and rats (Greeve et al., 1993). Unlike rats and mice, hamsters are similar 
to humans in that apoB editing occurs only in the intestine (Bravo et al., 1994).  
The major apoAI-containing lipoproteins are high-density lipoproteins (HDL), the 
most dense of the plasma lipoproteins. The major function of HDL is responsible for 
redistributing cholesterol among peripheral tissues, as well as returning cholesterol to the 
liver for catabolism and excretion (Rader, 2002). HDL also have important anti-
inflammatory properties (Cockerill et al., 1995; Calabresi et al., 1997). The predominant 
HDL core lipid is CE (30%), and the main HDL apolipoproteins are apoAI; apoAI is 
exchangeable. 
apoB-containing lipoprotein metabolism and heterogeneity  
Two major cascades for lipoprotein metabolism, the apoB-LP cascade and the HDL 
cascade, are interrelated (Fig. 1.7). The apoB-LP metabolic pathway is a lipolytic 
cascade that begins with lipoprotein lipase (LPL) mediated hydrolysis of TG from the 
TG-rich lipoproteins such as CM and VLDL. The lipolytic cascade arising from apoB48-
LP is also known as the exogenous pathway, while that of apoB100-LP is termed the 
endogenous pathway.  
The exogenous pathway is so called due to its role in transport of dietary lipids is 
known as the exogenous pathway (Fig. 1.7). As TG-rich apoB48-containing CM, are 
secreted from enterocytes, they pass first into lymph ducts and enter the bloodstream at 
the thoracic duct. In the blood, they bind to LPL, which hydrolyzes the core TG in the  
 16
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7   Lipoprotein metabolism. (Kwiterovich, 2000). 
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CM particles following activation by apolipoprotein CII (apoCII). Chylomicron 
hydrolysis yields CM remnants, which are quickly removed from the plasma (5-15 min), 
primarily by the interaction of apoE with LRP (Hussain et al., 1991). Thus, apoB48-
containing CM are not usually present in plasma of fasted animals. The exogenous 
pathway is influenced mainly by the rate of entry and tissue disposition of dietary lipid, 
which is regulated by LPL (Braun and Severson, 1992). Lipoprotein lipase can in turn be 
regulated by hormones such as insulin (Appel and Fried, 1992).  
The pathway for transport of hepatic lipid is described as the endogenous pathway 
(Fig. 1.7). As TG-rich apoB100-containing VLDL secreted from the liver enter the 
plasma, VLDL particles also interact with LPL in capillaries, and their core TG is 
hydrolyzed (Wang et al., 1992). VLDL hydrolysis yields VLDL remnants, which are 
hydrolyzed further by LPL to produce IDL. Intermediate-density lipoprotein particles 
have two fates. Some IDL are removed through the interaction of apoE or apoB with 
LDL receptor on the surface of liver and degraded, while others remaining in the plasma 
are converted through further hydrolysis by hepatic lipase (HL) to LDL (Nilsson-Ehle et 
al., 1980). LDL particles are normally removed from plasma by the interaction of 
apoB100 with the LDL receptor on the surface of hepatic and peripheral cells, whereas 
oxidized LDL are taken up by the scavenger receptors on the macrophages (Henriksen et 
al., 1981b).  
The endogenous pathway is a means of delivering cholesterol as well as TG to 
tissues, and for this reason is also referred to as "forward cholesterol transport," while 
the HDL pathway for transport of cholesterol out of tissues is termed "reverse 
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cholesterol transport" (Fig. 1.7) (Barter and Rye, 1996). Lipid-poor apoAI particles (Pre-
β HDL) secreted from the liver enter the plasma. In the circulation, the pre-β HDL 
acquire phospholipids and free cholesterol from peripheral tissues via the ATP-binding 
cassette protein-1 (ABC1) (McNeish et al., 2000) and form discoidal HDL. These 
particles become lipid-rich, mature HDL through transfer of redundant phospholipids 
from the surface of TG-rich lipoprotein particles undergoing lipolysis via phospholipid 
transfer protein (PLTP) and through esterification of cholesterol via the action of 
lecithin-cholesterol acyltransferase (LCAT) (Santamarina-Fojo et al., 2000). Mature 
HDL particles can return their cholesterol to the liver via the receptor SR-BI (Rigotti et 
al., 1997), or exchange cholesterol for TG from TG-rich lipoproteins via the action of 
cholesteryl ester transfer protein (CETP) (Tall, 1990). Interactions among apoB-LP and 
HDL serve to remodel particle composition. Intravascular remodeling is a fundamental 
driver for apoB-LP heterogeneity. 
apoB-containing lipoproteins are heterogeneous in particle diameter, density, lipid 
and apolipoprotein content and composition. Differences in these physical properties are 
thought to affect atherogenic potential of individual apoB-LP (Chapman et al., 1998; 
Krauss, 1994). The apoB-LP metabolic pathway is critical to understanding how apoB-
LP heterogeneity develops. Several lines of evidence have demonstrated that the 
physical properties of apoB-LP influence their subsequent metabolism and 
heterogeneity. Particle size and TG content of VLDL affect lipoprotein metabolic fate 
(Kasim-Karakas et al., 1997). The trace-labeled VLDL studies by Packard et al. (1984) 
showed that in humans most of large VLDL (VLDL1) particles were cleared rapidly, and 
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less than 10% were converted to LDL, while smaller, less TG-rich VLDL2 particles 
released by the liver were the major precursor to LDL. The same group (Gaw et al., 
1995) also found that the production of IDL and LDL was variable over the range of 
VLDL and was inversely related to the plasma TG level. Low-density lipoprotein 
heterogeneity, first reported by Fisher (1983), is strongly associated with the 
atherogeneity of lipoprotein class. 
Atherogenicity of apoB-containing lipoproteins 
Elevated circulating apoB-LP has long been linked to the premature development 
of ASCVD (Young, 1990). Although the National Cholesterol Education Program 
(NCEP) Adult Treatment Panel (ATP) III singled out LDL cholesterol as the principal 
target of therapy (NCEP, 2001), several points must be made about LDL. First, LDL-
apoB concentration, rather than LDL cholesterol concentration, defines the molar 
concentration of LDL particles in blood. Second, the clinical measurement of LDL 
cholesterol includes the cholesterol content of IDL as well as that of LDL, thus IDL 
probably rivals LDL in atherogenic potential (Tribble et al., 2001). Third, LDL and IDL 
are not all encompassing of atherogenic lipoproteins; some VLDL probably are also 
atherogenic (Grundy, 1997). Importantly, not all apoB-LP possess similar atherogenic 
potential. Some lipoprotein subclasses may be quite atherogenic, whereas others may 
carry little risk or even protect against ASCVD (Krauss, 1994; Krauss, 1998; Hodis et 
al., 1999). Currently, apoB-LP physical heterogeneity is believed to reflect atherogenic 
potential and so influence ASCVD risk (Steinberg et al., 1989a; Nigon et al., 
1991;Galeano et al., 1994; Gaw et al., 1995; Nielsen et al., 1996; Packard and Shepherd, 
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1997). For example, small VLDL remnant particles filter into the arterial wall more 
readily than larger particles (Nordestgaard and Nielsen, 1994). VLDL, CM and their 
remnants from patients with hypertriacylglycerolemia have the decreased ability to bind 
LDL receptor via apoE (Zannis and Breslow, 1982). Two distinct LDL phenotypes, 
pattern A and pattern B, were identified in humans (Krauss and Burke, 1982; Austin et 
al., 1988; Austin et al., 1990). Pattern A is characterized by large (diameter > 25.5nm), 
buoyant, CE-rich, monodisperse particles, and pattern B is characterized by 
predominately smaller (diameter < 25.5nm), denser, relatively CE-poor, polydisperse 
LDL particles. Genetic background is known to contribute to the determination of LDL 
phenotypes (Feingold et al., 1992), in part through diet responsive changes in TG-rich 
lipoprotein metabolism (Dreon et al., 1994). Despite these associations, the basis for 
apoB-LP atherogenicity has not been fully explained.  
The relation between the heterogeneity of apoB-LP particles and ASCVD has 
attracted considerable interest with numerous investigators working to determine the 
bases for differences in atherogenicity (Austin et al., 1988; Chapman et al., 1998). This 
interest has culminated in the definition of atherogenic lipoprotein phenotype (ALP) as a 
risk factor that is predictive of the development of ASCVD (Krauss, 1994; Lamarche et 
al., 1997) The ALP consists of elevated plasma TG concentrations, low HDL-cholesterol 
concentrations and small, dense LDL particles. Plasma TG is the major determinant of 
the appearance of ALP (Griffin et al., 1994).  
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Ginsberg (2000) proposed a metabolic mechanism for the production of small, dense 
LDL (Fig. 1.8). Due to some abnormal metabolic event, adipose tissue produces an 
increased flux of free fatty acid to the liver. Normally, over half of the fatty acids that 
derive from hydrolysis of apoB-LP by LPL can enter the adipose tissue; the remaining 
fatty acids are used by muscle or transported back to the liver (Betteridge et al., 1999). If 
there is a deficiency in fatty acid uptake by adipose tissue, such as occurs during insulin 
resistance, fatty acids will accumulate in plasma. Elevated plasma fatty acids increase 
liver fatty acids and in so doing increase liver TG. Increased liver TG will lead to VLDL 
overproduction. During circulation, the TG in VLDL is exchanged for CE on large LDL 
particles by CETP. In situations where VLDL-TG becomes very high, the more 
concentrations of VLDL and LDL particles shift towards VLDL causing the equilibrium 
driven CETP reaction to produce a TG-rich LDL. The TG in LDL can be hydrolyzed by 
LPL or HL, producing LDL particles that are depleted of CE and that are smaller and 
denser. Accumulation of fatty acids in plasma disrupts binding to lipases as well as 
lipase binding to the endothelium. These actions cause the VLDL to detach from the 
surface of the endothelial cell (Sniderman, 2000), and delay the clearance of apoB-LP 
and their remnants.  
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Figure 1.8   Mechanism of the production of small, dense low-density 
lipoprotein (Kwiterovich, 2000). 
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The above metabolic scenario appears to be relevant to three different clinical 
conditions and to be driven by apoB-LP overproduction. Indeed, subjects with familial 
combined hyperlipidemia exhibit a pattern B phenotype for LDL in association with 
other symptoms of familial combined hyperlipidemia. Subjects with familial combined 
hyperlipidemia overproduce VLDL, increasing secretion of large TG-rich VLDL1 
particles and small CE-rich VLDL2 (Demant and Packard, 1998). Following exchange of 
CE in LDL for TG in large VLDL1 by CETP, the TG in LDL can be hydrolyzed by 
hepatic lipase, producing small, dense LDL (Fig. 1.8).  
Impaired fatty acid uptake often occurs in patients with insulin resistance or 
“Syndrome X” (Sniderman et al., 2001). Patients with these conditions exhibit impaired 
insulin mediated suppression of TG lipolysis by hormone-sensitive lipase present in 
adipocytes. Failure to suppress hormone sensitive lipase activity promotes the hydrolysis 
and release of fatty acids from adipose tissue and elevated free fatty acid production 
(Ginsberg, 2000). The CE in HDL can also exchange, via CETP with the TG on VLDL, 
producing a TG-rich HDL. The delipidated apoAI is likely to be catabolized rapidly by 
the kidney, and hence small, dense LDL particles are often accompanied by decreased 
HDL cholesterol level. 
Small dense LDL are often observed in a shift from high-fat to high-carbohydrate 
diet. Dreon et al. (1994) analyzed changes in LDL pattern in 105 healthy men 
consuming high-fat diets for 6 wk followed by high-carbohydrate diets for another 6 wk 
and found that: one-third of men exhibiting a pattern A profile while consuming high-fat 
diet transformed to a pattern B profile while consuming the high-carbohydrate diet. In 
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other words, there was a shift in LDL particle from larger, less dense LDL to smaller, 
denser LDL. 
Altered VLDL and CM metabolism cause abnormal apoB-LP clearance and can also 
affect the apoB-LP physical properties. Indeed changes in apoB-LP physical properties 
appear to provide a ready index to particle clearance in some settings. Both VLDL and 
CM require LPL to hydrolyze TG. Overproduction of VLDL increases the number of 
VLDL particles available to compete with CM for LPL (Betteridge et al., 1999). As a 
result, degradation of TG-rich apoB-LP is retarded and removal of both VLDL and CM 
from plasma is delayed. Walzem et al. (1995) reported the delayed apoB-LP clearance 
increases the susceptibility of particles to oxidation.  
ALP appears to stem from a disturbance of the metabolism of TG-rich apoB-LP, 
with overproduction of VLDL from the liver or increased delivery of free fatty acids to 
the liver. As described above, the appearance of small dense LDL in plasma is believed 
to provide the key clinical marker of this type of metabolic dysfunction. The Quebec 
Cardiovascular Study disclosed that high levels of LDL pattern B (small dense LDL) 
were significantly more prevalent in patients with ASCVD, and were associated with a 
three-fold increased risk of coronary artery events (Lamarche et al., 1997).  
Several mechanisms are thought to render small dense LDL potentially more 
atherogenic than their larger and lighter counterparts. Cell culture studies (Nigon et al., 
1991) showed small dense LDL bound with lower affinity to the LDL receptor. Galeano 
et al. (1994) demonstrated that the modification of apoB structural conformation in the 
binding region of the polypeptide increased the residence time of small dense LDL in 
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serum, thereby allowing more time for infiltration across the endothelial barrier and 
interaction with components of the subendothelia. The influx rate of plasma lipoproteins 
across the endothelium and into the subendothelial space is a function of particle 
diameter (Nordestgaard and Nielsen, 1994). Thus, small dense LDL could infiltrate at a 
faster rate than either large LDL, IDL or VLDL, and would also pass out at a faster rate 
if not for their selective binding to components of the extracellular tissue matrix such as 
proteoglycans. However, a preferential binding of small dense LDL to proteoglycans 
causes them to be sequestered in the arterial wall (Anber et al., 1996), where they can 
undergo chemical and physical modifications that confer a number of pro-atherogenic 
properties (Heinecke et al., 1993). In this respect, small dense LDL seem to be the 
physical manifestation of increased particle age, a feature known to lead to increased 
susceptibility to oxidation (Walzem et al., 1995). Indeed, Tribble and Krauss showed 
that oxidative susceptibility in LDL particles was inversely related to particle diameter 
(Tribble et al., 1992). These findings have now been extended to documentation of a 
progressive increase in particle susceptibility to oxidation with progression through the 
lipolytic cascade leading to either LDL pattern A or pattern B (Tribble et al., 2001). 
Importantly IDL and LDL intermediates from pattern B subjects were always more 
susceptible to oxidation than comparable particles isolated from pattern A subjects. 
Oxidized LDL are more readily scavenged by vascular scavenger LDL receptors and 
have a longer residence time in the vascular matrix. This leads to enhanced lipid 
deposition in the arterial wall (Reusch, 2002). Small dense LDL often coexist with other 
lipoprotein abnormalities such as elevation in plasma TG and low HDL cholesterol 
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(Austin et al., 1990). Plasma TG concentrations have been recognized as an independent 
risk factor for ASCVD (Hokanson and Austin, 1996). Zilversmit (1979) proposed that 
elevated post-prandial TG concentrations exert their adverse effect by promoting the 
production of atherogenic CM remnants. CM remnants have the ability to mediate 
cholesterol influx into the arterial wall intima in human subjects, thereby promoting 
atherogenesis (Shaikh et al., 1991). 
The post-prandial lipemic response not only represents the influx of dietary TG to 
the circulation, but it is also a very significant period during which composition and 
metabolic fate of the cholesterol-rich lipoproteins, such as LDL and HDL, are 
determined. Elevated post-prandial lipemia promotes the catabolism of HDL, and low 
concentrations of HDL cholesterol are associated with an increased risk of ASCVD 
(Assmann et al., 1996). A strong inverse relationship between the concentration of HDL 
cholesterol and the incidence of ASCVD has been consistently observed in prospective 
epidemiological studies (Gordon et al., 1977; Robertson et al., 1977; Assmann et al., 
1996) and clinical intervention studies (Gordon et al., 1986; Mackness et al., 1993). The 
ability of HDL cholesterol to predict ASCVD independently of any other known risk 
factors is exemplified by data from a 6-year follow-up in the Prospective Cardiovascular 
Munster (PROCAM) study (Assmann et al., 1996). The results from the prospective 
studies by Gordon’s group (Gordon et al., 1989; Gordon and Rifkind, 1989) demonstrate 
ASCVD risk is increased by 2% in men and 3% in women for every 1 mg/dL (0.026 
mmol/L) reduction in HDL cholesterol. The correlation remains statistically significant 
after adjustment for other risk factors such as LDL cholesterol and TG concentrations. 
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Low concentrations of HDL cholesterol are frequently observed in patients with 
ASCVD, and attention has focused on low HDL cholesterol as a potential target for 
therapeutic intervention. Moreover, abnormalities in apoB-LP metabolism and HDL 
concentration are often metabolically interrelated. At present, it is unknown whether 
these interrelated lipoprotein pathways can be affected independently of one another. 
From the above, several points can be made about the atherogenicity of apoB-LP. 
First, an increased molar concentration of apoB-LP particles is not adequately 
represented by plasma cholesterol concentration due to the variability in size and 
cholesterol content of individual lipoprotein particles. Second, small dense LDL 
penetrate the vascular wall more readily and bind to proteoglycans more avidly, 
tendencies that put this LDL subclass “in harms way” more often than other larger 
particles. Third, the metabolic scenario that underlies the formation of small dense LDL 
by definition imposes some structural features on the LDL particles. In other words, the 
atherogenicity of apoB-LP in the majority of individuals arises from increased age and 
oxidization as suggested by the surrogate markers of small diameter and increased 
density, and not from its cholesterol content per se.  
Genetic Effect on apoB-containing Lipoprotein Metabolism in Transgenic Mice 
In human populations, complex lipid profiles comprised of lipoprotein particles of 
differing atherogenic potentials arise from genetic and environmental factors, including 
diet. As a multifactorial disease, ASCVD demands an in vivo system to complement in 
vitro work and to address those issues that are unanswerable in simplified systems. 
Transgenic and knockout mouse models constitute simplified in vivo model systems and 
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are providing surprising insight into lipoprotein metabolism and atherogenesis. In 
humans, mutations in one or both of the LDL receptor genes result in familial 
hypercholesterolemia (Goldstein et al., 1977). Ishibashi et al. (1993) generated LDL 
receptor-deficient mice by gene targeting embryonic stem cells. Both heterozygous and 
homozygous deficient mice developed elevated total plasma cholesterol levels. Kinetic 
studies demonstrated a significant delay in both VLDL and LDL clearance from the 
plasma of the LDL receptor knockout mice compared with control mice (Ishibashi et al., 
1993) Using homologous recombination in embryonic stem cells, Plump et al. (1992) 
disrupted specifically the apoE gene and generateD apoE-deficient mice, which showed 
delayed clearance of VLDL and led to accumulation of apoB-containing particles in the 
plasma as well as consequent premature atherosclerosis. Transgenic mice expressing the 
human apoB gene were developed via microinjection of a genomic apoB clone 
contained on a phagemid vector (Callow et al., 1995). The resultant mice showed high-
level expression of the human apoB transgene and human-like LDL and HDL 
concentrations in animal fed a low-fat, low-cholesterol diet. Interestingly, the human 
apoB transgene was expressed in the liver and heart, but transgene expression was 
completely absent in the intestine (McCormick and Nielsen, 1998). In addition, Young 
and his associates (Kim et al., 1998) used gene targeting to insert an apoB83 mutation in 
the mouse apoB gene to create a mouse model of familial hypo-beta-lipoproteinemia. 
This group (Raabe et al., 1998) again used gene targeting to knock out mouse 
microsomal triglyceride transfer protein (MTP) gene to create a mouse model for abeta-
lipoproteinemia, which is an inherited human disease characterized clinically by an 
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absence of apoB-LP in the plasma due to mutations in the gene for MTP. Inactivation of 
the murine MTP gene in liver caused a striking reduction in VLDL-TG and large 
decreases in both VLDL/LDL and HDL cholesterol concentrations (Raabe et al., 1999). 
In a separate study, this group (Farese et al., 1996) used gene targeting to introduce stop 
and nonstop mutations into the apoB48 editing codon in the mouse apoB to produce 
apoB100-only (Apob100/100) and apoB48-only (Apob48/48) mice. Veniant et al. (1997) used 
these mice to investigate the effect of apoB isoform on the susceptibility of these mice to 
atherosclerosis. Animals with similar cholesterol levels had similar amounts of 
atherosclerosis regardless of apoB isoform. The authors concluded that there was no 
intrinsic difference in the atherogenicity of apoB100 and apoB48 proteins. Differences 
in the atherogenicity of apoB100- and apoB48-containing lipoproteins in free-living 
humans must therefore arise from selective changes in particle metabolism. Veniant et 
al. (2000) next characterized Apob100/100 mice that were LDL receptor-deficient 
homozygous (Ldlr-/-Apob100/100), and compared them to Apob100/100 mice that were apoE-
deficient homozygous (Apoe-/-Apob100/100). Both mouse strains developed plaque when 
fed a low-fat chow diet. Although the total plasma cholesterol concentrations were 
approximately the same in the two types of mice, the Ldlr-/-Apob100/100 mice developed 
lesions that covered 14% of the arterial surface, while lesions in the Apoe-/-Apob100/100 
mice covered only 4.5% of the arterial surface. The observation that one set of mice had 
more plaque than the other at equal cholesterol concentrations does not expressly 
suggest increased numbers of small diameter particles. However when measured, almost 
all of the cholesterol in Apoe-/-Apob100/100 mice was in VLDL-sized particles, whereas 
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nearly all of the cholesterol in Ldlr-/-Apob100/100 mice was in LDL-sized particles. In 
separate studies, ablation of apoE from Apob48/48 mice reduced particle diameter but 
actually increased particle diameter in Apoe-/-Apob100/100 mice (Veniant et al., 1998). 
From these studies, it is apparent that: 1) in isolation, either apoB48 or apoB100 can give 
rise to atherogenic lipoproteins; 2) that the metabolic basis for their atherogenicity arises 
from delayed particle clearance; and 3) the metabolic defect of delayed particle 
clearance is physically manifested by a decrease in particle diameter. Thus in free-living 
humans, small dense lipoproteins are likely to provide a surrogate marker for delayed 
apoB-LP clearance. However, to date complex mixtures of apoB-LP types that occur in 
humans have not been investigated in a systemic way in these same mouse models. The 
issue is an important one in as much as dietary changes influence apoB48 and apoB100 
metabolism differently. 
                                      apoB-containing Lipoprotein Assembly 
apoB-containing lipoproteins are assembled in a complex, multistep process that 
involves interplay among protein and lipid biosynthetic, trafficking and maturation 
factors. A two-step model for lipoprotein assembly was initially suggested by the 
electron microscopy studies of Alexander et al. (1976). In the first step, two apoB-LP 
precursors, an apoB-containing apoB-LP precursor (first-step particle) and an apoB-
deficient, lipid-rich apoB-LP precursor (second-step particle) were proposed to produce 
independently (Alexander et al., 1976). In the second step, two apoB-LP precursors 
combined to form a mature VLDL particle.  
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Translating the immuno-electron microscopic images into measurable biochemical 
events proved challenging. Difficulties arose both from the membranous nature of the 
endoplasmic reticulum (ER) where apoB-LP assembly occurred and the models used to 
study the process. In vitro culture of transformed cell lines that retain metabolic features 
of their differentiated counterparts are attractive model systems. Spring et al. (1992) 
found that expression of various truncated versions of apoB100 in the human hepatoma 
cell line- HepG2 cells did result in the assembly of lipoprotein particles. However, they 
were unable to produce particles of VLDL-density leading them to observe that the 
second step of apoB-LP assembly was missing in this cell line. The now classic example 
of the two-step assembly of apoB-LP is found in apoB48 VLDL assembly in the McA-
RH7777 cell line (Boren et al., 1994). McA-RH7777 cells, rat liver derived cells, are the 
only hepatoma available that produces apoB-LP of VLDL-density that are also suitable 
for stable transfection with recombinant apoBs. McA-RH7777 cells cultured in the 
absence of oleic acid incorporate apoB48 into particles with a density similar to HDL, 
but when cultured in the presence of oleic acid, secrete apoB48 as particles of VLDL-
density.  
In order to demonstrate the two-step of lipoprotein assembly, the investigators 
employed pulse-chase methodology in which a “pulse” of radioactive amino acid labels 
proteins of interest, while the “chase” period allows investigators to track protein 
movement through the cell after replacement of the labeling media with “chase” media 
that contains no radioactive amino acids. S35-methionine is commonly used as a marker 
in such studies, and in general cultures are exposed to the label for 10 min and then 
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chased with surplus of cold methionine for periods between 0 and 180 min. Various 
other treatments such as the absence or presence of cycloheximide, to stop protein 
synthesis are also used to form certain experimental endpoints. When cultured in the 
absence of oleic acid, McA-RH7777 labeled apoB was recovered only in particles of 
HDL density. When cultures were supplemented with oleic acid, labeled apoB-VLDL 
were secreted (Boren et al., 1994). Such results clearly demonstrate that the small 
particles of HDL-density were converted to large particles of VLDL-density with 
increased availability of core lipid precursors. Further evidence for a two-step 
mechanism in this model came from the observation that Brefeldin A at low 
concentration inhibited only the secretion of apoB48-VLDL but not apoB48-HDL 
(Rustaeus et al., 1995; Rustaeus et al., 1998). Brefeldin A is known to inhibit guanine 
nucleotide exchange proteins which acts as on adenosine diphosphate ribosylation factor 
1 (Donaldson et al., 1992) This finding suggested that the first step of assembly occurred 
but not the second as addition of bulk TG during the second step would be expected to 
transform apoB48-HDL into less dense apoB48-VLDL. Furthermore, based on the 
results of elegant morphological studies, Hamilton et al. (1998) confirmed that VLDL-
sized lipid droplets exist in the secretory pathway when no apoB is produced in the cell. 
The observation also suggests that formation of the second-step particle is an 
independent process. Recently, by combining an extraction procedure with pulse-chase 
experiments, Stillemark et al. (2000) showed efficient VLDL assembly requires apoB 
chains of at least apoB48 size. Nascent polypeptides as small as apoB20 were associated 
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with particles in the HDL density range. Thus, the structural requirements of apoB to 
form HDL-like first-step particles differ from those to form second-step VLDL.  
In general, apoB100 and apoB48 appear to assemble into apoB-LP through similar 
two-step mechanisms (Glickman et al., 1986). This process was illustrated in cartoon 
form by (Rustaeus et al., 1995) (Fig. 1.9). Henceforth this review will focus on the 
assembly and secretion of apoB100-containing lipoproteins. 
Formation of apoB-containing apoB-LP precursor 
apoB-containing apoB-LP precursor is formed in rough ER during the translation 
and translocation of apoB to the lumen of the rough ER through a short post-translation 
period (Boren et al., 1992; Rustaeus et al., 1998). apoB is synthesized by the ribosomes 
on the rough ER, translocated into the lumen of the ER by a process in which apoB is 
only loosely associated with the translocon (Rustaeus et al., 1998). The lipid components 
of the first-step particle are added co- and post-apoB translation by MTP, which can bind 
and transfer several classes of lipid molecules (TG, CE and phospholipids) between  
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Figure 1.9   Assembly of very low-density lipoprotein. Two precursors are formed 
independently. apoB-containing VLDL precursor is produced during the translation and 
concomitant translocation of apoB to the lumen of ER and during a short period after the 
protein has been completely synthesized. The process is dependent on MTP. apoB-free 
lipid-rich precursor is formed in a process that is catalyzed by MTP. Two precursors are 
fused to form a mature VLDL particle (Olofsson et al., 1999). 
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membranes (Atzel and Wetterau, 1993). The MTP-mediated lipid transfer process 
produces a partially lipidated apoB-containing apoB-LP precursor, i.e. the first-step 
particle. MTP is essential for apoB lipidation, and it is the lack of functional MTP that 
leads to abeta-lipoproteinemia (Wetterau et al., 1992). The partially lipidated apoB-
containing apoB-LP precursor is loosely associated with the ER membrane, and may 
form a mature lipoprotein particle that is eventually secreted from the cell. 
Formation of lipid-rich apoB-deficient apoB-LP precursor 
Using immunology with electron microscopy, Alexander et al. (1976) showed 
VLDL-sized particles without immuno-detectable apoB being present in the smooth ER. 
This observation indicated that lipid-rich apoB-deficient precursor was formed in the 
lumen of smooth ER. To date, the mechanism for the formation of the lipid-rich 
precursor is not clear. Raabe et al. (1999), using a liver-specific knockout of MTP, 
showed that VLDL-sized particles disappeared when the MTP gene was ablated. In 
addition, Wang et al. (1999) reported that an inhibition of MTP inhibited the transfer of 
TG from the cytosol to the lumen of the apoB-LP secretory pathway. These results 
suggest that MTP is also needed for the formation of lipid-rich apoB-deficient apoB-LP 
precursor, (i.e. second-step assembly intermediate). 
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Assembly and secretion of the apoB-LP particle  
Alexander et al. (1976) showed that immuno-detectible apoB appeared in association 
with VLDL-sized LP particles both in the smooth termini of the rough ER and in the 
distal portion of the secretory pathway. Thus, in a two-step model, it is proposed that 
apoB-containing LP precursor and lipid-rich apoB-deficient LP precursor form 
separately and are then assembled within the lumen of the ER (Fig. 1.10) by an as yet 
poorly described process. The process that joins the two assembly intermediates appears 
to be independent of MTP (Stillemark et al., 2000), but requires chaperone proteins and 
energy (Olofsson et al., 2000). The nascent apoB-LP particles then move to the Golgi 
complex where their structure and composition can be modified (e.g., by glycosylation) 
(Voet et al., 1999). The Golgi vesicles filled with nascent apoB-LP migrate to the cell 
surface where apoB-LP are exported by exocytosis into the subendothelial space (Fig. 
1.11). 
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Figure 1.10   A two-step model for the assembly of apoB-containing 
lipoproteins. The two-step hypothesis predicts that two assembly precursors are 
assembled within the lumen of the ER. In step 1, small, dense, partially lipidated 
apoB-containing particles (first-step particles) are released from the rough ER 
membrane. In step 2, lipid-rich apoB-free particles (second-step particles) are 
formed in the lumen of smooth ER. The two precursors join together, producing a 
completed nascent apoB-LP. (Hamilton et al., 1998). 
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Regulation of the assembly and secretion of apoB-LP 
Studies from cultured cells and animal models show that the availability of lipid, and 
apoB and MTP activity all influence the assembly and secretion of apoB-LP. Lipid 
availability greatly influences translocation and post-translational regulation of apoB for 
assembly into lipoprotein particles and secretion (Dixon and Ginsberg, 1993). The 
translocation of apoB is atypical for secretory proteins in that it slows or even stops, 
depending on the availability of lipid. If lipid is inadequate, inefficient translocation 
results in exposure of apoB to the cytosol where it complexes with heat shock protein 70 
(HSP 70) (Zhou et al., 1995), and this, in turn, leads to ubiquitination and proteasomal 
degradation of nascent apoB (Fisher et al., 1997). In contrast, if lipid is available, apoB 
translocation is efficient, and apoB is targeted for assembly and secretion. Many studies 
demonstrate that TG availability is the major factor in the post-translational regulation of 
apoB-LP assembly and secretion, and the mechanism of apoB secretion stimulated by 
fatty acid appears to stimulate TG synthesis and secretion. Arbeeny et al. (1992) reported 
that fatty acid synthesis, TG synthesis and apoB secretion were inhibited when primary 
hamster hepatocytes were treated with an inhibitor of acetyl coenzyme A carboxylase, a 
key regulatory enzyme of de novo fatty acid synthesis, but when oleic acid, an end 
product of fatty acid synthesis, was added to the medium, the inhibition of fatty acid 
synthesis was reversed. Similar effects were observed when HepG2 cells were treated 
with an inhibitor of fatty acid synthetase (Wu et al., 1994). However, the type of fatty 
acid supplied to hepatocytes has a marked influence on the assembly and secretion of 
apoB-LP. For example, while oleic acid promotes apoB secretion by stimulating TG 
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synthesis and availability, while n-3 fatty acids inhibit apoB secretion, presumably by 
reducing the ability of hepatocytes to synthesize or mobilize TG for secretion (Lang and 
Davis, 1990; Wang et al., 1994). The availability of intracellular cholesterol and 
cholesteryl ester also regulates the assembly and secretion of apoB-LP. Some 
investigators (Cianflone et al., 1990; Spector et al., 1979) reported a major regulatory 
role for the intracellular cholesterol esterifying enzyme ACAT, which is located in the 
rough ER of rat liver. Cianflone et al., (1990) reported that lovastatin or inhibitor of 
ACAT (58-035) decreased CE synthesis as well as apoB secretion.  
Phospholipids are also required for the assembly and secretion of apoB-LP. 
Phosphatidylcholine is the predominant phospholipid in plasma lipoproteins, and 
secretion of apoB-LP was impaired in choline-decificent rats (Verkade et al., 1993). 
Phospholipids are made in both smooth ER and rough ER (Van Golde et al., 1971), and 
have a long half life in liver (several hours in PL versus < 1 hour in TG) (Glaumann et 
al., 1975). Therefore, under most metabolic conditions phospholipids would be available 
for assembly into lipoproteins.  
Availability of lipid is important not only in the regulation of apoB turnover and 
availability for apoB-LP assembly and secretion, but also influences the heterogeneity of 
secreted apoB-LP. For example, Ellsworth et al. (1986) observed that when HepG2 cells 
were incubated with oleic acid, secreted apoB and TG were both redistributed from the 
LDL to the VLDL density range. Wang et al. (1988) reported that 47% of the TG 
secreted by HepG2 cells was present in the IDL density range. Therefore, the supply of 
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nutrients to the liver cell may play an important role in determining the heterogeneity of 
lipoprotein that is secreted.  
As described above, under most metabolic conditions, the requirement for lipid to 
drive apoB-LP assembly is greater than the requirement for apoB. However, the 
availability of lipid is determined by nutritional status. Studies in rat hepatocytes 
provided evidence that hepatocytes from fasted rats displayed a marked decrease in the 
secretion of apoB-LP, in contrast hepatocytes from rats fed carbohydrate-rich diets 
displayed increased secretion of apoB-LP (Ford et al., 1968; Bell-Quint and Forte, 
1981). Recently, evidence from animal studies (Taghibiglou et al., 2000) and clinical 
trials (Parks et al., 1999) showed that a diet high in carbohydrate induced TG synthesis 
and elevated TG concentration. Increased availability of TG increases VLDL assembly 
and secretion, and can result in the overproduction of VLDL. In summary, the assembly 
and secretion of apoB-LP can be significantly influenced by the availability of lipid, 
which could be mainly determined by diet supply. 
apoB is another important factor that regulates the assembly and secretion of apoB-
LP. apoB gene knockout mice demonstrated reduced plasma apoB levels (Farese et al., 
1995). Furthermore, Linton et al. (1993a) reported that plasma concentrations of LDL 
and human apoB were increased in transgenic mice expressing human apoB100. 
However, a controversy regarding the regulation at the apoB mRNA level exists. Some 
studies (Pullinger et al., 1989; Leighton et al., 1990; Moberly et al., 1990) showed that 
apoB mRNA level does not change when apoB secretion is altered over a wide range, 
indicating that apoB mRNA level does not regulate apoB secretion. Dashti et al. (1989) 
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also demonstrated that apoB mRNA concentrations were increased by insulin or oleic 
acid, whereas other studies suggested that it is possible that apoB secretion is partially 
regulated at the mRNA level. For example, Hennessy et al. (1992) reported that the 
hepatic apoB mRNA level was 87% higher in Cebus monkeys fed coconut oil and 
cholesterol than in animals fed corn oil without cholesterol. Dashti (1992) and Theriault 
et al. (1992) demonstrated that 25-hydroxycholesterol and thyroid hormone increased 
apoB mRNA levels and regulated apoB secretion at the transcriptional level. The apoB 
mRNA level and translational rate in hepatic cells are largely constitutive (Yao et al., 
1997). Thus the assembly and secretion of apoB-LP are regulated primarily at the levels 
of co- and post-translational degradation of apoB, with degradative sorting being linked 
to apoB failure to acquire sufficient lipid to attain proper conformation for subsequent 
assembly processes (Fisher et al., 2001)  
Normally, apoB are produced in excess, and the availability of cellular lipid and 
other factors regulate apoB secretion (Davis, 1999). Thus, translated apoB may enter 
either the degradation pathway or be assembled into lipoproteins that are subsequently 
secreted. There are three pathways leading to apoB degradation. The first pathway is 
ER-associated degradation. Newly synthesized apoB in ER are initially complexed with 
small amounts of lipid shuttled by MTP (Berriot-Varoqueaux et al., 2000). During lipid 
deprivation (Dixon and Ginsberg, 1993) or MTP deficiency (Wetterau et al., 1992), this 
initial lipidation step fails, and the lipid-poor apoB becomes misfolded leading to its 
ubiquitinylation and targeting to proteasomal degradation (Fisher et al., 1997). The 
second mechanism is a post-ER, pre-secretory, proteolytic degradative pathway, which 
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was recently proposed by Fisher group (Fisher et al., 2001; Williams and Fisher, 2001). 
The process occurs between particle lipidation and assembly in the ER and export across 
the plasma membrane (Fisher et al., 2001). Post-ER, pre-secretory proteolysis can be 
triggered by n-3 fatty acids through a signal responsible for targeting apoB-LP to 
degradation in cells before the particles exit from the ER. This signal serves to trigger 
the appropriate trafficking of the doomed substrate to post-ER degradation. It has been 
suggested that insulin-stimulated apoB degradation involves phosphoinositide 3-kinase 
(PI3K) translocation to the ER membrane and the sorting of apoB to a post-ER 
degradative pathway (Phung et al., 1997).  
The third mechanism for degradation of newly synthesized apoB is the re-uptake 
pathway. Re-uptake can occur after fully assembled apoB-containing particles have been 
exported across the plasma membrane but before they have diffused from the vicinity of 
the cell (Williams et al., 1990; Williams et al., 1992). Nascent particles have a chance of 
encountering cell surface receptors, including LDL receptors (Williams et al., 1990) and 
heparan sulfate proteoglycans (Williams et al., 1992), and being taken back into the cell 
for destruction in the lysosomes. The nature of LDL receptor ligand affinity would select 
against smaller diameter particles. Thus, the availability of lipid modulates apoB 
degradation as well as the level of apoB mRNA. However, between these two factors, it 
appears that the availability of lipid is more important in the regulation of apoB-LP 
assembly and secretion. 
Research has established that MTP is required for apoB-LP assembly. The first direct 
evidence that linked MTP and a defect in apoB-LP production came from studies 
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(Wetterau et al., 1992) of abeta-lipoproteinemia. This genetic disorder is characterized 
by a defect in the production of CM and VLDL, due to defects in the MTP. Jamil et al. 
(1998) used an MTP inhibitor to inactivate MTP in HepG2 cells, and found that resultant 
decrease in MTP activity produced a proportional decrease in apoB secretion.  
Several studies indicated that MTP plays an important role in the early stages of 
lipoprotein assembly. Cell culture studies (Gordon et al., 1994) showed that the products 
of the first-step of lipoprotein assembly, small, dense apoB-LP, were not observed in the 
absence of MTP. Raabe et al. (1999) reported that in MTP knockout mice, VLDL-sized, 
lipid–rich particles (putative second-step particles) within the ER were not detected. 
However, the role of MTP in the second-step of apoB-LP assembly remains 
controversial. Some studies (Gordon et al., 1996; Rustaeus et al., 1998) showed that TG 
addition to the nascent VLDL was MTP independent, whereas others (Wang et al., 1999) 
found that it was MTP dependent. In animal models, MTP large subunit gene expression 
is regulated in response to diet (Bennett et al., 1996; Lin et al., 1994). A high-fat diet 
increases MTP gene expression by 50% in liver and 200% in the intestines of hamsters 
(Bennett et al., 1996). 
As mentioned above, lipoprotein particles are complex and include at least four 
different kinds of lipid, and the relative availability of each class of lipids found in apoB-
LP influence their assembly and secretion. The synthesis of all VLDL lipid classes is 
coordinately changed in response to nutritional and hormonal state (Davis, 1999). 
Fasting decreased, whereas carbohydrate feeding increased, the synthesis of all VLDL 
lipids (Boogaerts et al., 1984), suggesting a co-ordinated regulation of metabolic 
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pathways related to the regulation of the assembly and secretion of apoB-LP. There are 
several interrelated systems that regulate gene expression to control the flux through 
various lipid metabolic pathways. Recently, sterol regulatory element binding proteins 
(SREBP) were linked to control of several pathways related to cholesterol and fatty acid 
metabolism (Brown and Goldstein, 1997). The SREBP are a superfamily of nuclear 
transcription factors (proteins) that bind to sterol regulatory element-1 (SRE-1). The 
SRE-1 is an upstream promoter sequence binding of SREBP present on some genes 
involved in the biosynthesis and metabolism of different classes of lipid. SRE-1 activates 
expression of these genes. The SREBP regulate transcription of a number of genes 
(Table 1.2) including 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, 
HMG-CoA synthase, farnesyldiphosphate synthase and squalene synthase. The SREBP 
also modulate expression of LDL receptor, fatty acid synthase, glycerol-3-phosphate 
acyltransferase and other enzymes involved in lipid metabolism (Gurr et al., 2002).  
Dietary Effect of High-carbohydrate Diet on apoB-containing Lipoproteins 
As discussed above, the assembly and secretion of apoB-LP is a complex, process 
modulated by a variety of factors. Lipid, apoB and MTP are all required for the assembly 
and secretion of apoB-LP. In particular, the availability of all lipids, and most 
particularly TG can be significantly modulated by diet. Thus, diet has the potential to 
play a major role in both targeting apoB for secretion and determining the heterogeneity  
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TABLE 1.2 
 
Genes whose expression is regulated by the sterol regulatory element binding protein 
(SREBP) system 
 
Gene Function in cell 
LDL-receptor Import of LDL particles 
HMG-CoA systhase de novo cholesterol synthesis 
Squalene synthase de novo cholesterol synthesis 
Farnesyl diphosphate synthasr de novo cholesterol synthesis 
Lanosterol synthase de novo cholesterol synthesis 
Acetyl-CoA carboxylase de novo fatty acid synthesis 
Fatty acid synthase de novo fatty acid synthesis 
Stearoyl-CoA desaturase Synthesis of oleate 
Glycerol 3-phosphate acyltransferase Triacylglycerol and phospholipid synthesis 
Lipoprotein lipase Import of lipoprotein-triacylglycerol 
PPAR-γ Induction of adipocyte differentiation 
Leptin Signal fat store size 
 
Stimulation occurs in response to low cellular cholesterol content (Gurr et al., 2002). 
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of the secreted apoB-LP. Both of these processes may significantly affect the 
metabolism and the potential atherogenicity of the plasma apoB-LP. 
High-carbohydrate diet is known to decrease plasma LDL cholesterol, a positive 
effect with regards to spontaneous risk for ASCVD (Grundy, 1986; Grundy et al., 1986; 
Krauss et al., 2000). Current dietary guidelines for reducing the risk for ASCVD 
emphasize the replacement of saturated fat with complex carbohydrates so that total fat 
intake does not exceed 30% of energy intake (Krauss et al., 2000). However, as early as 
1950, Watkin et al. (1950) observed that the carbohydrate-induced decreases in plasma 
LDL cholesterol concentration was frequently accompanied by elevation of plasma TG, 
an independent risk factor for ASCVD (Criqui et al., 1993). Over the past five decades 
many studies by numerous investigators have examined the effects of high-carbohydrate 
diet on risk factors for ASCVD. The debate as to whether a net benefit to ASCVD risk is 
provided by consumption of low-fat, high-carbohydrate diet has continued (Connor and 
Connor, 1997; Katan et al., 1997; Ornish, 1998; Rudel, 1998). This section focuses on 
the effect of high-carbohydrate diets on apoB-LP biology.  
The increase in plasma TG concentration is a major, consistent and reproducible 
effect of increasing dietary carbohydrate (> 55% Kcals from carbohydrate). This effect 
has been observed from clinical trials (Bantle et al., 2000; Melish et al., 1980; Reaven et 
al., 1965) and animal experiments, including different animal species (Kasim-Karakas et 
al., 1996; Kazumi et al., 1985; Kazumi et al., 1986; Remillard et al., 2001; Taghibiglou 
et al., 2000). The hypertriacylglycerolmia produced by high-fat diet (> 30% Kcals from 
fat) is believed to increase atherosclerotic risk (Austin et al., 1998). High-fat diet 
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increases the influx of dietary TG within circulation, resulting in elevated plasma TG 
concentrations, which is risk factor for atherosclerosis. Whether carbohydrate-induced 
hypertriaclyglycerolmia shares metabolic mechanisms with lipid–induced 
hypertriacylglycerolemia, and creates a similar atherogenic risk has been the subject of 
intense study. Studies demonstrated that consumption of high-carbohydrate diet is 
associated with elevation in both the amount of TG per apoB-LP particle (Schonfeld, 
1970) and the number of apoB-LP particles in the plasma (Ginsberg et al., 1981). 
Reaven et al. (1965) proposed that carbohydrate-induced hypertriacylglycerolemia 
resulted primarily from overproduction of TG. In addition, carbohydrate-induced 
hypertriacylglycerolemia reflected a defect in peripheral clearance mechanisms in as 
much as clearance rate did not match production rates (relative overproduction of 
VLDL) (Huff and Nestel, 1982). The most obvious metabolic explanation for 
carbohydrate-induced hypertriacylglycerolemia would be increased conversion of 
carbohydrate to fat in the liver via the de novo lipogenesis pathway, resulting in VLDL-
TG overproduction. However, evidence has shown the fractional contribution from 
hepatic de novo lipogenesis to total VLDL-TG fatty acids is less than 5% (Hellerstein et 
al., 1991) in healthy subjects consuming high-fat diet. Obese, hyperinsulinmic human 
exhibit a de novo lipogenesis contribution of < 3-fold higher, but this still represents < 
10% of VLDL TG (Hellerstein et al., 1991). Currently, some investigators (Howard et 
al., 1987; Reaven, 1997) propose that the metabolic mechanism of carbohydrate-induced 
hypertriacylglycerolemia involves an impaired ability of insulin to suppress adipose 
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tissue lipolysis, which leads to higher free fatty acid flux and increased VLDL 
production.  
Small dense LDL are often observed in persons who consume high-carbohydrate 
diet. Dreon et al. (1994) analyzed changes in LDL pattern in 105 healthy men 
consuming high-fat and high-carbohydrate diets for 6 wk each and found that: 1) men 
exhibiting the pattern B profile of small dense LDL exhibited a 2-fold greater fall in 
LDL cholesterol than those starting the trial with a pattern A profile when consuming 
high-carbohydrate diet, 2) that one-third of men exhibiting a pattern A profile while 
consuming high-fat diet transformed to a pattern B profile while consuming the high-
carbohydrate diet. In other words, there was a shift in LDL particle mass from larger, 
lipid-rich LDL1 and LDL2 to smaller, lipid-depleted LDL3 and LDL4. These results 
suggested that the reduction in LDL cholesterol that occurred when a high-carbohydrate 
diet was consumed was due to a shift from larger, more cholesterol-rich LDL to smaller, 
cholesterol-depleted LDL without reduction in apoB concentrations. Importantly, when 
studies were performed under isocaloric conditions, it was reported that 
hypertriglyceridemia caused by an isocaloric high-carbohydrate intake is not associated 
with a decrease in LDL particle size (Kasim-Karakas et al., 1997). Weight loss 
(Lichtenstein et al., 1994) and exercise (Koutsari et al., 2001) under isocaloric conditions 
also can attenuate the negative effects of high-carbohydrate diet on LDL diameter. Both 
of these latter factors should reduce adipose-linked free fatty acid concentrations.  
Another important consequence of high-carbohydrate diet in human is a lowering of 
plasma HDL cholesterol, which has been a compelling reason to discourage the 
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consumption of these diets. Low plasma HDL cholesterol is a major cardiovascular risk 
factor that is independent of other known risk factors (Rader, 2002). Turley et al. (1998) 
reported that high-carbohydrate (22%, 6% and 59% energy from total, saturated, and 
carbohydrate, respectively) consumption was associated with a significant reduction in 
HDL cholesterol compared with high-fat (36%, 18%, and 43% energy from total, 
saturated, and carbohydrate, respectively) values. Currently, the proposed mechanism of 
high carbohydrate-induced lowering of HDL cholesterol in humans involves exchange 
CE from the core of HDL with TG present in the VLDL core via CETP (Kwiterovich, 
2000) than high-fat diet. Interestingly, hamsters fed a high-carbohydrate diet exhibited 
elevated HDL cholesterol despite increased plasma CETP activity (Remillard et al., 
2001).  
Carbohydrate-induced ALP characterized by an elevation of plasma TG, a reduction 
in HDL cholesterol and the presence of small dense LDL is often in association with 
insulin resistance. Insulin resistance is a common metabolic abnormality that is 
associated with an increased risk of both atherosclerosis and type 2 diabetes. Studies 
from humans and animals (Farquhar et al., 1966; Ford et al., 1968; Kasim-Karakas et al., 
1996; Taghibiglou et al., 2000) have demonstrated that hyperinsulinemia and glucose 
intolerance could correlate with the degree of TG elevation during carbohydrate feeding. 
ALP is often observed in patients with insulin resistance and type 2 diabetes. Fisher et al. 
(1993) reported that large VLDL are typically overproduced in insulin resistant states 
such as are found with obesity and type 2 diabetes, characterized by a predominance of 
small, dense LDL in the plasma compartment.  
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Insulin has anti-inflammatory and vasodilatory actions on the vasculature under 
normal circumstances (Garg et al., 2000). Existing data indicate that insulin-mediated 
vasodilation is blunted in patients with type 2 diabetes (Williams et al., 1996). 
Maintenance of hemostasis is mediated through factors such as plasmingen activator 
inhibitor and tissue plasminogen activator. Insulin could increase the levels of 
plasmingen activator inhibitor and tissue plasminogen activator, diminishing fibrinolytic 
potential and increasing thrombotic risk (Meigs et al., 2000). The multiple lipoprotein 
changes observed with ALP commonly aggregate with other ASCVD risk factors, 
including insulin resistance, hypertension and a procoagulant state to form a syndrome 
of multiple metabolic risk factors called metabolic syndrome or Syndrome X. Recently, 
National Cholesterol Education Program Adult Treatment Panel III (NECP-ATP III) 
defined metabolic syndrome as the second target of risk-reduction therapy after the 
primary target, LDL cholesterol (NCEP, 2001). The suggestion that insulin resistance 
represents a major underlying abnormality driving cardiovascular disease has not been 
well documented, but several mechanisms have been suggested. Ginsberg and his 
associates (Ginsberg, 2000; Ginsberg and Huang, 2000) proposed that the underlying 
metabolic abnormality driving this dyslipidemia is an increased assembly and secretion 
of VLDL particles, leading to an increased plasma level of TG. 
Hypertriacylglycerolemia, in turn, results in a reduction in the HDL level and the 
generation of small, dense LDL; these events are mediated by CETP and hepatic lipase. 
In animals such as rats (Matsui et al., 1997), mice (Kamata et al., 2001) and hamsters 
(Kasim-Karakas et al., 1996), fructose feeding has been found to cause high TG and 
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insulin resistance, however, no data to date show that whether LDL particle size 
becomes small or not in fructose-fed rats or mice that typically lack CETP or whether 
fructose feeding cause the manifestations of Syndrome X in hamsters that express CETP. 
Fructose feeding stimulates de novo lipogenesis by bypassing a key regulatory step- 
phosphofructokinase-1 and increases pathway flux through triose phosphates, NADPH 
and the pentose cycle, increasing the availability of acetyl CoA and NADPH, stimulating 
fatty acid synthesis (Frayn and Kingman, 1995). Furthermore, it has been shown that 
high-fructose diets enhance the release of NEFA from adipose tissue (Vrana et al., 
1974). The elevation of NEFA concentration in the plasma, in turn, leads to a significant 
increase of hepatic TG secretion as well as VLDL-TG synthesis. Zammit et al. (2001) 
proposed that insulin stimulation of hepatic TG secretion is the etiology of insulin 
resistance. Frequent stimulation of insulin secretion by carbohydrate feeding would 
result in a chronic stimulation of VLDL secretion, and increase delivery of acyl moieties 
to muscle. When acyl moieties core provided in excess of the oxidative needs of the 
tissue, they induce insulin resistance in muscle. Subsequently, insulin resistance in 
adipose tissue can develop due to the coordinate changes of muscle and adipose tissue 
caused by increased VLDL-TG. When insulin resistance occurs in adipose tissue, TG 
not only accumulates in hypertrophied adipocytes, but also in pancreatic β cells, where it 
is associated with disruption of glucose-induced insulin secretion. In adipose tissue, 
resistance to the anti-lipolytic effects of insulin would lead to increased concentrations 
of plasma NEFA. Increased NEFA concentration, which act as substrates for VLDL-TG 
secretion and induce lipoapoptosis in β cells, would thus link insulin resistance and 
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obesity to the development of type 2 diabetes. High-carbohydrate diet rather than high 
fat diet stimulates hepatic VLDL secretion and exacerbates the degree of insulin 
resistance (Chen et al., 1995; Reaven, 1997). Despite the extensive use of the 
fructose-fed hamster model, little is known about what changes occur in the physical 
properties of lipoproteins in those animals. 
Summary 
Currently, apoB-LP heterogeneity is believed to reflect variation in the 
atherogenicity of individual apoB-LP subclasses. The physical properties of apoB-LP 
isolated from blood reflect the summated actions of peripheral metabolism on 
lipoproteins following particle assembly and secretion. Little is known about the 
relationship of initial particle composition and structure and the physical properties of 
circulating apoB-LP. The initial properties of apoB-LP would define their initial 
substrate properties during peripheral metabolism and could be key determinants of 
particle metabolism. Specific genetic or dietary mechanisms can regulate the 
structure-function relations of apoB-LP via changes in the metabolism of circulating 
lipoproteins and the assembly and secretion of nascent lipoprotein particles. 
Objectives of Study 
The overall goal of this dissertation was to develop a better understanding of the 
pathobiological mechanisms of ASCVD. The specific objectives of this research were: 
1) To assess several genetic components that impinge on ASCVD through a 
statistical model that was developed to describe the relations among apoB-LP 
physical properties, plasma cholesterol concentration and arterial plaque 
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formation. Independent data for the model were produced by quantifying specific 
physical properties of apoB-LP in four strains of transgenic mice that differed in 
the extent of plaque formation, plasma total lipid concentrations and lipoprotein 
density class distributions when fed a non-purified chow-type diet. 
2) To assess certain dietary and metabolic modifiers of ASCVD, mainly the 
physical properties of circulating apoB-LP in a second rodent model, the Syrian 
Golden hamster was described and quantified after selected nutritional 
manipulation. Hamsters were selected as the model system as their native 
lipoprotein metabolism and response to diet are similar to those of humans in 
many respects. Specifically, modifications in dietary carbohydrate composition 
were used to vary insulin responses in order to model the human "Syndrome X" 
that is associated with increased ASCVD risk. 
3) To assess whether altered nascent apoB-LP structure is a component in 
carbohydrate-induced changes in apoB-LP physiology. ApoB-LP assembly 
intermediates were isolated from the livers of hamsters fed diets of differing 
carbohydrate composition for characterization of physical properties. 
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CHAPTER II 
SELECTIVE DELAYS IN APOLIPOPROTEIN B-CONTAINING 
LIPOPROTEIN CLEARANCE AFFECT CIRCULATING 
PARTICLE DIAMETER DISTRIBUTION AND PLAQUE 
FORMATION 
Introduction 
Apolipoprotein B-containing lipoproteins (apoB-LP) differ with regards to B-
isoform, lipid content and composition, particle density and diameter. In clinical 
populations apoB-LP heterogeneity is associated with differences in ASCVD risk, 
although the exact changes most associated with increased risk are contentious (Campos 
et al., 2002; Williams et al., 2003). Dissecting the metabolic mechanisms that create 
atherogenic apoB–LP in free living human populations is problematic due to 
incompletely characterized sources of variation. In genetically homogeneous murine 
models fed identical diets, observed differences in the physical properties of circulating 
apoB-LP presumably result from the passage of nascent apoB-LP through the 
intravascular lipolytic cascade and associated remodeling and removal processes. Diet is 
known to impose additional variation to apoB-LP physical properties even in the setting 
of homogeneous genetic background (Rudel et al., 1998). Such model systems provide 
the means to dissect the mechanisms that influence apoB–LP physical properties and 
atherogenicity. 
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Delay in apoB-LP clearance was proposed to be a fundamental mechanism that 
converts native particles into atherogenic species (Walzem et al., 1995). Mice 
genetically engineered to express exclusively apoB100 or apoB48 showed marked 
reductions in apoB-LP particle diameter when clearance was delayed by concomitant 
ablation of the LDL receptor (LDLR) or apolipoprotein E (apoE), respectively (Veniant 
et al., 1998). apoB isoform per se did not affect the extent of arterial plaque formation, 
which was directly related to plasma cholesterol concentration. Separate studies showed 
that the LDL receptor related protein (LRP) played no significant role in the clearance of 
apoB100, while apoB48 was actively removed by both LRP and LDLR (Veniant et al., 
1998). This difference in particle biology may underlie observed differences in turnover 
rates within apoB100 and apoB48 pools (Li et al., 1996) and with the extent of particle 
diameter change with genetic suppression of particle clearance mechanisms. For 
example, selective ablation of apoE or LDLR in apoB100-only mice produces similar 
plasma cholesterol concentrations, but cholesterol was associated with apoB-LP of 
VLDL diameter (mean, 53.4 nm) with apoE deficiency and LDL diameter (mean, 22.1 
nm) with LDLR deficiency. Arterial plaque was much more extensive in apoB100–only 
mice lacking the LDLR than those lacking apoE. Exacerbation of plaque formation in 
the LDLR deficient apoB100-only mice resulted from the increased molar concentration 
of apoB–LP particles represented by smaller particles providing a similar plasma 
cholesterol concentration. 
Relationships observed between particle diameter, cholesterol and apoB 
concentrations and plaque formation in models expressing exclusively one apoB100 or 
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apoB48 serve to clarify isoform specific effects, but may not fully replicate more 
complex interactions possible with heterogeneous apoB isoforms and/or differential rates 
of particle clearance as occur in free-living humans. As a first step towards development 
of systematic modeling approaches for these complex interactions we compared 
relationships between apoB–LP physical properties and arterial plaque formation in 
apoB wild-type mice relative to apoB100–only mice under in which apoB isoform 
specific clearance defects were created. Relationships among some of these parameters 
were reported previously for apoB100-only mice in this same sample set (Veniant et al., 
2000). 
Materials and Methods 
Mice 
Creation of these mouse strains was described (Veniant et al., 2001). Briefly, 
apoB100-only mice were generated by mutating apoB codon 2153 to prevent the 
expression of a stop codon in mouse embryonic stem (ES) cells (Farese et al., 1996). The 
genetic background of the mice was 50% C57BL/6 and 50% 129/Sv. The apoB100-only 
mice were bred with apoE-deficient mice (Piedrahita et al., 1992) to generate 
apoE-deficient apoB100-only (Apoe-/-Apob100/100) mice, and also bred with 
LDLR-deficient mice (Ishibashi et al., 1993) to generate LDLR-deficient apoB100-only 
(Ldlr-/-Apob100/100) mice. ApoE-deficient mice homozygous for a wild-type apoB allele 
(Apoe-/-Apob+/+) and LDLR-deficient mice homozygous for a wild-type apoB allele 
(Ldlr-/-Apob+/+) were also generated. Genotyping was performed by Southern blot 
analysis of genomic DNA. Each of the four mouse strains had a 75% C57BL/6 and 25% 
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129/Sv genetic background. The mice were weaned at 21 d, housed in a barrier facility 
with 12-h light/dark cycle and fed a chow diet containing 4.5% fat. Experiments were 
conducted when the mice were 40 wk old. 
Blood collection and lipoprotein separation 
At 40 wk of age, female mice were fasted 4 h prior to subjecting them to anesthesia 
and exsanguination via heart puncture. Whole blood was drawn into tubes that contained 
1 mg EDTA and 10 U each streptomycin sulfate and procaine penicillin G/mL whole 
blood. Plasma was isolated by centrifugation at 2500 rpm at 4°C for 20 min, and then 
held at 4°C before apoB-LP isolation, particle diameter distribution determination and 
quantitation of apoB isoform concentrations. To minimize proteolytic degradation, 1.0 
µL/mL plasma of phenylmethyl sulfonyl fluoride and 5 µL/mL plasma of aprotinin were 
added to fresh plasma. Total plasma apoB-LP were isolated as the d < 1.07 g/mL 
fraction of plasma (Chapman et al., 1981; Walzem et al., 1994) following 18 h of 
centrifugation at 40,000 rpm in a TFT 50.3 rotor at 14°C within a Beckman L8-70M 
ultracentrifuge. Particle diameter distributions were immediately determined in apoB-LP 
fractions of individual mice. Following analysis, the fractions were stored at –80°C prior 
to apoB isoform quantification. 
Total plasma cholesterol and TG concentrations were measured in plasma samples 
using colorimetric assays (Spectrum cholesterol assay, Abbott Laboratories, Irving, TX; 
GB Triacylglycerol Kit, Boehringer Mannheim Biomedicals, Indianapolis, IN) (Veniant 
et al., 2000) 
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Apolipoprotein B-containing particle diameter distributions 
Apolipoprotein B-containing particle diameters were determined by dynamic light 
scattering analysis using a Microtrac series 250 Ultrafine Particle Analyzer with a laser 
probe tip (UPA-250; Microtrac, Clearwater, FL) (Walzem et al., 1994; Veniant et al., 
2000). Following ultracentrifugation, samples were carefully removed from the rotor and 
uncapped. The laser probe was gently placed on the top layer of the supernatant fraction. 
Great care was taken to not mix the sample layer or allow air bubbles to form at the 
probe liquid interface. Due to the low lipoprotein content of some samples, a 
measurement time of 600 sec was used for all samples. Raw particle size distributions 
were converted to area, number and volume population percentiles, which were used to 
calculate median particle size for the respective distributions. 
Quantitation of apoB100 and apoB48 
The concentrations of apoB100 and apoB48 in apoB-LP isolated from Apoe-/- 
Apob100/100, Apoe-/-Apob+/+, Ldlr-/-Apob100/100 and Ldlr-/-Apob+/+ mice were determined 
by analytical sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
following Coomassie staining of the separated apolipoproteins (Kotite et al., 1995). 
The protein content of isolated apoB-LP was analyzed by a modified Lowry assay 
(Lowry et al., 1951). Sample volumes containing 50-200 µg protein were combined with 
60 µg apotransferritin carrier protein prior to delipidation in order to insure quantitative 
apolipoprotein recovery (Kotite et al., 1995). Samples were delipidated overnight at –
20°C in an ethanol-diethyl ether (3:1 vol/vol) system in which 400–1,200 µL of sample 
were mixed with 10 vol of ice-cold ethanol-diethyl ether in a 15-mL conical, glass 
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stoppered tube and thrice inverted. The delipidated mixture was centrifuged for 25 min 
at 1250 rpm to facilitate removal of the organic phase by a glass transfer pipet. The 
pellet was then extracted twice with 4 mL cold anhydrous diethyl ether. The resultant 
whitish pellet was dissolved in 50–100 µL sample buffer containing 10% glycerol, 3% 
SDS, 1.5% dithiothreitol (DTT), 1% mercaptoacetic acid and 0.02% bromphenol blue in 
1 M Tris, pH 6.8. Excess ether was removed under a gentle stream of nitrogen, and the 
dissolved apolipoproteins were denatured at 100°C for 3 min prior to application to a 
SDS-PAGE gel. 
Individual apoB isoforms were separated using the SDS-PAGE gradient gel and 
conditions described by Kotite et al. (Kotite et al., 1995) with some modifications. 
Briefly, the 3–12% gradient polyacrylamide gel was cast using a two-chamber gradient 
mixer (Bio-Rad Laboratories, Hercules, CA). The 3% polyacrylamide solution contained 
3% acrylamide, 0.08% bisacrylamide, 0.1% SDS, 0.03 g/mL glycerol, 0.06% 
ammonium persulfate (APS) and 0.05% N,N,N,N-tetramethylethylenediamine 
(TEMED) in 0.376 M Tris, pH 9.2 in the resolving gel, and pH 6.8 in the stacking gel. 
The 12% polyacrylamide solution contained 12% acrylamide, 0.33% bisacrylamide, 
0.1% SDS, 0.10 g/mL glycerol, 0.06% APS and 0.05% TEMED in 0.376 M Tris, pH 
9.2. Apolipoprotein separation was effected using a Mini-PROTEIN 2 Vertical gel 
apparatus (Bio-Rad Laboratories Inc, Hercules, CA) (Laemmli, 1970) containing two 
minigels in each separation. After loading 50 µL delipidated apoB-LP or standard in 
each well, a Bio-Rad PowerPAC 300 (Bio-Rad, Laboratories Inc, Hercules, CA) was 
used to apply 76V to the gels for the first 30 min, followed by 96V until the dye front 
  
 61
was 1 mm from the bottom of the gel. Narrow-cut human LDL served as the source for 
the apoB100 used as the reference protein within the standard curves. 
Following electrophoresis, gels were stained for 15–30 min at 60°C with staining 
solution containing ethanol:water:glacial acetic acid, 3:8:1 (vol/vol/vol), and 0.15% 
Coomassie Brilliant Blue R-250 (Sigma Chemical Co., St. Louis, MO). The gels were 
then destained for 30-60 min at 60°C with a destaining solution of ethanol:water:glacical 
acetic acid, 3:8:1 (vol/vol/vol). After destaining, the gels were placed between two 
sheets of cellophane gel wrap (BioDesign Inc. of New York. Carmel, NY), and dried in a 
fume hood overnight. The dry gels were scanned using a laser scanner (Fluor-STM 
MultiImage; Bio-Rad, Laboratories Inc, Hercules, CA) equipped with an Image Quant 
Software Package to automatically integrate the volume of each stained apolipoprotein 
band. The standard curve for apoB100 was constructed by relating the intensity of dye 
uptake of each band to its known mass. The line of fit was evaluated by the method at 
least squares for the power function y = axb (Kotite et al., 1995). Because apoB100 and 
apoB48 have equal chromogenicities (Bergeron et al., 1996), the same standard curve 
was used to analyze both apoB isoforms. The concentrations of individual apoB species 
in apoB-LP was calculated from the regression equation relating the absorbance of 
individual apoB100 standard bands to the amount of apoB100 standard applied to the 
gel.  
Analysis of arterial plaque 
Mice arterial plaque was quantified in pinned-out aortas as described by Tangirala et 
al. (1995). The mice were perfused and the tissues were fixed prior to removal of the 
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portion of the aorta between the aortic valve and the bracheocephalic artery and then 
pinned flat on a black wax surface. The image of the pinned-out aortas was recorded 
with a Polaroid digital microscope camera (Polaroid Corporation, Cambridge, MA), the 
image was analyzed and plaque was quantified as the percentage of the aortic surface 
covered by plaque. 
Statistical analysis 
The results are presented as the mean ± SEM unless otherwise noted. Regression 
analysis was used to test the strength of association between the percentage of total 
apoB-LP particles found within individual machine–defined diameter ranges and arterial 
plaque area. Information regarding those diameter ranges found to have significant 
associations (positive or negative) with plaque formation was used in subsequent 
ANOVA models. The arterial plaque area attributable to genotype was tested by one-
way ANOVA, while the ability of surrogate markers (e.g. particle diameter, plasma 
cholesterol concentration) to describe genotype-driven effects on arterial plaque area 
were modeled by GLM (Proc GLM, SAS Institute, Carey NC). F-testing and partial 
correlation coefficients were used to determine the significance of individual 
components of the linear model. Differences among mean values were tested by a least-
squares means procedure. Differences were considered significantly different at P < 
0.05. All these analyses were performed using statistical analysis system procedures 
(SAS Institute, Inc., Cary, NC) 
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Results 
Plasma lipids and bodyweight 
Mice of the Apob+/+ Ldlr-/- genotype weighed significantly less than mice of either 
apoB genotype lacking apoE; bodyweights of apoB100–only mice lacking the LDLR 
were intermediate (Table 2.1). The plasma total cholesterol concentration was higher in 
Apoe-/-Apob+/+ mice (461 ± 29 mg/dL) than in the other three groups, while there was 
much lower cholesterol concentration in Ldlr-/-Apob+/+ (190 ± 6 mg/dL) mice. 
Apoe-/-Apob100/100 mice (278 ± 7 mg/dL) and Ldlr-/- Apob100/100 (296 ± 6 mg/dL) did not 
have significantly different cholesterol concentrations (Table 2.1). Significant 
differences were also found in plasma HDL cholesterol concentrations (HDLc, Table 
2.1), with Ldlr-/-Apob+/+ mice having the greatest concentration (55.5 ± 3 mg/dL), 
significantly greater than the 42.6 ± 1 mg/dL observed in Apoe-/-Apob100/100 mice. That 
concentration was in turn significantly greater than the 34.8 ± 2 mg/dL observed in 
Apoe-/-Apob+/+ mice or the 32.9 ± 0.7 mg/dL observed in Ldlr-/- Apob100/100 mice, the 
latter two values were not different from one another. Plasma triacylglycerols in Apoe-/- 
Apob100/100 mice, being (127 ± 18 mg/dL) were significantly higher than in any other 
genotype. Plasma triacylglycerol concentrations in both Apoe-/-Apob+/+ mice (87 ± 10 
mg/dL) and Ldlr-/- Apob100/100 (82 ± 5 mg/dL) mice were similar and significantly higher 
than that of Ldlr-/-Apob+/+ mice (65 ± 6 mg/dL). 
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TABLE 2.1 
 
Body weight, plasma cholesterol and triacylglycerol concentrations in different 
mouse genotypes1 
 
Genotype Body weight  Cholesterol HDL-
cholesterol 
Triacylglycerol 
 g mg/dL mg/dL mg/dL 
Apoe-/-Apob100/100 28.22 ± 0.81a 278 ± 7b 42.61 ± 1.06b 126.66 ± 17.60a
Apoe-/-Apob+/+ 29.20 ± 1.25a 461 ± 29a 34.84 ± 2.33c 86.62 ± 9.70b
Ldlr-/-Apob100/100 27.86 ± 1.45ab 296 ± 6b 32.85 ± 0.68c 82.42 ± 4.54b
Ldlr-/-Apob+/+ 25.75 ±0 .52b 190 ± 6c 55.49± 2.77a 64.93 ± 5.80c
             
  1 Values are mean ± SEM, n = 14 per genotype. Values sharing a common 
superscript are significantly different (P < 0.05) 
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TABLE 2.2 
 
apoB-LP particle diameters and percentage of aortic plaque in different 
mouse genotypes1 
 
Genotype Particle diameter          Plaque 
 nm                       % 
Apoe-/-Apob100/100 62.26 ± 1.37a 4.50 ± 0.53b 
Apoe-/-Apob+/+ 38.83 ± 0.14b 6.58 ± 0.96b 
Ldlr-/-Apob100/100 24.72 ± 0.05c 14.38 ± 0.57a 
Ldlr-/-Apob+/+ 30.30 ±0 .08b 0.41 ± 0.16c 
             
    1   Values are mean ± SEM of the 50th percentile of particle diameter 
distributions, n = 14 per genotype.  Values sharing a common superscript are 
significantly different (P < 0.05). 
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Arterial plaque analysis 
Analysis of the aortas revealed that the Ldlr-/-Apob100/100 mice (14.38 ± 0.57%) had 
significantly more lesions than did Apoe-/- Apob100/100 mice (4.5 ± 0.53%) and 
Apoe-/-Apob+/+ mice (6.58 ± 0.96%), whereas the Ldlr-/-Apob+/+ mice had no arterial 
plaque formation (Table 2.2.) 
Characterization and concentration of apoB 
Individual apoB isoforms in plasma were quantitated optically in stained gels 
following separation of apoB100 and apoB48 by SDS-PAGE. Figure 2.1 is a 
representative example of a 3-20% gel prepared to show the total apoprotein profile of 
the apoB-LP plasma fractions from each mouse genotype. Mouse apoB-LP contained 
apoB of variable isoform in accordance with genotype in combination with apoA, apoC 
and apoE. Note that no apoB48 was present in plasma from apoB100-only mice, and 
similarly that not apoE was present in apoE-/- mice. The image of a typical gel used to 
separate and quantify apoB isoforms is shown in Figure 2.2. apoB100 was distinctly 
separated from apoB48 and the apotransferritin carrier protein was apparent at the 
bottom of the gel. A standard curve for apoB with 44 points was generated over a range 
of 0.795-27.2 µg apoB100 using 6 individual gels. The linear standard curve is shown in 
Figure 2.3. The concentration of individual apoB isoforms in individual samples was 
calculated using this aggregate standard curve for dye uptake. Two standard lanes 
containing different concentrations of human apoB100 were included in every sample 
gel. Differences in the MW of apoB100 and apoB48 were corrected and final values 
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were expressed as µmol/L plasma. Figure 2.4 shows the mean concentration of apoB 
isoforms for each genotype studied. Overall, the greatest difference in total apoB 
concentration existed between Apoe-/-Apob+/+ mice and Apoe-/-Apob100/100 mice. The 
total apoB concentration in plasma from Apoe-/-Apob+/+ mice was 0.55 ± 0.08 µmol/L, 
which is more than three times greater than the 0.15 ± 0.02 µmol/L in plasma from 
Apoe-/-Apob100/100 mice (P < 0.001). Notably, the 0.25 ± 0.05 µmol/L total apoB in 
plasma from Ldlr-/-Apob+/+ mice was not significantly different from the amount in 
plasma from Apoe-/-Apob100/100 mice. Similarly, the 0.43 ± 0.03 µmol/L of total apoB in 
Ldlr-/- Apoe-/-Apob100/100 mouse plasma was not significantly different from the amounts 
of total apoB in the Apoe-/-Apob+/+ strain. Thus, Ldlr-/-Apob100/100 mice and 
Apoe-/-Apob+/+ mice had similar total apoB concentrations in plasma, with the latter 
possessing a mixture of apoB100- and B48-containing lipoproteins. The 
Apoe-/-Apob100/100 and Ldlr-/-Apob+/+ mice had total apoB concentrations in plasma that 
were similar to one another and significantly lower than those of the other two 
genotypes; again, the apoB+/+ strain possessed both apoB100 and apoB48. 
Total apoB consisted of only apoB100 in apoB100/100 mouse strains. The ratio of 
apoB48/apoB100 was not identical in the Apob+/+ strains. Mice of the Ldlr-/-Apob+/+ 
strain possessed an apoB48/apoB100 of 1.0, while the ratio was 17.0 in Apoe-/-Apob+/+ 
mice. Considering only apoB100, mice of the Ldlr-/-Apob100/100 strain possessed the 
greatest amount, 0.43 ± 0.03 µmol/L, while the lowest concentration of apoB100, 0.03 ± 
0.01 µmol/L, was observed in plasma from the Apoe-/-Apob+/+ mice. Intermediate 
concentrations of plasma apoB100 were present in plasma from Apoe-/-Apob100/100 mice, 
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0.15 ± 0.02 µmol/L, and Ldlr-/-Apob+/+ mice, 0.14 ± 0.03 µmol/L. No apoB48 was 
present in plasma from Apoe-/-Apob100/100 mice. The apoB48 plasma concentration in 
Apoe-/-Apob+/+ mice was 0.51 ± 0.29 µmol/L, and was much higher (P < 0.05) than the 
0.13 ± 0.02 µmol/L in Ldlr-/-Apob+/+ mice. Thus the total apoB concentration in 
Apoe-/-Apob+/+ mice was 0.55 ± 0.08 µmol/L, more than twice as much as the 0.25 ± 
0.05 µmol/L in Ldlr-/-Apob+/+ mice. The fraction of apoB whose clearance was delayed 
was estimated in Apoe-/-Apob+/+ mice as [µmol/L apoBtotal x (apoB48/apoBtotal)], in 
Ldlr-/-Apob+/+ mice as [µmol/L apoBtotal x (apoB100/apoBtotal)]. Due to the exclusive 
reliance of native LDL on LDLR for clearance, 100% of the apoB in Ldlr-/-Apob100/100 
mice was assumed to be impaired. In Apoe-/-Apob100/100 mice, the fraction of apoB whose 
clearance was delayed was estimated as µmol/L apoBtotal x [(µmol/L apoBtotal in 
Apoe-/-Apob100/100 mice - µmol/L apoB100/100 in Apoe-/-Apob+/+ mice)/ µmol/apoBtotal]. 
Apolipoprotein B-containing particle diameter in transgenic mice 
The mean of apoB-LP (d < 1.07 g/mL) particle diameter across all mice was 36.9 ± 
1.8 nm, with the diameter of particles at the 10th percentile being 24.0 ± 0.9 nm and the 
90th percentile being 53.4 ± 3.1 nm. The percentage of apoB-LP with diameters smaller 
than 75 nm was 94.4 ± 1.2%. There were significant differences in particle diameters of 
mice with different genotypes (Table 2.2, Fig. 2.5). The 50th population percentile 
particle diameter was the largest in Apoe-/-Apob100/100 mice (62.3 nm). This diameter was 
significantly larger than that of particles from Apoe-/-Apob+/+ mice (38.8 nm) and 
Ldlr-/-Apob+/+ mice (30.3 nm), however the Ldlr-/-Apob100/100 mice had the smallest 
particle diameter (24.7 nm). 
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Figure 2.5   Dynamic light scattering-determined diameter distributions of apoB-
containing lipoproteins (apoB-LP), d < 1.07 g/mL, isolated from mice of four different 
genotypes. 
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A further analysis of apoB-LP size is shown in a histogram plot (Fig. 2.6). Individual 
correlations were calculated between plaque formation and the fractional amount of 
apoB-LP that were present in fixed diameter intervals defined by the optics of the 
Microtrac® instrument. This plot shows that apoB-LP with diameters between 13.9 nm–
23.4 nm (PV1) were positively correlated with plaque formation, while apoB-LP with 
diameters between 33.19 nm-43.0 nm (PV2) were negatively associated with plaque 
formation. The interval between these two ranges, 23.4–33.1 nm, contained the 
inflection point of the particle diameter versus plaque severity relationship, but the 
correlation coefficients in this region were not significant. When all four genotypes were 
considered together (Figure 2.7), the percentage of total apoB-LP with diameters less 
than 13.9nm was 7.6%, between 13.9–23.4 was 17.2%, between 25.5–30.4 nm was 
21.2%, between 33.1-43 nm was 25.9%, between 43.0-72.3 nm was 18.5%, and particles 
with diameters larger than 72.3 nm accounted for 9.7% of the total.  
Relations among surrogate markers and plaque formation 
Mouse genotype could describe nearly all plaque formation (r2 = 0.857, P < 0.0001) 
within the pooled mouse population, suggesting minimal environmental influence on 
disease development. Seven surrogate markers were used in that analysis, and the pooled 
population statistics are shown in Table 2.3. General linear models were then developed 
to test the ability of surrogate markers to model plaque formation using at least 1 and up 
to 7 markers. Model statements systematically evaluated all combinations of markers 
both with and without adjustment for variation in apoB clearance. Only two models  
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Figure. 2.6   Correlation coefficients for individual particle diameters (number 
distribution) and arterial plaque. n = 62, Critical value for r = 0.250, P < 0.05. Striped 
bars indicate that the correlations between the percentages of total particles present in a 
stated diameter interval were significantly correlated to plaque formation (positive 
values) or lack of plaque (negative values). 
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Figure 2.7   Aggregate apoB–LP particle diameter distribution profile. A total of 62 
mice from four genotypes were used to construct the curve. Values are means ± SEM. 
Particle diameters represented by empty bars were significantly associated with plaque 
formation (P < 0.05) while stippled bars represent particle diameters that were negatively 
associated with plaque formation (P < 0.05). Associations to plaque formation were not 
significant for those particle diameters represented by solid bars. 
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TABLE 2.3 
Best and worst models at different levels of variable inclusion 
Rank    Delay in apoB–LP 
Particle Clearance 
Adj/Unadj Variable or Model r2Adjusted r2Unadjusted 
1/1 HDL cholesterol (HDLc) 0.392 0.392 
2/3 apoB 0.308 0.153 
3/2 Cholesterol (Chol) 0.180 0.180 
4/4 Moderate Diameter Particles (PV2) 0.038 0.038 
5/5 Bodyweight (BW) 0.038 0.038 
6/6 Small Diameter Particles (PV1) -0.008 -0.008 
7/7 Triacylglycerols (TG) -0.014 -0.014 
1/1 apoB + HDLc 0.522 0.473 
21/21 PV1 + TG -0.015 -0.015 
1/1 PV2 + Chol + HDLc 0.612 0.612 
35/35 PV1 + BW + TG 0.026 0.026 
1/1 PV1 + PV2 + Chol + HDLc 0.659 0.659 
35/34 PV1 + PV2 + BW + TG 0.165 0.165 
32/35 apoB + PV1 + BW + TG 0.293 0.144 
1/1 PV1 + PV2+ BW + Chol + HDLc 0.683 0.683 
4/9 apoB + PV1 + PV2 + BW + HDLc 0.638 0.588 
21/21 PV1 + ApoB + BW + TG + Chol  0.358 0.236 
1/1 apoB + PV1 + PV2 + BW + Chol + HDLc 0.696 0.687 
7/7 apoB + PV1 + BW + TG + Chol + HDLc 0.541 0.516 
NA apoB +PV1 + PV2 + BW +TG +Chol + HDLc 0.691 0.682 
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based on single surrogate markers (HDLc or apoB) were significant (Appendix 1), and 
apoB (r2 = 0.308, P < 0.02) became non-significant when the adjustment for delayed 
particle clearance was omitted from the model (r2 = 0.153, P > 0.1). Models containing 
two or more markers were better able to account for disease formation (Table 2.3, and 
Appendix 1). Thirteen of the possible twenty-one 2-marker models (62%) were 
significant, while 30 of 35 possible 3-marker models (85%), and all 5-marker and 6-
marker models were significant. However, in each model that included apoB, failure 
toadjust for delay in particle clearance reduced the ability of the model to account for 
plaque formation (Table 2.3). Non-adjustment of apoB increased the number of non-
significant model statements from (Appendix 1) from19 to 35. Another consistent effect 
was that removal of HDLc from any model statement reduced the ability of the model to 
describe plaque formation. For example, a 4 variable model using BW, TG, PV1 and 
HDLc was better able to account for plaque formation (r2 = 0.485, P < 0.001), than one 
where Chol replaced HDLc (r2 = 0.219, P >0.05). In this case, replacement of PV1 with 
Chol (BW, TG, Chol, HDLc) improved the model (r2 = 0.467, P < 0.001). In the full 7 
marker model, adjustment for delays in apoB clearance continued to improve model fit, 
r2 = 0.691, P < 0.0001, for adjusted, versus r2 = 0.682, P < 0.001 for unadjusted. A 6-
marker model that omitted TG was best able to account for plaque formation, r2 = 0.696, 
P < 0.001, and r2 = 0.687, P < 0.001 for the apoB-clearance adjusted and unadjusted 
models, respectively. 
Correlation analysis was used to assess the strength of association of individual 
model components within the 7 component model adjusted for delay in apoB-LP 
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clearance. This analysis found that plasma TG (r2 = 0.266, P < 0.04), and Chol (r2 = 
0.313, P < 0.02) varied directly with bodyweight, but were weakly related to one another 
(r2 = 0.226, P = 0.08). Plasma Chol was inversely related to HDLc (r2 = -0.355, P = 
0.005). Body weight, did not correlate to plaque (r2 = 0.232, P = 0.071), apoB 
concentration (r2 = 0.221, P = 0.084) or PV1 (r2 = -0.182, P = 0.156) or PV2 (r2 = 0.247, 
P = -.053). However PV1 did correlate inversely with PV2 (r2 = -0.887, P < 0.0001), TG 
(r2 = -0.428, P = 0.005), and Chol (r2 = -0.393, P = 0.006).  In contrast, PV2 correlated 
directly with TG (r2 = 0.307, P = 0.0005) and Chol (r2 = 0.510, P < 0.0001) did not 
correlate with HDLc (r2 = 0.013, P = 0.919). Plasma total Chol varied directly (r2 = 
0.440, P = 0.003) while plasma HDLc varied inversely (r2 = -0.630, P < 0.0001) with 
plaque. Plasma apoB concentration was highly and directly correlated (r2 = 0.565, P < 
0.0001) to plaque formation, as well as Chol (r2 = 0.630, P < 0.001), but highly inversely 
correlated to plasma HDLc (r2 = -0.345, P < 0.0001). If the adjustment for delay in 
apoB-LP clearance was omitted from the analysis, apoB associations with plaque (r2 = 
0.409, P = 0.001) and Chol (r2 = 0.519, P < 0.0001) remained significant but were 
markedly reduced, while correlation with HDLc became non-significant (r2 = -0.185, P = 
0.151)  
Discussion 
We used gene knock-out and gene-targeting to create strains of mice in which apoB-
LP particle clearance was variably impaired. We used several strains in combination in 
order to develop a population-based model to assess the relation of plaque formation to a 
number of clinically relevant surrogate markers such as bodyweight, plasma lipid 
  
 80
concentrations and apoB-LP particle diameters. Measurement of individual apoB 
isoform concentrations allowed us to estimate the fraction of plasma total apoB 
undergoing prolonged circulation (delayed clearance). Several previous observations led 
to this approach including: 1) apoB48 and apoB100 are assembled into particles of 
similar diameters when they are the sole isoform present in the animal (Veniant et al., 
1997); 2) particles assembled from either isoform are equally atherogenic and show 
similar disease causing potential in relation to plasma cholesterol concentration in mice 
expressing a single isoform and fed identical diets (Veniant et al., 1997); and 3) 
apoB48–LP are cleared by both LRP and LDLR via apoE, while apoB100 is cleared 
nearly exclusively by LDLR (Veniant et al., 1998). We assumed that when fed a low-fat 
chow diet the primary mechanisms influencing particle clearance rates would be those 
imposed by deliberate genetic modification. This assumption suggested that we could 
use quantification of apoB100 and apoB48 as an approach to make first approximation 
estimates of delays in apoB–LP particle clearance within mixed particle populations. 
Because delays in apoB–LP particle clearance decrease the particle oxidative stability 
measured in vitro (Walzem et al., 1995), we proposed that delayed particle clearance 
was a fundamental metabolic defect capable of converting native apoB–LP to 
atherogenic species. We were curious to determine whether adjustment for variable 
delays in apoB–LP clearance would influence the ability of traditional surrogates to 
estimate plaque formation within this well defined but highly genetically diverse 
population of animals. As a corollary question, we were interested to determine whether 
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information regarding apoB-LP particle diameters could be used to enhance disease risk 
estimates. 
 In humans, plasma total cholesterol and LDL cholesterol have a direct relationship to 
ASCVD risk and are the primary indexes used to detect and evaluate treatment to reduce 
that risk (NCEP, 2001). Plasma HDL cholesterol concentration varies inversely with 
ASCVD risk and is an independent risk factor. The results of our studies in mice agree 
with human-based population estimates in this regard. In the Adult treatment Panel III 
(ATP III) persons with diabetes without ASCVD were considered to be at equivalent 
risk to those with overt ASCVD. Diabetes is often presaged or accompanied by the 
Metabolic syndrome (Reusch, 2002) and an associated atherogenic dyslipidemia 
characterized by high triacylglycerol, low HDL cholesterol and a predominance of 
small–diameter LDL particles. In our mouse population apoB–LP particle diameter 
became smaller when particle clearance was delayed by selective ablation of particle 
clearance mechanisms. Correlation analysis identified diameter-specific apoB–LP 
subpopulations that were significantly related to plaque formation in either a positive 
(diameter = 13.9 – 23.4 nm, PV1) or negative fashion (diameter = 33.1-43 nm, PV2), 
albeit the range associated directly with plaque formation as not identical to that 
proposed for humans (Dreon et al., 1994). There were a number of methodological 
differences in particle diameter measurements that may account for the discrepancy, or it 
may reflect a species difference. To our knowledge, this is the first time a subpopulation 
of apoB–LP particles has been identified that is negatively associated with plaque 
formation and the basis for this association requires further study. In contrast to the 
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metabolic syndrome, the increase in small–diameter apoB–LP predominance within this 
population of mice was not correlated to bodyweight and was inversely correlated to 
plasma TG and Chol. Notably, these mice were not obese, and plasma triacylglycerol 
concentrations, while generally higher than those found in comparable mice with intact 
particle clearance mechanisms (Farese et al., 1996), did not reach the 200-300 mg/dL 
levels associated with murine insulin resistance (Siri et al., 2001). The negative 
associations between predominance of smaller diameter apoB–LP and plasma 
cholesterol and triacylglycerol concentrations may be the result of intact hepatic lipase 
activities (Dichek et al., 1998; Deeb, S. et al., 2003, in press,) in conjunction with normal 
apoB production rates. In several instances, PV1 appeared in model statements that 
effectively explained plaque formation (Table 2.3). For example, the best 4-marker 
model was PV1 + PV2 + Chol + HDLc. However, Chol + HDLc provided most of the 
explanatory power, as replacement of these markers with BW + TG produced the 
poorest model. Similarly, combining apoB + PV1 +BW + TG produced the third poorest 
model. In clinical settings BW, Chol, HDLc, TG and PV1 are associated with increased 
risk due to metabolic syndrome. The predictive power of a 5-marker model based on 
these parameters ranked 16th out of 21 possible models. The best 5–marker model was 
PV1 + PV2 + BW + Chol + HDLc.  The degree of mobility in model ranking suggests 
that the merits of PV1 to improve the explanatory value of a model will be highly 
situation dependent. For example, it is known that monounsaturated and saturated fat 
increase LDL particle diameter in several animal models including LDLR-null, human 
apoB100–overexpressing transgenic mice (Rudel et al., 1998), while LDL diameters 
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became smaller in similar human apoB100–overexpressing transgenic mice when insulin 
resistance was imposed by brown adipose tissue ablation (Siri et al., 2001). These latter 
observations suggest that the apoB–LP particle diameters that will have positive (or 
negative) associations with plaque formation will differ in different settings. While this 
speculation remains to be confirmed by experimental data, it seems probable that a fixed 
particle diameter interval will have a variable relationship to disease rates caused by 
different underlying pathologies. Indeed as the interactions of different dietary 
components with the disparate genetic backgrounds present in the human populations 
become described, new markers of greater or complementary diagnositic value may be 
identified. In this regard, it would be of interest to compare the outcomes of this study 
with those of the same mice fed saturated or monounsaturated fat, or under conditions 
that provoke insulin resistance. If apoB–LP particle diameter proves highly malleable to 
underlying pathogenic mechanisms it seems unlikely to be suitable as a global 
independent indicator of disease risk. Indeed apoB–LP particle diameter may have its 
greatest use in differential diagnosis. In this connection is should be noted that Apob+/+, 
Ldlr-/- mice exhibited plasma apoB100 concentrations equivalent to those of Apoe-/-, 
Apob100/100 mice in addition to possessing an equivalent concentration of apoB48, and 
yet these mice did not develop plaque while the latter did. Thus it seems no single 
marker is impervious to situational effect. 
In this study, correcting for delays in apoB particle clearance improved the ability of 
the variables measured to explain plaque formation. This observation is consistent with 
hypothesized mechanisms of atherogenesis (Walzem et al., 1995; Tabas and Krieger, 
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1999), and would be a common metabolic defect in human genetic disease (as modeled 
by these mice strains) or diet induced apoB–LP overproduction as occurs with obesity, 
insulin resistance, or saturated fat intake. Reduced apoB–LP particle diameters may well 
provide a surrogate estimate of delays in particle clearance in some clinical settings. 
Interestingly, the frequency of LDL phenotype B (small dense LDL) was not prevalent 
in a population living on an isolated Mediterranean island, but when the pattern did 
occur it associated with increases in plasma triacylglycerol concentrations. As in 
populations in the United States (Dreon et al., 1994), individuals in this Mediterranean 
population that exhibited LDL phenotype B had higher body mass indexes and 
prevalence of diabetes and hypertriacylglycerolemia (Rizzo et al., 2003). While more 
sophisticated turnover methods would improve estimates of delay in apoB–LP particle 
clearance, the simple approach used here shows that delayed particle clearance is indeed 
an underlying mechanism to convert native LP species into atherogenic counterparts.  
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CHAPTER III 
EFFECTS OF HIGH-CARBOHYDRATE DIETS ON PHYSICAL 
PROPERTIES OF PLASMA LIPOPROTEINS IN HAMSTERS 
Introduction 
Atherosclerotic cardiovascular disease (ASCVD) is a major cause of morbidity and 
mortality in much of the world (Braunwald, 1997). Lipoprotein profiles provide 
powerful risk factors for the development of ASCVD. That diet can affect lipoprotein 
metabolism and atherosclerosis is well documented (Campos et al., 1991; Dreon et al., 
1994; Krauss, 1995). Dietary macronutrient composition can influence lipoprotein 
synthesis, metabolism clearance and arterial retention. Targeting specific dietary habits 
might lead to reductions in morbidity and mortality associated with ASCVD. Diets that 
provide more than > 55% energy from carbohydrate are known to decrease plasma LDL 
cholesterol (LDL-C), a risk factor for ASCVD (Hatch et al., 1955; Krauss et al., 2000). 
However, as early as 1950, Watkin et al. (1950) observed that reductions in plasma 
LDL-C concentration caused by high-carbohydrate diets were frequently accompanied 
by elevations of plasma triacylglycerol (TG), an independent risk factor for ASCVD 
(Hokanson and Austin, 1996). In humans, a high-carbohydrate diet enhances hepatic TG 
synthesis (Frayn and Kingman, 1995). Elevated plasma TG concentration is associated 
with the appearance of atherogenic lipoprotein phenotype (ALP), which consists of high 
plasma TG, low concentration of high-density lipoproteins (HDL) and small, dense LDL 
(Austin et al., 1988). When insulin resistance accompanies the ALP, the condition is 
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termed the "metabolic syndrome" or "Syndrome X," which carries with it a high risk for 
ASCVD (NCEP, 2001; McKeigue and Davey, 1995; Wingard et al., 1995). 
Many studies have been carried out to unravel the mechanism by which high-
carbohydrate diets affect lipoprotein metabolism and ALP. Evidence from rat studies 
demonstrated that diets high in fructose elevate plasma TG concentration and lower 
HDL concentration (Hwang et al., 1987; Tobey et al., 1982). The hamster has proven to 
be a good animal model to study the effects of diet on lipoprotein and lipid metabolism 
(Dietschy et al., 1993). The plasma lipoprotein profile and cholesterol ester transfer 
protein (CETP) activity of the hamster more closely resemble those of humans than do 
those of the rat or mouse (Bravo et al., 1994; Stein et al., 1990). The hamster also 
exhibits a metabolic response to dietary lipids that is similar to the response exhibited by 
humans (Stein et al., 1990). 
The effects of a high-fructose diet on lipid metabolism have been investigated in the 
hamster. Several investigators observed that diets containing 60% fructose elevate 
plasma TG concentration in hamsters and cause insulin resistance (Kasim-Karakas et al., 
1996; Remillard et al., 2001; Taghibiglou et al., 2000). Distinct from humans and rats, 
however, hamsters fed a high-fructose diet exhibit increased HDL-C concentration in 
plasma (Remillard et al., 2001). Elevated plasma HDL-C has been associated with a 
reduction in coronary events that is independent of changes in LDL-C and TG 
(Manninen et al., 1988). It is not known whether hamsters fed high-fructose diets exhibit 
changes in lipoprotein particle diameter and chemical composition indicative of ALP. 
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An objective of this study was to establish the features of the plasma lipoprotein profile 
in hamsters fed a fructose-rich diet.  
Previous studies of plasma lipoprotein profiles (Remillard et al., 2001; Taghibiglou 
et al., 2000) compared the effects of a control rodent chow diet with those of a purified 
fructose-rich diet. Chow is a nonpurified diet comprised of a mixture of intact food. In 
contrast, purified diets provide macronutrients as purified ingredients. For example, 
carbohydrate in chow diets is derived from complex mixtures of corn and wheat flakes, 
wheat middlings, ground corn, and dried whey. In addition to carbohydrate, these 
ingredients provide variable amounts of protein, fat, vitamins, minerals and various 
phytochemicals and other nutrients. However, carbohydrate in a fructose-rich diet only 
consists of a single simple monosaccharide – fructose. Thus, there is a quantifiable but 
variable difference in composition of any chow and purified diet. Starches can be highly 
purified but because they are polysaccharides, retain unique chemical and physical 
characteristics. Starch can be a straight or branched chain polymer comprised of 
thousands of glucose molecules. Starch polymers must be digested to liberate individual 
glucose molecules for transport into the bloodstream. Thus, starch-glucose is absorbed 
more slowly than glucose consumed as a mono or disaccharide producing a lower 
postprandial rise in insulin and glucose (Truswell, 1994). Furthermore, variation in the 
glycemic indexes of starchy foods is the result of variations in the ratios of amylose to 
amylopectin (Jenkins et al., 1981). Amylose, a resistant starch, is incompletely digested 
in the small intestine and produces smaller increases in postprandial insulin than does 
amylopectin (Behall and Howe, 1995). In the present study, a cornstarch-rich diet was 
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used as the control diet, and cornstarch was isocalorically substituted for fructose. Chow 
diet also was included in this study in order to compare results with those of previous 
studies. To determine the effect of fructose and starch on the size, lipid and 
apolipoprotein composition of lipoproteins, hamsters were fed semi-purified diets 
containing 60% fructose or cornstarch. 
Materials and Methods 
Animals 
Male golden Syrian hamsters (Charles Rivers Laboratory, Wilmington, MA) initially 
weighing 80–90 g and aged 6–8 wk were housed at 22°C with a 12h light/dark cycle 
(lights were on 7 a.m. to 7 p.m.) and free access to water and chow diet (#W-8604, 
Harlan Teklad, Madison, WI). After an adaptation period of 2 wk, the animals averaged 
115 g. The animals were randomly assigned to one of 3 groups comprised of 15 
hamsters each. One group was fed a fructose-rich diet, a second group was fed a 
cornstarch-rich diet and the third group remained on the chow diet. Food intakes were 
monitored daily, and body weight was measured twice weekly. At the end of 2 wk, all 
animals were fasted for 12–16 h, prior to blood collection. The hamsters were 
anesthetized (isoflurane, 4% in 100% oxygen), and blood was collected via cardiac 
puncture. All animals were cared for as outlined in “Guide for the Care and Use of 
Laboratory Animals,” prepared by the National Academy of Sciences and published by 
the National Institutes of Health, Bethesda, MD (NIH publication No. 86-23, revised 
1985). Protocols were approved by the University Laboratory Animal Care Committee 
at Texas A& M University (AUP #9-398). 
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Diets 
The compositions of the purified diets are shown in Table 3.1. The energy 
compositions of the three experimental diets are shown in Table 3.2. The basal diet was 
a closed formula cereal-based Rodent chow diet (#W-8604, Harlan Teklad, Madison, 
WI). The fructose-rich diet (#161506, Dyets Inc., Bethlehem, PA) was nutritionally 
adequate and contained 7.09% cellulose. The starch-rich diet (#161511, Dyets Inc., 
Bethlehem, PA) was similar to the fructose-rich diet with the exception that the source of 
carbohydrate was 60% cornstarch. All diets were stored at 4°C. 
Blood samples 
Cardiac blood was collected individually from the hamsters via heart puncture under 
isoflurane anesthesia (4% in 100% oxygen). Blood (3 mL/per hamster) was drawn into 
tubes containing sodium azide (0.01%), Na2-EDTA (0.12%), pencillin (10,000 
U/mL)/streptomycin (10 mg/mL)/neomycin (10 mg/mL) and aprotinin (0.01 TIU/mL). 
Plasma was separated within 2 hours of blood collection by centrifugation at 1200 × g, 
for 20 min at 4°C. A cocktail containing reduced glutathione (0.5 mg/mL), leupeptin (0.5 
µg/mL) and benzamidine (1 mM) was added to preserve the native lipoprotein structure. 
Lipoprotein isolation 
Plasma lipoproteins were sub-fractionated based on their hydrated density by 
sequential density-gradient ultracentrifugation (Chapman et al., 1981; Walzem et al., 
1994). Very low-density lipoprotein (VLDL) was isolated from 1 mL plasma at d <  
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                                                         TABLE 3.1 
 
               Composition of fructose-enriched and starch-enriched diets 
Components Diets 
 Fructose-enriched Starch-enriched 
 g/kg, as fed  
Vitamin free casein 220 220 
Cornstarch 0 600 
Fructose 600 0 
Corn oil 60 60 
Cellulose 70.9 70.9 
NRC Salt mix 35 35 
NRC Vitamin mix 10 10 
Choline bitartrate 2 2 
L-Arginine 1 1 
L-Tryptophane 1.1 1.1 
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                                                 TABLE 3.2 
 
                          Major composition of the experimental diets 
Composition Chow1  Fructose-enriched Starch-enriched 
  %  
Carbohydrate 60.0 60.02 60.03 
Protein 24.5 224 224 
Fat 4.4 6.05 6.05 
Fiber 3.7 7.16 7.16 
 
1 Harlan Teklad chow diet #W-8604, mixture of intact food. 
2 Purified carbhydrate: fructose; 3 Purified carbhydrate: cornstarch. 
4 Casein; 5 Corn oil; 6 Cellulose. 
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1.006 g/mL by aspiration with a narrow-bore pipet following 18 h centrifugation at 
40,000 rpm in a TFT 50.3 rotor held at 14°C within a Beckman L8-70M ultracentrifuge 
(Beckman Coulter, Sunnyvale CA). The density was increased to 1.053 g/mL, and LDL 
were isolated by a second centrifugation for 18 h at 40,000 rpm. The HDL were isolated 
at d 1.053–1.21 g/mL following a third centrifugation for 18 h at 40,000 rpm (Chapman 
et al., 1981). Particle diameter distributions were immediately determined in each 
lipoprotein fraction isolated from plasma. Following diameter analysis, the fractions 
were stored at –80°C prior to compositional analysis. 
Metabolic analysis 
Plasma TG concentrations were determined enzymatically using a kit from Sigma 
(Procedure No. 339, Sigma Chemical, Co., St. Louis, MO). Plasma non-esterified fatty 
acid (NEFA) and glucose concentrations were determined by spectrophotometric method 
using kits from WAKO (NEFA C Code No. 994-75409; Glucose C2 Code No. 994-
90902, WAKO, Richmond, VA). Plasma insulin concentration was measured by ELISA 
using a rat insulin ELISA kit (Catalog #: INSKR020, Crystal Chem. Inc., Chicago, IL) 
that has 79% cross-reactivity to hamster insulin. 
Lipid analysis 
Plasma cholesterol distribution was determined by analytical size-exclusion 
chromatography (Kieft et al., 1991). Typically, 20 µL of fresh plasma were injected onto 
a Superose 6 HR 10/30 size-exclusion column (Amersham Pharmacia Biotech, 
Piscataway, NJ) by an ASI-100 automated sample injector (Dionex Co., Sunnyvale, 
CA), and eluted with saline containing 0.02% sodium azide at a flow rate of 0.5 mL/min 
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(Dionex P580 Pump, Dionex Co., Sunnyvale, CA). Plasma total cholesterol distribution 
was determined enzymatically (Sigma Chemical, Co., St. Louis, MO) using an in line 
PDA-100 photodiode array detector (Dionex Co. Sunnyvale CA) with primary 
chromophore detection at 505 nm. Total cholesterol (Tch), free cholesterol (Fch) and 
phospholipids (PL) were measured enzymatically (Cholesterol CII Cat. No. 276-64909; 
Free Cholesterol C Cat. No. 274-47109; Phospholipids B Code No. 990-54009, WAKO, 
Richmond, VA) in plasma, isolated lipoprotein fractions and lipid standards. Cholesterol 
ester (CE) was calculated by multiplying the difference between Tch and Fch by 1.67. 
Analysis of lipoprotein fractions particle size 
VLDL particle diameters were determined by dynamic light scattering analysis with 
a Microtrac series 250 ultrafine particle analyzer with a laser probe tip (UPA-250; 
Microtrac, Clearwater, FL) (Walzem et al., 1994). Following ultracentrifugation, 
samples were carefully removed from the rotor and uncapped. The laser probe was 
gently placed on the top layer of supernatant portion of the sample. It was critical not to 
mix the sample layer or allow air bubbles at the probe liquid interface. Due to the low 
lipoprotein content of some samples, a measurement time of 540 sec was used for all 
samples. The results of primary data collection can be expressed in particle number, 
particle area or particle volume in order to adequately describe different aspects of the 
same VLDL particle population with respect to their colloidal properties (Walzem, 
1996). Particle number, area and volume distributions are collectively termed density 
functions of lipoprotein particles. Particle number distribution describes the frequency 
distribution of VLDL particles of the specified diameter (e.g., a hamster could have 
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14.3% of all VLDL particles as 55.7-nm particles). Particle volume distribution 
describes the distribution of total VLDL volume among particles of different diameters 
(e.g., the same hamster could have 12.6% of all VLDL volume contained within 
particles 57.7 nm in diameter). The two distributions provide complementary 
information: the 55.7-nm particles accounted for 12.6% of all VLDL volume, and for 
14.3% of all VLDL particle number. Particle volume distribution is sensitive to the 
presence of large diameter particles because the volume of a sphere increases as a cubic 
function of particle radius. Particle area distribution is calculated using information from 
particle number and particle volume distribution. Particle area distribution is calculated 
first because it is less sensitive to the presence of a few large particles. Raw particle size 
distributions were converted to area, number and volume population percentiles, which 
were used to calculate median particle size. 
LDL and HDL particle size were measured using non-denaturing gradient gel 
electrophoresis (NDGGE) (Nichols et al., 1986). Typically, a 15-µL portion of fresh 
LDL or HDL was applied onto a non-denaturing gradient gel (Alamo Gels Inc., San 
Antonio, TX). Gels with a linear gradient range of 2–16% polyacrylamide were used to 
measure the diameter of LDL particles, and gels with a linear gradient range of 4–30% 
polyacrylamide were used to measure the diameter of HDL particles. A high 
molecular-weight standard (Amersham Pharmacia Biotech, Piscataway, NJ) was also 
applied onto each gel. Electrophoresis was performed using a model GE-2/4 LS vertical 
electrophoresis apparatus (Pharmacia, Uppsala, Sweden) at a constant voltage of 125 V 
for 24 h at 4°C. Gels were stained with 0.15% Coomassie brilliant blue in 
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ethanol:water:glacial acetic acid, 3:8:1 (vol/vol/vol) for 15 min at 60°C, and then 
destained at 60°C in a destaining solution of ethanol:water:glacial acetic acid, 3:8:1 
(vol/vol/vol) until backgrounds were clear. Migration of lipoproteins in gel was 
measured using an Odyssey imager and Odyssey software (LI-COR, Inc., Lincoln, NE). 
Calibration curves for LDL proteins were constructed by plotting the logarithm of 
particle diameter against the distance migrated relative to that of Rf (abscissa). Particle 
sizes were calibrated by comparison with migration distances of standard proteins of 
known diameter (Shore, 1991).  
Quantitation of apolipoprotein B in VLDL  
The concentration of apolipoprotein B (apoB100) in VLDL was determined by 
analytical sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) with 
Coomassie blue staining (Kotite et al., 1995). Because apoB100 is the only lipoprotein in 
hamster LDL particles (data not shown), the concentration of apoB in LDL was 
determined by a modified Lowry assay (Lowry et al., 1951) using bovine serum albumin 
(Sigma Chemical Co., St. Louis, MO) as a standard. 
The protein concentration of VLDL and LDL were measured by a modified Lowry 
method (Lowry et al., 1951) using bovine serum albumin as the standard. Sample 
volumes containing 50–200 µg protein were combined with 60 µg apoferritin carrier 
protein prior to delipidation to insure quantitative apolipoprotein recovery (Kotite et al., 
1995). Samples were delipidated overnight at –20°C in an ethanol-diethyl ether (3:1, 
v/v) system in which a 400–1,200 µL sample was mixed with 10 volumes of ice-cold 
ethanol-diethyl ether in a 15-mL conical, glass stoppered tube and inverted. The 
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delipidated mixture was centrifuged for 25 min at 1250 rpm with a Sorvall TR 6000B 
centrifuge to facilitate removal of the organic phase. The pellet was extracted twice with 
4 ml cold anhydrous diethyl ether. The resultant whitish pellet was dissolved in 50–100 
µL sample buffer containing 10% glycerol, 3% SDS, 1.5% dithiothreitol, 1% 
mercaptoacetic acid and 0.02% bromphenol blue in 1 M Tris, pH 6.8. Excess ether was 
removed under a gentle stream of nitrogen, and the dissolved apolipoproteins were 
denatured at 100°C for 3 min prior to application to the SDS–PAGE gel. 
Individual apoB isoforms were separated using the SDS-PAGE gradient gel 
described by Kotite et al. (1995) with some modifications. The 3–12% gradient 
polyacrylamide gel was cast using a two-chamber gradient mixer (Bio-Rad Laboratories, 
Hercules, CA). The 3% acrylamide solution contained 3% acrylamide, 0.08% 
bisacrylamide, 0.1% SDS, 0.03 g/mL glycerol, 0.06% ammonium persulfate (APS) and 
0.05% N,N,N,N-tetramethylethylenediamine (TEMED) in 0.376 M Tris, pH 9.2 in 
resolving gel, and pH 6.8 in the stacking gel. The 12% acrylamide solution contained 
12% acrylamide, 0.33% bisacrylamide, 0.1% SDS, 0.10 g/mL glycerol, 0.06% APS and 
0.05% TEMED in 0.376 M Tris, pH 9.2. Apolipoprotein separation was effected using a 
Mini-PROTEIN II Vertical gel apparatus (Bio-Rad Laboratories Inc, Hercules, CA) 
(Laemmli, 1970) containing two minigels for each separation. After loading 50 µL 
delipidated VLDL or standard in each well, a Bio-Rad PowerPAC 300 (Bio-Rad, 
Laboratories Inc, Hercules, CA) was used to apply 76V to the gels for first 30 min, 
followed by 96V until the dye front was 1 mm from the bottom of the gel. Narrow-cut 
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human LDL served as the source for the apoB100 used as the reference protein within 
the standard curves. 
The procedures for staining and destaining of SDS-PAGE gels were similar to that of 
NDGGE gels. After destaining, gels were placed between two sheets of cellophane gel 
wrap (BioDesign Inc. of New York. Carmel, NY) and dried in a fume hood overnight. 
The dry gels were scanned using a laser scanner (Fluor-STM MultiImage; Bio-Rad, 
Laboratories Inc, Hercules, CA) equipped with an Image Quant Software Package to 
automatically integrate the volume of stained apolipoprotein band. The standard curve 
for apoB100 was constructed by relating the intensity of dye uptake of each band to its 
known mass. The line of fit was evaluated (Kotite et al., 1995) at least squares for the 
power function y = axb. The concentrations of apoB100 in VLDL and LDL were 
calculated from the regression equation relating the absorbance of apoB100 standard 
bands to the amount of apoB100 standard applied to the gel. 
Statistical analysis 
The results are presented as the mean ± SEM unless otherwise noted. Comparisons 
among three groups were performed using analysis of variance (one way ANOVA). 
Difference in mean values was tested by a least-squares means procedure. Values of P < 
0.05 were considered statistically significant. All analyses were performed using the 
statistical analysis system procedures (SAS Institute, Inc., Cary, NC). 
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Results 
Physiological and metabolic changes 
Final body weight, body weight gain and food intake after 2 wk of consuming the 
diets were similar among these groups, but the livers of the hamsters fed fructose were 
about 10% heavier (P < 0.05) than those of animals fed starch or chow (Table 3.3). 
Plasma glucose was not significantly different among the three dietary groups, while 
fasting insulin was nearly 2-fold higher in the fructose-fed group than in the starch group 
and chow group. Plasma TG concentration in fructose-fed hamsters was 59% higher (P < 
0.001) than those from chow-fed, and 72.2% higher than that of starch-fed hamsters (P < 
0.001). Similarly, fructose-fed animals had significantly higher fasting plasma NEFA 
concentrations than either starch-fed animals (32%) or chow-fed animals (14%). 
Plasma total and lipoprotein cholesterol 
Plasma lipoprotein cholesterol profiles were obtained by size-exclusion HPLC. 
Plasma cholesterol distribution in lipoproteins in hamsters fed chow, fructose and starch 
diets for 2 wk were shown in Figure 3.1. The fructose-fed hamsters had higher 
concentrations of total plasma cholesterol (P < 0.05), VLDL cholesterol (VLDL-C) (P < 
0.01) and HDL cholesterol (HDL-C) (P < 0.05) compared with those of chow-fed and 
starch-fed hamsters. Plasma LDL cholesterol (LDL-C) concentration were similar in all 
diet groups. Animals fed either purified carbohydrate diet had consistently and 
significantly higher fractional VLDL-C; the values being 6.2% in chow-fed hamsters, 
8.7% in starch-fed hamsters and 9.3% in fructose-fed hamsters. The LDL-C fraction 
accounted for 21.9% of total cholesterol in the chow-fed group. In contrast, LDL-C  
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TABLE 3.3 
 
Plasma physiological and metabolic changes in hamsters fed chow, 
fructose-enriched and starch-enriched diets for 2 wk1 
 Chow Fructose-enriched Starch-enriched 
Body weight (g) 122.94 ± 4.50 126.19 ± 3.21 123.96 ± 2.40 
Weight gain (g) 9.44 ± 1.59 11.06 ± 1.16 9.46 ± 0.90 
Food intake (g) 9.77 ± 0.46 9.47 ± 0.34 9.92 ± 0.21 
Liver weight (g) 21.50 ± 1.50b 25.03 ± 0.82a 22.42 ± 0.54b 
Glucose (mg/dL) 138.78 ± 7.40 125.71 ± 4.70 130.45 ± 5.40 
Insulin (ng/mL) 0.64 ± 0.08b 1.10 ± 0.22a 0.68 ± 0.21b 
Triacylglycerol 
(mmol/L) 
0.90 ± 0.06b 1.43 ± 0.09a 0.83 ± 0.04b 
Free fatty acids 
(mmol/L) 
0.58 ± 0.04b 0.663 ± 0.09a 0.501 ± 0.06b 
Cholesterol 
(mmol/L) 
3.13 ± 0.14c 4.22 ± 0.15a 3.59 ± 0.17b 
 
1 Values are means ± SEM, n = 15. Means within a row having different superscripts 
are significantly different (P < 0.05)  
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Figure 3.1   Distribution of cholesterol in plasma lipoproteins from 
hamsters fed chow, fructose-enriched and starch-enriched diets for 2 wk. Values 
are means ± SEM, n = 15 per treatment group. Values that do not share a letter 
differ (P < 0.05). 
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accounted for a significantly lower 18.6 and 18.7% of total cholesterol in the fructose 
and starch fed groups, respectively. There was no significant difference in percentage of 
HDL-C among the three groups, which averaged 72%. The retention time of VLDL 
particles from hamsters fed the fructose diet were shorter than those of animals fed either 
the starch or chow diet (P < 0.05) (Table 3.4). Reduced elution times indicate a large 
particle diameter. LDL particles from the fructose-fed group eluted more slowly than 
those from either chow-fed or starch-fed animals (P < 0.05). HDL eluted more quickly 
(P < 0.05) in animals fed either purified carbohydrate when compared to those fed chow. 
Size distributions of lipoprotein fractions 
The changes in particle diameter suggested by size-exclusion HPLC were confirmed 
by independent techniques. The raw density function plot for VLDL particle area 
distribution is given in Figure 3.2.There was marked heterogeneity in particle diameter 
of VLDL from plasma of hamsters fed the three diets. Diameter distributions were 
asymmetric and tailed towards small diameter particles. Chow-fed hamster VLDL 
particles range from 38 to 89 nm, with median particle diameter = 57 nm; the diameter 
of VLDL from fructose-fed hamsters ranged from 44 to 96 nm, with the median particle 
diameter = 63 nm. The diameter of VLDL from starch-fed hamsters ranged from 40 to 
91 nm with median = 59 nm. Testing of percentile distributions of VLDL area 
accumulation plot showed that plasma VLDL particles from fructose feeding group were 
significantly larger than those of chow and starch feeding groups at the 20th through 60th 
area percentiles (Figure 3.3). 
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                                                      TABLE 3.4 
 
   Retention time of plasma lipoprotein particles after feeding diets for 2 wk1 
 
Diets VLDL LDL HDL 
 min 
Chow 19.66 ± 0.01b 25.63 ± 0.04b 33.89 ± 0.06a 
Fructose-enriched 19.53 ± 0.02a 25.90 ± 0.05a 33.36 ± 0.07c 
Starch-enriched 19.61 ± 0.02b 25.55 ± 0.15b 33.54 ± 0.03b 
 
1 Values represent means ± SEM, n = 15 per treatment group. Means within a 
column having different superscripts are significantly different (P < 0.05). 
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Figure 3.2   Dynamic light scattering-determined diameter distribution of 
VLDL, d < 1.006 g/mL, isolated from hamsters fed a chow, fructose-enriched or 
starch-enriched diet for 2 wk. 
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Figure 3.3   Distribution percentile of plasma very low-density 
lipoprotein (VLDL) particle density function (area) among hamsters fed a 
chow, fructose-enriched or starch-enriched diet for 2 wk.  Within percentile 
class and density function,*  indicates significant difference. 
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The effect of carbohydrate feeding on the diameter of LDL and HDL particles was 
analyzed using non-denaturing polyacrylamide gradient gels. All the lipoproteins bands 
exhibited a polydisperse diameter profile, indicating particle diameter heterogeneity 
(Figure 3.4). The gradient gel with 2–16% polyacrylamide was used to evaluate the size 
of LDL particles. LDL particles from fructose-fed hamsters ranged from 21.51 nm to 
26.19 nm, with the average of median diameters of 23.61 nm (Table 3.5). These particles 
were significantly smaller than those in the starch-fed group, which ranged from 22.15 
nm to 27.01 nm and averaged 24.40 nm, and those in the chow-fed group, which ranged 
from 22.10 nm to 25.71 nm and averaged 23.76 nm. Hamster HDL lipoproteins fractions 
analyzed by electrophoresis in 4–30% gradient gels showed that HDL diameters in 
hamsters fed the fructose-containing diet were slightly larger as than those of hamsters 
fed either starch-containing diet (P = 0.07) or the chow diet (P < 0.05). There was a wide 
range in HDL particle diameter and overlap in diameter distributions from hamsters fed 
the different diets. Within HDL gels, a large band averaging 21 nm was noted for a 
number of animals. The frequency of this LDL-size bands was 12/15 in fructose-fed 
animals, 3 times and 4 times more frequent than in chow-fed and starch-fed hamsters 
respectively. 
Concentration and chemical composition of plasma lipoprotein fractions 
Both the concentration and chemical composition of lipoprotein VLDL fractions 
varied among the groups of hamsters (Table 3.6). In general, fructose-fed hamsters had 
the highest concentrations of all VLDL components, with progressive decreases in those  
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                                                 TABLE 3.5 
 
Plasma LDL and HDL particle diameters after feeding diets for 2 wk1 
Diets LDL HDL Frequency of 
LDL band on 
HDL gels 
 nm nm  
Chow 23.76 ± 0.07a 10.31 ± 0.08a 4/15 
Fructose-enriched 23.61 ± 0.05a 10.53 ± 0.04b 12/15 
Starch-enriched 24.40 ± 0.08a 10.45 ± 0.05b 3/15 
 
1 Values are means ± SEM, n = 15 per treatment group. Statistical analysis used 
a complete weighted least square means analysis. Values across column, not 
sharing a common superscript, differ at P < 0.05. 
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TABLE 3.6 
 
Concentration and chemical composition of lipoproteins from the 
d < 1.006 g/mL density fraction (VLDL) separated from plasma 
of hamsters fed chow, fructose-enriched and starch-enriched diets1 
Measurement Chow Fructose-enriched Starch-enriched 
 µg/mL plasma 
TG2 600.03 ± 24.19b 1084.77 ± 64.84a 596.82 ± 22.83b 
CE 55.59 ± 4.01c 104.54 ± 8.58a 84.50 ± 3.75b 
Fch 30.33 ± 2.41c 74.20 ± 8.09a 44.01 ± 3.17b 
PL 97.51 ± 11.24b 181.74 ± 21.93a 103.16 ± 8.10b 
PRO 67.75 ± 4.12b 91.24 ± 6.21a 83.42 ± 4.93a 
    
  % Composition  
TG 70.5 ± 1.4a 70.5 ± 1.6a 65.4 ± 6.0b 
CE 6.5 ± 0.5b 6.8 ± 0.7b 9.3 ± 0.7a 
Fch 3.6 ± 0.3b 4.8 ± 0.5a 4.8 ± 0.5a 
PL 14.3 ± 1.2a 11.8 ± 0.6b 11.3 ± 4.0b 
PRO 7.9 ± 0.8a 5.9 ± 0.6b 9.2 ± 1.5a 
1 Values are means ± SEM, n = 15 per treatment group. Statistical analysis used a 
complete weighted least square means analysis. Values across rows, not sharing a 
common superscript differ at P < 0.05. 
2  Abbreviations: TG, triacylglycerol; Fch, free cholesterol; CE, cholesterol ester; 
PL, phospholipid; PRO, apolipoprotein. 
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values seen in starch-fed hamsters and the chow-fed hamsters. Differences in the amount 
of each chemical component between fructose-fed and chow-fed hamsters were 
significant (P < 0.001). The concentrations of all components except VLDL protein were 
significantly higher (P < 0.01) in fructose-fed hamsters than those in starch-fed hamsters. 
ApoB100 in VLDL was quantified using a 3–12% gradient SDS-PAGE (Fig. 3.5). The 
amount of apoB100 in VLDL from fructose-fed hamsters was higher than that in VLDL 
from either starch-fed (20.6% higher, P = 0.04) or chow-fed (68.9% higher, P = 0.02). 
Surprisingly, there was no significant difference in the amount of apolipoprotein in LDL 
among the three dietary groups, which averaged 0.23 umol/L in all groups. There was 
similar amount of total apoB in apoB-LP in the plasma from fructose-fed (0.37 umol/L) 
and starch-fed animals (0.36 umol/L), which were significantly higher than that from 
chow-fed animals (0.24 umol/L) (Fig. 3.6). 
 The fractional composition of VLDL from starch-fed hamsters contained 65.4% 
triacylglycerol (TG), 9.3% cholesterol ester (CE), 4.8% free cholesterol (Fch), 11.3% 
phospholipids (PL) and 9.2% protein (PRO). The fractional contribution of TG in the 
fructose-fed group, being 70.5%, was significantly higher than that of starch-fed group. 
VLDL from the fructose-fed group was poorer in CE (6.8% versus 9.3%, P < 0.05) than 
that of the starch-fed group. Starch feeding selectively increased the fractional 
concentration of VLDL cholesterol (Fch + CE), while not stimulating that of TG. Both 
purified carbohydrates elevated VLDL fractional content of cholesterol. VLDL from 
fructose-fed hamsters (5.9%) was significantly poorer in PRO than that from chow-fed 
(7.9%) and starch-fed animals (9.2%). 
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Figure 3.5   Gels from 3–12% gradient SDS-PAGE to quantify hamster plasma 
VLDL apoB.  
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Figure 3.6   apoB concentration in VLDL and LDL particles from 
plasma hamsters fed chow, fructose-enriched and starch-enriched diets. 
Values are means ± SEM, n = 15 per treatment group. Comparisons are 
made among chow, fructose-enriched and starch-enriched diets. Values 
that do not share a letter differ (P < 0.05). 
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Purified carbohydrate feeding significantly increased the concentration of LDL-Fch and 
LDL-PL in hamsters (Table 3.7). Fructose significantly increased LDL-TG 
concentration, producing a 42.5% increase at the expense of a 20% reduction in LDL-CE 
concentration. The concentration of LDL-CE was significantly higher in starch-fed 
hamsters than in either fructose-fed or chow-fed hamsters. However, the amount of 
LDL-PRO in fructose-fed animals was slightly lower than that in the starch-fed and 
chow-fed groups (P = 0.08). The LDL from starch-fed hamsters contained 15.8% TG, 
33.6% CE, 10.8% Fch, 22.6% PL and 22.5% PRO. The fractional contribution of TG in 
the fructose-fed hamsters was higher (P < 0.01) than those of the chow-fed and 
starch-fed hamsters. The ratio of surface (PL + Fch)/ core (TG + CE) lipid is often used 
to indicate the particle size. However, the ratio of surface/ core in fructose-fed animals 
(0.74) was smaller than that of the chow-fed (1.11) and starch-fed hamsters (1.18). 
Again purified carbohydrate significantly increased the fractional content and 
concentration of Fch. LDL from starch-fed group was CE enriched. However, LDL from 
fructose-fed (20.5%) and starch-fed animals (22.5%) were significantly poorer in PRO 
than were those of chow-fed animals (27.1%). 
The concentration and chemical composition of lipoproteins in the HDL fraction of 
plasma from hamsters fed chow, fructose and starch diets are shown in Table 3.8. 
Fructose-fed animals had the highest concentrations, starch-fed the next highest and 
chow-fed hamsters the lowest concentrations of HDL-Fch, HDL-CE, HDL-PL and 
HDL-PRO. Differences between fructose-fed and chow-fed hamsters were significant (P  
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TABLE 3.7 
Concentration and chemical composition of lipoproteins from the 1.006 < d < 1.053 
g/mL density fraction (LDL) separated from plasma of hamsters fed chow, fructose-
enriched and starch-enriched diets1 
Meaurement Chow Fructose-enriched Starch-enriched 
 µg/mL plasma 
TG2 73.74 ± 3.52c 119.07 ± 8.27a 88.02 ± 6.14b 
CE 140.80 ± 3.03b 151.28 ± 9.80b 187.80 ± 8.10a 
Fch 40.70 ± 7.46a 63.40 ± 7.32a 60.40 ± 4.20a 
PL 107.69 ± 1.80b 135.40 ± 13.52a 126.38 ± 8.80a 
PRO 134.59 ± 2.78 120.96 ± 7.44 125.56 ± 6.70 
    
 % Composition 
TG 14.8 ± 0.8b 20.2 ± 1.3a 15.8 ± 0.7b 
CE 28.2 ± 1.2b 25.6 ± 0.7b 33.6 ± 0.6a 
Fch 8.2 ± 0.7b 10.7 ± 0.6a 10.8 ± 2.3a 
PL 21.6 ± 0.8 22.9 ± 0.9 22.6 ± 0.5 
PRO 27.1 ± 3.2a 20.5 ± 2.8b 22.5 ± 1.1b 
1 Values are means ± SEM. n = 15 per treatment group. Statistical analysis used a 
complete weighted least square means analysis. Values across rows, not sharing a 
common superscript, differ at P < 0.05. 
2 Abbreviations were given in legend of Table 3.6. 
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TABLE 3.8 
Concentration and chemical composition of lipoproteins from the 1.053 < d < 1.21 g/mL 
density fraction (HDL) separated from plasma of hamsters fed chow, fructose-enriched 
and starch-enriched diets1 
Measurement Chow Fructose-enriched Starch-enriched 
 µg/mL plasma 
TG2 68.48 ± 10.20b 78.89 ± 3.37a 66.61 ± 4.30b 
Fch 103.01 ± 8.90c 215.83 ± 9.54a 144.23 ± 9.94b 
CE 778.40 ± 48.63c 1399.82 ± 28.77a 990.49 ± 33.23b 
PL 933.68 ± 73.40b 1562.48 ± 50.07a 1089.21 ± 70.10b 
PRO 1089.16 ± 67.49b 1363.64 ± 53.37a 1082.03 ± 46.59b 
 % 
TG 2.3 ± 0.3a 1.7 ± 0.1b 1.9 ± 0.1b 
CE 26.2 ± 0.6b 30.3 ± 0.2a 28.7 ± 0.3b 
Fch 3.5 ± 0.1b 4.7 ± 0.1a 4.2 ± 0.1a 
PL 31.4 ± 0.5b 33.8 ± 0.1a 31.6 ± 0.8b 
PRO 36.6 ± 0.8a 29.5 ± 0.6c 33.6 ± 0.7b 
1 Values are means ± SEM, n = 15 per treatment group. Statistical analysis used a 
complete weighted least square means analysis. Values across rows, not sharing a 
common superscript, differ at P < 0.05. 
2 Abbreviations are given in legend of Table 3.6. 
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< 0.001). However, the concentration in plasma or fractional content of HDL was not 
significantly higher in fructose-fed hamsters than in starch-fed and chow-fed hamsters. 
HDL from starch-fed hamsters contained 1.9% TG, 28.7% CE, 4.2%, Fch 31.6% PL and 
33.6% PRO. HDL from the fructose-fed group was significantly richer in Fch, CE and 
PL than in the chow-fed and starch-fed groups. The fractional contribution of TG in the 
fructose-fed group (1.7%) was lower than that of chow-fed (2.3%; P = 0.03) and starch-
fed (1.9%. P = 0.08) groups. The lower fractional HDL-TG was due to the higher 
fractional HDL-CE in the fructose-fed group. HDL from fructose-fed animals (29.5%) 
was poorer in PRO than that of chow-fed (36.6%, P < 0.01) and starch-fed animals (33.6 
%) (P = 0.04). 
Discussion 
Current trends in health promotion emphasize low-fat, high-carbohydrate diets. 
However, human studies demonstrate that as dietary fat is decreased and carbohydrate is 
increased, the desired lowered LDL cholesterol can be accompanied by 
hypertriglycerolemia (HTG) and low HDL cholesterol. Whether low-fat, 
high-carbohydrate diets offer protection against heart disease is the subject of current 
debate (Connor and Connor, 1997; Katan et al., 1997; Ornish, 1998; Rudel, 1998). 
Recently, research relative to fructose-enriched diets, insulin resistance and 
abnormalities in lipoprotein metabolism has been carried out using the hamster as an 
animal model (Kasim-Karakas et al., 1996; Taghibiglou et al., 2000). These studies have 
shown that HTG and insulin resistance develop when hamsters consume fructose-rich 
diets, however, none of these studies reported detailed lipoprotein profiles of all 
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lipoprotein species. The objective of the present study was to systemically characterize 
all plasma lipoproteins in hamsters fed high-carbohydrate diets specifically. The effect 
of fructose and starch on the physical and biochemical properties of lipoproteins was 
determined. As in previous studies (Kasim-Karakas et al., 1996; Remillard et al., 2001; 
Taghibiglou et al., 2000), the fructose feeding induced increased plasma TG 
concentration in association with hyperinsulinemia and normoglycemia. Taghibiglou et 
al. (2000) used in vivo Triton WR-1339 injection and in vitro experiments with primary 
hamster hepatocytes to demonstrate that both VLDL-TG and VLDL-apoB are over 
produced in hepatocytes from fructose-fed hamsters as compared with chow-fed 
animals. Observed changes in lipoproteins in the present study support their results. 
However, fructose slightly increased the plasma concentration of VLDL-PRO, but 
significantly decreased the fractional VLDL-PRO. The results indicated that in 
fructose-fed hamsters, VLDL particle number tended to be slightly higher, but that each 
VLDL particle contained a greater fraction of lipid, and was significantly larger as 
compared with those from chow-fed or starch-fed hamsters. The results from retention 
time and diameter determination were consistent. Circulating particle diameter is 
determined by initial particle diameter at assembly and subsequent metabolic effects. For 
example, the particle diameter could decrease due to the TG lipolysis mediated by 
lipoprotein lipase.  
The two major factors responsible for maintenance of the concentrations of VLDL-
TG and VLDL-PL are synthesis and secretion of TG and PL by liver and removal of TG 
by extrahepatic tissues. VLDL-TG synthesis is derived from three sources (Karpe, 
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1997), plasma NEFA, the main substrate for hepatic TG synthesis; hepatic uptake of 
partly lipolyzed chylomicron and VLDL remnants; and de novo synthesis of TG from 
carbohydrate. In the present study, fructose significantly elevated plasma NEFA and 
insulin concentrations indicating that fructose feeding caused insulin resistance. In 
insulin resistance, increased efflux of NEFA from adipose tissue and impaired 
insulin-mediated skeletal muscle uptake of NEFA increase hepatic NEFA concentrations 
(Ginsberg and Huang, 2000). NEFA are the principal substrate for hepatic TG, PL 
synthesis, and subsequently, the increased production of TG and PL, and the 
overproduction of TG and PL that could result in abnormal assembly in VLDL particle.  
The liver, the principal lipogenic organ, is responsible for the conversion of excess 
dietary carbohydrates to TG. Feeding a high-carbohydrate diet induces the synthesis of 
glycolytic and lipogenic enzymes including acetyl-CoA carboxylase, fatty acid synthase, 
stearoyl-CoA desaturase, glycerol-3-phosphate acyltransferase, ATP citrate lyase, malic 
enzyme, glucose-6-phosphate dehydrogenase, and pyruvate kinase (Granner and Pilkis, 
1990; Ntambi et al., 1988; Sul and Wang, 1998). The coordinated induction of these 
enzymes is due to sterol regulatory element binding protein (SREBP)-stimulated gene 
transcription (Horton et al., 1998b; Shimano et al., 1996; Shimano et al., 1999; 
Shimomura et al., 1998). The induction of lipogenic gene transcription, as a result, 
increases fatty acid and TG concentration in the liver. The excess TG is incorporated and 
secreted by the liver as VLDL-TG.  
SREBPs are transcription factors that belong to helix-loop-helix leucine zipper 
family and regulate enzymes responsible for the uptake and synthesis of cholesterol, 
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fatty acid synthesis and desaturation, TG and phospholipid synthesis, and glucose 
metabolism (Brown and Goldstein, 1997; Edwards et al., 2000; Foretz et al., 1999a; 
Horton and Shimomura, 1999). The SREBPs are synthesized as precursors and bound to 
the ER prior to activation. When activated, SREBPs are released from the membrane and 
translocate the nucleus as a mature protein following a sequential proteolytic cleavage 
process (Brown and Goldstein, 1997). Two genes, SREBP-1 and SREBP-2, encode three 
SREBP isoforms, SREBP-1a, -1c and –2, each with a molecular mass of 125 KD 
(Brown and Goldstein, 1997). SREBP-1a is a potent activator of all SREBP-responsive 
genes including those that mediate the synthesis of cholesterol, fatty acids and TG. 
SREBP-1c, a predominant SREBP-1 isoform in the liver, preferentially enhances 
transcription of genes required for fatty acid but not cholesterol synthesis (Shimano et 
al., 1999; Shimomura et al., 1998). Changes in hepatic mature SREBP-1c protein levels 
were found to parallel those of mRNAs for lipogenic genes in the liver using a dietary 
manipulation (Horton et al., 1998a). Moreover, targeted disruption of SREBP showed 
that SREBP-1 is crucial for the carbohydrate mediated stimulation of lipogenic genes in 
mice (Shimano et al., 1999). SREBP-2 is relatively selective in transcriptionally 
activating cholesterol biosynthesis (Shimano et al., 1997). Studies showed that the 
relative expression of SREBP-1a, -1c and –2 in vivo is complex and can be affected by 
the nutritional and hormonal status (Flier and Hollenberg, 1999; Foretz et al., 1999a). 
These studies linked lipid and carbohydrate metabolism via insulin action and SREBPs. 
The content of SREBPs in livers from obese ob/ob mice and transgenic aP2-SREBP-
1c436 (aP2-SREBP-1c) mice that overexpress nuclear SREBP-1c only in adipose tissue 
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was investigated (Shimomura et al., 1999). Both lines of mice develop hyperinsulinemia, 
hyperglycemia, and hepatic steatosis, but aP2-SREBP-1c mice exhibit a syndrome that 
resembles congenital generalized lipodystrophy in humans. Nuclear SREBP-1c protein 
levels were significantly elevated in livers from ob/ob and aP2-SREBP-1c mice 
compared with wild-type mice. Increased nuclear SREBP-1c protein was associated with 
elevated mRNA levels for known SREBP target genes involved in fatty acid 
biosynthesis, which led to significantly higher rates of hepatic fatty acid synthesis in 
vivo. Foretz et al. (1999a; 1999b) reported that treatment of isolated hepatocytes with 
insulin both prevented the decline in SREBP-1 levels and also introduced the genes such 
as acetyl-CoA carboxylase, fatty acid synthase, glucokinase and pyruvate kinase. 
Addition of a dominant negative form of SREBP-1c blocked the stimulatory effect of 
insulin on these target genes.  Expression of a dominant positive SREBP –1c stimulated 
the expression of these same insulin-activated target genes in the absence of insulin 
(Foretz et al., 1999a). These results indicate that insulin stimulates the transcription of 
SREBP-1c and that the mature protein, together with a signal derived from glucose, 
result in enhanced transcription of gene involved in both lipogenesis and glucose 
metabolism.  In this present study, fructose feeding induced insulin resistance, thus 
elevated insulin levels could increase the transcription of SREBP-1c and SREBP-1c-
dependent genes, resulting in increased hepatic synthesis of fatty acids and TG. Starch 
increased plasma cholesterol level rather than inducing insulin resistance and elevating 
TG level. Starch feeding appears to induce a different response and may be due to the 
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effect of starch on SREBP-2. However, the precise mechanism for this action remains 
unknown. 
Despite overproduction of apoB in liver, most apoB will be degraded through three 
mechanisms (Fisher et al., 2001). Newly synthesized apoB in endoplasmic reticulum 
(ER) is initially complexed with small amounts of lipid that are shuttled by microsomal 
triglyceride transfer lipoprotein (MTP). The apoB can be degraded via ER-associated 
degradation because of lipid deprivation or MTP deficiency. Assembly of VLDL 
depends on the relative availability of all lipid-cholesterol, PL, TG and CE (Davis, 
1999). Davis and Boogaerts (1982) suggested the relative availability of CE to TG 
determines the relative composition of hydrophobic lipid in the core of newly secreted 
VLDL. In addition, the availability of free cholesterol may act as a regulator of the 
assembly of VLDL. These findings may explain why overproduction of TG, PL and 
apoB but deficiency of cholesterol resulted in formation of TG-rich large diameter 
VLDL particles instead of overproduction of VLDL particles. The results also indicate 
that VLDL assembly can be influenced by diet.  
Plasma LDL is mainly derived from the plasma VLDL-LDL delipidation cascade 
(Eisenberg et al., 1973). The present study showed that there was no difference in 
LDL-PRO mass in plasma from the fructose-fed, starch-fed and chow-fed animals. This 
suggested that high-carbohydrate diets did not increase LDL particle number. When 
estrogen was used to treat post-menopausal females, the amount of large diameter VLDL 
increased in subjects with high–normal plasma TG concentration (Walsh et al., 1991). 
Large VLDL was postulated to not form LDL to a significant degree (Packard et al., 
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1984; Stalenhoef et al., 1984). The studies of these researchers may help to explain the 
increased VLDL particle diameter and number, in the absence of a change in average 
LDL particle number in hamsters fed with high-carbohydrate diets in the present study. 
Characteristic abnormalities in the lipid profile in type-2 diabetes include increased 
concentrations of small, dense LDL (Feingold et al., 1993; Stewart et al., 1993). The 
present results showed that fructose feeding also induced the formation of small, dense 
LDL. However, these LDL were relatively rich in TG and poor in CE. In contrast, 
increased LDL lipoprotein mass in starch-fed hamsters were enriched in CE. In these 
short-term studies it is not possible to determine the atherogenicity of large CE-rich LDL 
associated with starch feeding relative to that of small TG-rich LDL associated with 
fructose feeding.  
HDL play an important role in the prevention and treatment of ASCVD. 
Epidemiological studies and clinical trials demonstrated that elevated HDL-C has a 
direct anti-atherosclerotic potential, which is not secondary to its relation to other 
coronary risk factors (Sacks, 2002). HDL can impede the oxidation of LDL and transfer 
cholesterol from macrophage back to the plasma. Low plasma concentrations of HDL 
represent the common abnormality in the metabolic syndrome. Elevated concentrations 
of TG-rich lipoproteins lower HDL concentrations by promoting exchanges of 
cholesterol from HDL to VLDL via CETP and catabolizing TG-rich HDL (Bruce et al., 
1998; Ginsberg, 2000). Insulin resistance with ASCVD more commonly has the 
combination of elevated TG and low HDL than elevated total and LDL-C 
concentrations. Functional defects in HDL may also contribute to ASCVD. In diabetic 
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patients, HDL does not prevent LDL oxidation as well as it does in non-diabetic patients 
(Gowri et al., 1999). However, in the fructose-fed hamster model used in the present 
study, several HDL characteristics were different from those observed in human studies. 
First, hamsters fed fructose- or starch-containing diets had significantly higher 
concentrations, not lower concentrations, of plasma HDL-C than did chow-fed hamsters. 
This result was also observed by Remillard et al. (2001). Also, the concentration and 
fraction of HDL-C were significantly higher in the fructose-fed hamsters than in starch-
fed hamsters. Second, fructose feeding significantly increased all HDL lipid 
concentrations, but reduced the relative amount of HDL-TG. Third, fructose tended to 
increase the plasma concentration of HDL-PRO; however, the percentage of HDL-PRO 
was significantly lower when compared with the plasma concentration in either 
chow-fed or starch-fed animals in accordance with its observed large diameter. These 
characteristics suggested that fructose diet resulted in the formation of lipid-rich HDL. 
Increased HDL mass in both purified carbohydrate-fed groups indicates that hamsters 
have a different response to simple carbohydrates than other model species. The 
mechanism for the response is under investigation. 
The following factors are thought to affect HDL cholesterol or particle number. First, 
apoAI is the major apolipoprotein component, which indicates the concentration of 
HDL-C or particle number. The composition and gel results showed that apoAI 
increased in fructose- and starch-fed hamsters. Mooradian et al. (1997) reported that 
plasma apoA1 and hepatic apoA1 mRNA concentrations in young rats or aged rats fed 
either a 60% fructose diet or a 60% glucose diet were significantly higher than in rats fed 
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rat chow. These investigators suggested that apoA1 expression in rats is modulated by 
factors related to the nature of dietary carbohydrates rather than insulin resistance being 
associated with feeding a high-fructose diet. Second, transgenic overexpression of 
LCAT in mice substantially increased HDL cholesterol and increased the plasma 
concentration of CE-rich, large HDL to an even greater extent (Francone et al., 1997; 
Vaisman et al., 1995). apoAI activates LCAT (Francone et al., 1997), thus, more apoAI 
means greater LCAT activation. Third, transfer of CE from HDL to apoB-LP in 
exchange for TG by CETP is the major pathway by which HDL cholesterol is returned 
to liver in humans (Tall, 1990). Remillard et al. (2001) reported a significant increase in 
the concentration and activity of CETP, both in plasma and adipose tissue of fructose-
fed hamsters. In hamsters, adipose tissue and muscle are the major sources of CETP 
(Jiang et al., 1991), and lipoprotein composition analysis (Goulinet and Chapman, 1993) 
also demonstrated that the hamster is partially deficient in neutral lipid (CE, TG) transfer 
activity. Thus, fructose-fed hamsters produced large CE-rich HDL, increased HDL-C 
and particle number rather than lowering HDL-C. Third, both cellular protein ABCA1, 
which facilitates cholesterol and PL transport between HDL particles and peripheral 
cells, and SR-BI, which facilitates the uptake of HDL-CE by liver, can affect HDL-C 
and particle number. Species differences or specific HDL metabolic pathways are also 
likely to contribute to the different responses. Whether the increased HDL plays the 
protective role for ASCVD is not clear. HDL isolated from subjects with non-insulin-
dependent diabetes mellitus exhibited a decreased capacity to induce cholesterol efflux 
(Gowri et al., 1999). The composition and protective effects of HDL2, but not of HDL3, 
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differed significantly between control and diabetic subjects. HDL2 from diabetics, which 
were TG-enriched and cholesterol depleted compared with those from control subjects, 
were less able to protect LDL from oxidation and oxidation induced apoB100 
fragmentation. In the present study, HDL types were not separated, nor was HDL 
function measured. It is not clear whether the hamsters fed a fructose-rich diet had HDL2 
enriched with TG and depleted of cholesterol while total HDL were enriched with 
cholesterol and depleted of TG. 
Plasma lipoprotein and lipid metabolism are important in understanding the 
mechanism of ASCVD. The metabolism of plasma lipoproteins is highly interrelated, 
and it is critical to consider the entire lipoprotein and lipid profiles, rather than to focus 
on one or two lipoproteins. It is concluded that a high-carbohydrate diet significantly 
changes the entire lipoprotein and lipid profiles, as well as the physical properties of 
plasma lipoprotein particles. Further studies will be needed to define the role of HDL 
(type and function) and the mechanism of induction of a high HDL concentration in 
plasma. Further investigations will provide new insight into lipoprotein metabolism and 
the effect of high-carbohydrate diets on ASCVD in hamsters. 
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CHAPTER IV 
DIETARY EFFECTS ON THE ASSEMBLY AND SECRETION OF 
apoB-CONTAINING LIPOPROTEINS IN HAMSTERS 
Introduction 
apoB-containing lipoproteins (apoB-LP) including chylomicrons, very low-density 
lipoproteins (VLDL), intermediate-density lipoproteins (IDL) and low-density 
lipoproteins (LDL) serve to deliver essential lipid and energy through out the body. The 
assembly of apoB-LP occurs in liver, small intestine, human heart and mammalian yolk-
sac endoderm. (Young et al., 1995; Farese et al., 1996; Nielsen et al., 1998). Pathologies 
of abetalipoproteinaemia (Sharp et al., 1993) and familial hypobetalipoproteinaemia 
(Innerarity et al., 1990) are linked to genetic dysfunction in apoB-LP. Both VLDL and 
chylomicrons are metabolized to their remnants (IDL, LDL and chylomicron remnants) 
Convincing evidence indicates that apoB-LP are a major determinant of atherosclerotic 
cardiovascular disease (ASCVD) risk (Young, 1990; Packard and Shepherd, 1997). 
Specific changes in the physical properties (mass, composition, size, etc.) of apoB-LP 
constitute a metabolic profile that is closely associated with the incidence of ASCVD. 
For example, larger VLDL are cleared more rapidly, and produce fewer LDL than do 
smaller VLDL (Packard and Shepherd, 1997). Small dense LDL are more susceptible to 
oxidative damage than are large, less dense LDL (Chait et al., 1993). Intracellular and 
probably plasma membrane-associated processes control the physical properties of 
circulating apoB-LP, which define the features of apoB-LP for lipolytic and remodeling 
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proteins. Diets influence the physical properties of circulating apoB-LP, thus the dietary 
effect on apoB-LP is probably exerted during assembly and secretion processes. 
The assembly of apoB-LP is a complex, multi-step process that occurs within the 
rough and smooth endoplasmic reticulum (ER) and subsequent compartments of the 
secretory pathway in the Golgi complex in hepatocytes. The process of particle assembly 
can be divided into two general steps, precursor formation and precursor joining 
(Alexander et al., 1976; Boren et al., 1994; Hamilton et al., 1998). Within the first step, 
two precursors are formed. First, a lipid-poor apoB-containing apoB-LP precursor is 
assembled within the rough ER, and a lipid-rich apoB-deficient apoB-LP precursor (a 
VLDL-sized lipid droplet) forms within the smooth ER. During the second step, these 
two precursors combine by as yet undescribed processes to form nascent apoB-LP 
particles. Some molecular details for the formation of the apoB-containing apoB-LP 
precursor are known (Boren et al., 1992; Rustaeus et al., 1995; Hamilton et al., 1998; 
Rustaeus et al., 1998). For example, apoB destined for assembly can translocate across 
the ER membrane to generate a transmembrane apoB in which the bulk of the protein 
mass is situated on the cytosolic side of the ER membrane (Rustaeus et al., 1999). If 
lipid becomes available, transmembrane apoB can undergo a process of post-
translational lipid-facilitated translocation into the lumen of the ER (Sakata et al., 1993). 
Little is known about the processes involved in formation of the apoB-deficient lipid 
core, but these processes appear to depend on microsomal triacylglycerol transfer protein 
(MTP). However, combination of the two precursors to form mature nascent apoB-LP 
may not depend on MTP (Gordon et al., 1996). 
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It is known that the consumption of a high-carbohydrate diet can induce the 
formation of small dense LDL in the bloodstream. small dense LDL are thought to be 
more atherogenic than their larger counterparts (Dreon et al., 1994). In contrast, 
consumption of a high-fat diet can cause large, less dense LDL to appear in the blood 
(Rudel, unpublished data). It is not known whether high-carbohydrate-induced small 
dense LDL are more atherogenic than high-fat-induced large, less dense LDL in humans. 
It is also not clear whether changes in the physical properties of circulating lipoproteins 
stem solely from pathological intravascular metabolism or whether they result from 
changes to the physical properties of apoB-LP during assembly and prior to secretion 
into systemic circulation. Most studies of apoB-LP assembly have been performed in 
vitro in cell lines (e.g., HepG2 and McA-RH 7777 cells) or primary hepatocytes (Boren 
et al., 1992; Cianflone et al., 1992; Hamilton et al., 1998; Taghibiglou et al., 2000b). 
Studies in vitro showed that some defects in HepG2 cells resulted in defective 
triacylglycerol (TG) mobilization (Wu et al., 1996). Human studies in vivo (Parks et al., 
1999) showed that a high-carbohydrate diet could alter rates of VLDL secretion, e.g., a 
high-carbohydrate diet induced VLDL-TG and VLDL-apoB overproduction and 
secretion. However, because of complicated effects of human multiple genes and 
environmental factors (e.g. diet, exercise), It is difficult to define the impact of physical 
properties of metabolic origin of apoB-LP on that of circulating apoB-LP in human 
studies. Using animal models, an investigator can easily define some factors (e.g. genes) 
and keep experimental conditions as similar as possible. Recently, (Taghibiglou et al., 
2000a) introduced a fructose-fed hamster model for VLDL study. Studies with this 
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model showed that fructose feeding increased the concentration of VLDL and their 
components, enhanced TG percentage, increased VLDL particle size and small dense 
LDL (see Chapter III). That work demonstrated that high-carbohydrate diets changed the 
physical and biochemical features of circulating lipoproteins in Golden Syrian hamsters. 
However, little is known about how a high-carbohydrate diet impacts the size and 
composition of apoB-LP assembly intermediate particles; these are features that could 
influence the subsequent metabolism of nascent particles and their atherogenic potential. 
In hamsters, lipemia and insulin resistance are directly related to the content of fructose 
in the diet. The present study assessed whether nascent apoB-LP structure is altered by 
high-carbohydrate diets. The physical and biochemical features of nascent apoB-LP and 
apoB-LP assembly intermediates were characterized in livers from hamsters fed diets 
differing in carbohydrate composition.  
Materials and Methods 
Animals 
Male golden Syrian hamsters from Charles Rivers laboratory (Wilmington, MA), 
aged 6 wk and weighing 90 g were housed in pairs at 22°C with a 12 h light/dark cycle 
(lights were on 7 a.m. to 7 p.m.) and had free access to water and food over an 
adaptation period of 2 wk. The average weight of the animals at this time was 110 g, and 
they were randomly assigned into 3 groups of 40 hamsters each and were fed either a 
closed formula cereal-based Harlan Teklad rodent chow (#W-8604, Harlan Teklad, 
Madison, WI), a 60% fructose-rich diet (#161506, Dyets Inc, Bethlehem, PA) or a 60% 
corn starch-rich diet (#161511, Dyets Inc, Bethlehem, PA). The animals had free access 
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to the experimental diets for 2 wk. At this time, 10 animals from each group were 
assigned to the secretion study, and 30 hamsters were assigned to the assembly study. 
Food intakes were monitored every day, and body weight was measured twice a week. 
All experiments were carried out on animals fasted for 16 h. All animals were cared for 
as outlined in “Guide for the Care and Use of Laboratory Animals,” prepared by the 
National Academy of Sciences and published by the National Institutes of Health, 
Bethesda, MD (NIH publication No. 86-23, revised 1985). All experimental procedures 
were approved by the University Laboratory Animal Care Committee at Texas A& M 
University. 
Triton WR-1339 injection and isolation of nascent VLDL 
After 2 wk on the diets, blood for measurement of plasma TG was obtained from the 
periorbital venous sinus of hamsters under isoflurane (4% in 100% oxygen) anesthesia 
and then were injected Triton WR-1339 (20% solution in saline) through cardiac 
puncture at a dose of 600 mg/kg body weight. Sixty minutes after Triton injection, the 
animals were anesthetized and blood was collected via cardiac puncture into tubes that 
contained sodium azide (0.01%), Na2-EDTA (0.12%), pencillin (10,000 
U/mL)/streptomycin (10 mg/mL)/neomycin (10 mg/mL) and aprotinin (0.01 TIU/mL). 
Within 2 h of blood collection, plasma was separated by Sorvall TR 6000B centrifuge 
(Sorvall-Dupont, Wilmington, DE) at 2500 rpm, for 20 min at 4°C, and a mixture of 
reduced glutathione (0.5 mg/mL plasma), Leupeptin (0.5 µg/mL plasma) and 
benzamidine (0.16 mg/mL plasma) was added to preserve the native lipoprotein 
structure. VLDL was isolated from 1 mL plasma at d < 1.006 g/mL by aspiration with a 
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narrow-bore pipet following 18 h centrifugation at 40,000 rpm in a TFT 50.3 rotor at 
14°C within a Beckman L8-70M (Beckman Coulter, Sunnyvale, CA) ultracentrifuge. 
Triton WR-1339 is an alkaline polyether anionic detergent that blocks the removal of 
VLDL from plasma (Otway and Robinson, 1967). The hepatic secretion rate of VLDL 
fraction is proportional to the rate of increase in plasma concentration of VLDL 
component over time (Kazumi et al., 1986). The secretion rate of VLDL, in µg/100 g 
body weight/min, from liver into plasma was calculated using the following formula:  
VLDL-X secretion rate  = (VLDL-X60 – VLDL-X0)/60 × V × W/100 
where VLDL-X0 is plasma VLDL component concentration (µg/mL plasma) before 
Triton administration, VLDL-X60 is plasma VLDL component concentration (µg/mL 
plasma) 60 min after Triton injection, V is plasma volume (mL) and W is body weight. 
Plasma volume was determined as 3.86 mL/100 g body weight (Holt and Dominguez, 
1980). Plasma concentrations of VLDL components were determined colorimetrically as 
described below. Triton injection enhances the secretion of VLDL and blocks the 
removal of VLDL, resulting in nascent VLDL accumulation in plasma. Thus, VLDL 
isolated from hamster plasma after Triton injection was assumed to represent nascent or 
Golgi VLDL, so called "nascent VLDL" or "nascent apoB-LP."  
Isolation of rough endoplasmic reticulum  
As described above, after the 2-wk feeding period, the hamsters were anesthetized 
with isoflurane and exsanguinated by cardiac puncture. Livers were removed 
immediately and rinsed in ice-cold saline. Rough ER was isolated by calcium 
precipitation (Hamilton et al., 1999). Livers were minced finely and 10–12 g were 
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suspended in 2 mL/g of ice-cold 140 mM KCl and homogenized by using a Polytron 
PT3100 (KINEMATICA AG, Lucern, Switzerland) at setting 10 for 30 sec. The 
homogenized liver was divided equally into two 50-mL Sorvall centrifuge tubes and 
mixed with additional ice-cold 140 mM KCl to a volume of 40 mL. The homogenate 
was centrifuged in a Sorvall SS-34 rotor (Sorvall-Dupont, Wilmington, DE) at 8,000 
rpm for 10 min at 4°C. After centrifugation, air bubbles and floating fat were removed 
by water aspiration, the supernatant solution was decanted into another centrifuge tube 
and the volume was adjusted to 40 mL with 140 mM KCl. This procedure was repeated 
until there was no visible floating fat. The final supernatant portion from each group 
livers was titrated with ice-cold 8 mM CaCl2 at 20–25 mL/min. Rough ER pellets were 
obtained by centrifugation in a SS-34 Sorvall rotor at 8,000 rpm for 10 min at 4°C. To 
remove any lipid droplets, rough ER pellets were washed with KCl via resuspention of 
ER pellets in KCl (final concentration of 0.5 M) and centrifugating for 62 min at 34,000 
rpm in a TFT 50.3 rotor at 21 C° (Kulinski et al., 2002). 
Isolation of apoB-containing lipoprotein assembly intermediates from rough ER 
Rough ER lumen contents were separated from the membrane of the rough ER after 
membrane rupture with 100 mM Na2CO3, pH 11.2 and centrifugation for 18 h at 35,000 
rpm in a TFT50.3 rotor at 4 C°. apoB-containing lipoprotein assembly intermediate 
particles were recovered from the lumen contents. After centrifugation, the top layer was 
cut with a tube cutter to collect the top fraction, and the bottom fraction (floating yellow 
cloud next to pellet) was drawn up with pasteur pipette. The top layer fraction contained 
putative apoB-deficient assembly intermediates (second-step particle), while the bottom 
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fraction contained putative apoB-containing assembly intermediates (first-step particle). 
Both fractions were further purified by centrifugation at 30,000 rpm in a TFT 50.3 rotor 
at 4°C for 18 h. For apoB-deficient assembly intermediates, overlayed 4 mL/each tube 
0.9% saline slowly without mixing to the top layer fraction (2.5 mL/each tube) prior to 
centrifugation. For apoB-containing assembly intermediates, overlayed 4 mL/each tube 
with1.053 g/mL NaCl/ NaBr density solution, slowly without mixing to the bottom 
fraction followed by adjusting the density of the bottom fraction with solid dessicated 
KBr to 1.3 g/mL. After ultracentrifugation, both intermediate particles were collected 
and dialyzed against saline with 0.01% EDTA for 24 h at 4°C. 
Electron microscopy 
To identify rough ER and assess homogeneity, rough ER pellets were fixed, 
dehydrated, embedded and stained as described by Hamilton et al. (1999) Pieces of 
pellets were punched with a pasteur pipette into fresh fixative (2 % glutaraldehyde–1% 
paraformaldehyde in 0.1 M sodium cacodylate buffer, pH 7.4) and fixed for 24 h. After 
the fixed samples were washed with buffer, they were transferred into 2% osmium 
tetroxide overnight, then dehydrated in acetone and embedded in Epon. The sample 
sections were stained with 0.8% lead citrate for 5 min and examined with a Siemens 101 
electron microscope (Siemens/CTI Corp., Knoxville, TN).  
Analysis of biochemical markers 
To assess purity of the ER, biochemical markers for rough ER and other membranes 
were assayed in whole liver homogenate and in the rough ER fraction. The activities of 
glucose-6-phosphatase (deDuve et al., 1955) and diacylglycerol acyltransferase (DGAT), 
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a major enzyme in the synthesis of TG (Ozasa et al., 1989) were measured as markers of 
ER. 3-hydroxy-3-methylglutaryl co-enzyme A (HMG-CoA) reductase , a rate-limiting 
enzyme of cholesterol biosynthesis, was determined as a smooth ER marker (Erickson et 
al., 1990). RNA was extracted from rough ER (Quantum Prep Aquapure RNA Isolation 
Kit Cat # 732-6370; Bio-Rad Laboratories, Hercules CA) and RNA concentration was 
estimated by measuring absorbance at 260 nm. To assess contamination of the ER by 
other membranes, succinate INT reductase was measured as a mitochondrial marker 
(Pennington, 1961), 5'-nucleotidase as a plasma membrane marker (Emmelot et al. 
(1964), acid phosphatase as a marker enzyme for lysozyme (deDuve et al., 1955) and 
GM130 as a marker of the Golgi complex (Nakamura et al. (1997), Golgi matrix protein 
of 130 KDa, is a protein isolated from Triton-insoluble Golgi matrix and associated with 
the cis-compartment. GM130 functions as a structural element of the Golgi complex. To 
measure GM130, proteins were separated by SDS-PAGE following in-gel Western 
blotting. Liver homogenates (40 µg) and rough ER pellets (40 µg) were fractioned by 
SDS-PAGE on a 4–15% gel. Following electrophoresis, the gels were washed with 50% 
isopropanol and ultrapure water, and blocked in Odyssey Blocking Buffer (LI-COR, 
Inc., Lincoln, NE). IRDye700™-labeled goat anti-mouse secondary antibody (LI-COR, 
Inc., Lincoln, NE) was used to detect mouse anti-rat primary antibody (BD Biosciences, 
San Diego, CA). Bands were visualized by an Odyssey imager and calculations were 
made using Odyssey software (LI-COR, Inc., Lincoln, NE). 
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Size analysis of nascent VLDL and apoB-containing lipoprotein assembly 
intermediate particles 
The particle diameters of nascent VLDL and apoB-containing lipoprotein assembly 
intermediates were measured by dynamic laser light-scattering analysis using a 
Microtrac series 250 ultrafine particle analyzer with a laser probe tip (UPA-250; 
Microtrac, Clearwater, FL), and Microtrac software (Honeywell, Inc., Ft. Washington, 
PA) (Walzem et al., 1994; Mack et al., 1994). Following ultracentrifugation, the 
centrifuge tubes containing the samples were removed from the rotor and uncapped. The 
laser probe was gently placed on the top layer of supernatant portion. It is critical not to 
mix the sample layer or prevent air bubbles at the probe liquid interface. Due to the low 
lipoprotein content of some samples, a measurement time of 540 sec was used for all 
samples. The results of primary data collection can be expressed in particle number, 
particle area or particle volume in order to adequately describe different aspects of the 
same particle population with respect to their colloidal properties (Walzem, 1996). 
Particle number distribution describes the frequency distribution of particles of the 
specified diameter. Particle volume distribution describes the distribution of total particle 
volume among particles of different diameter. Particle volume distribution is sensitive to 
the presence of large diameter particles because the volume of a sphere increases as a 
cubic function of particle radius. In this chapter, particle number will be used to describe 
the particle diameter in order to compare particle diameter from different sources. Raw 
particle diameter distributions were converted to area, number and volume population 
percentiles, which were used to calculate median particle diameter. 
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Composition analysis of nascent VLDL and apoB-containing lipoprotein assembly 
intermediate particles 
Nascent VLDL and dialyzed apoB-containing lipoprotein assembly intermediate 
particles were used in composition studies. Protein (PRO) was measured by a modified 
Lowry method (Lowry et al., 1951) using bovine serum albumin as the standard. 
Triacylglycerol concentration was determined enzymatically using a kit from Sigma 
(Procedure No. 339, Sigma Chemical Co., St. Louis, MO). Total cholesterol (Tch), free 
cholesterol (Fch) and phospholipids (PL) were measured by use of enzymatic kits 
(Cholesterol CII Cat. No. 276-64909; Free Cholesterol C Cat. No. 274-47109; 
Phospholipids B Code No. 990-54009, WAKO, Richmond, VA). Esterified cholesterol 
(CE) was calculated by multiplying the difference between Tch and Fch by 1.67 
(Chapman et al., 1981). The assay for total cholesterol or free cholesterol depends on the 
1) hydrolysis of CE, which releases Fch, 2) the oxidation of Fch in a reaction that 
generates hydrogen peroxide and 3) the colorimetric measurement of the hydrogen 
peroxide produced (Richmond, 1973). In the assay of phospholipids, choline-containing 
phospholipids are hydrolyzed by phopholipase D to free choline, which is subsequently 
oxidized with the production of hydrogen peroxide, which is measured colorimetrically 
(Takayama et al., 1977). Non-esterified fatty acid (NEFA) of apoB-LP assembly 
intermediate particles was determined by a spectrophotometric method using kits (NEFA 
C Code No. 994-75409, WAKO, Richmond, VA). This method depends on the acylation 
of coenzyme A (CoA) by the fatty acids in the presence of acyl-CoA synthetase. The 
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acyl-CoA produced is oxidized with generation of hydrogen peroxide and the hydrogen 
peroxide is measured colorimetrically (Elphick, 1968). 
Electrophoretic analyses of apolipoproteins 
Isolation of apoB. Apolipoprotein B in isolated assembly intermediates was 
identified by SDS-PAGE and subsequent in-gel Western blotting. The protein 
concentration of assembly intermediates was determined by a modified Lowry assay 
(Lowry et al., 1951). Sample volumes containing 50-200 µg protein were combined with 
60 µg apoferritin carrier protein prior to delipidation to insure quantitative 
apolipoprotein recovery (Kotite et al., 1995). Samples were delipidated overnight at –
20°C after mixing 400–1200 µL sample with 10 volumes of ice-cold ethanol-diethyl 
ether in a 15-mL conical, glass-stoppered tube. The delipidated mixture was centrifuged 
for 25 min at 1250 rpm in a Sorvall TR 6000B centrifuge to facilitate removal of the 
organic phase. The pellet was extracted twice with 4 mL cold anhydrous diethyl ether. 
The resultant pellet was dissolved in 50–100 µL sample buffer containing 3% SDS, 
1.5% dithiothreitol, and 1% mercaptoacetic acid. Excess ether was removed under a 
gentle stream of nitrogen, and the dissolved apolipoproteins were denatured at 100°C for 
3 min prior to application to the SDS–PAGE gel.  
Apolipoproteins were separated using the SDS-PAGE gradient gel described by 
Kotite et al. (1995) with some modifications. The 3–12% and 3–20% gradient 
polyacrylamide gels were cast using a two-chamber gradient mixer (Bio-Rad 
Laboratories, Hercules, CA). A 3–12% gradient polyacrylamide gel was used to identify 
and quantify apoB, while a 3–20% gradient polyacrylamide gel was used to observe the 
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apolipoprotein profile in the assembly intermediate particles. Apolipoprotein separation 
was effected using a Mini-PROTEIN II Vertical gel apparatus (Bio-Rad Laboratories 
Inc., Hercules, CA) (Laemmli, 1970) containing two minigels for each separation. After 
loading 50 µL delipidated VLDL or apoB100 standard in each well, a Bio-Rad 
PowerPAC 300 (Bio-Rad, Laboratories Inc, Hercules, CA) was used to apply 76V to the 
gels for 30 min, followed by 96V until the dye front was 1 mm from the bottom of the 
gel. Narrow-cut human LDL served as the source for the apoB100 used as the reference 
protein within the standard curves.  
Identification of apoB in assembly intermediate particles. In-gel Western blotting 
was employed in this study to identify apoB in assembly intermediate particles. Aliquots 
of 0.3-2 ug of sample (first-step particle, second-step particle and plasma VLDL) and 
apoB100 standard proteins were subjected to SDS-PAGE electrophoresis. Following 
electrophoresis, one of the gels was washed with 50% isopropanol and ultrapure water, 
and subsequently blocked in Odyssey Blocking Buffer (LI-COR, Inc., Lincoln, NE) 
After phosphate buffer saline (PBS) (0.1% Tween-20 in PBS) washing, the gel was 
incubated for 1 h with a rabbit antiserum specific for hamster apoB (Lampire Biological 
Laboratories, Pipersville, PA) Following PBS washing, the gel was incubated with an 
IRDye700™-labeled goat anti-rabbit secondary antibody (LI-COR, Inc., Lincoln, NE). 
After PBS washing, the gel was screened using an Odyssey Infrared Imaging System 
(LI-COR, Inc., Lincoln, NE) equipped with an Odyssey Software Package. 
Quantification of apoB. apoB was quantitatively characterized by analytical 
SDS-PAGE with Coomassie brilliant blue staining (Kotite et al., 1995). Aliquots of 30-
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40 ug of sample (first-step particle, second-step particle and plasma VLDL) and 
apoB100 standard proteins were subjected to SDS-PAGE electrophoresis. Following 
electrophoresis, gels were stained with 0.15% Coomassie brilliant blue in staining 
solution for 15 min at 60°C, and then destained at 60°C in a destaining solution until 
backgrounds were clear. The gels were scanned using an Odyssey Infrared Imaging 
System (LI-COR, Inc. Lincoln, NE) equipped with an Odyssey Software Package to 
automatically integrate the volume of stained apolipoprotein bands. The standard curve 
for apoB was constructed by relating the intensity of dye uptake of each band to its 
known mass. The line of fit was evaluated (Kotite et al., 1995) at least squares for the 
power function y = axb. The concentrations of apoB in assembly intermediate particles 
were calculated from the regression equation relating the absorbance of apoB standard 
bands to the amount of apoB standard applied to the gels. 
Statistical analysis 
The results are presented as the mean ± SEM unless otherwise noted. Comparisons 
among three groups were performed using analysis of variance (ANOVA). Difference in 
mean values was tested by a least-squares means procedure. P values less than 0.05 was 
considered statistically significant. All analyses were performed using the statistical 
analysis system procedures (SAS Institute, Inc., Cary, NC). 
Results 
Morphology of isolated rough endoplasmic reticulum 
The electron micrograph of the rough ER isolated from hamster liver is shown in 
Figure. 4.1. Rough ER membrane consisted of many short strips of curved or parallel  
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Figure 4.1   Electron micrograph of the rough endoplasmic reticulum (ER) isolated 
from hamster livers. Rough ER fractions consisted of many short strips of curved or 
parallel non-vesiculated membrane fragments. Electron dense ribosomes are on the 
outside surface. (× 40.000) 
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non-vesiculated membrane fragments. The electron dense ribosomes were on the outside 
surface of the ER. For some rough ER fragments, inside the sac (cisterna) was flocculent 
material-the newly synthesized proteins. 
Analyses of biochemical markers 
Table 4.1 presents the data for biochemical markers measured in homogenate and 
rough ER fraction from hamster livers. The rough ER fraction was enriched 3.7-fold in 
glucose-6-phosphatase, 3-fold in RNA and 3.8-fold in DGAT as compared with 
activities in the homogenate. However, mitochondria marker succinate INT reductase 
and smooth ER marker HMG-CoA reductase activities were barely detectable in rough 
ER fraction compared with homogenate, and the activities of plasma membrane marker 
5' nucleotidase (10-fold), lysozme marker acid phosphatase (5-fold) and Golgi complex 
maker GM130 (13-fold) were lower than their activities in homogenate. 
Effects of diet on hepatic secretion of VLDL  
The plasma VLDL mass from hamsters fed chow, fructose-enriched and starch-
enriched diets was increased about 2-fold in all dietary groups 60 min following the 
administration of Triton WR-1339 (Figure 4.2). The mean increase was greater for 
VLDL mass from the starch-fed (2.6-fold) compared with the chow- (2.1-fold) or 
fructose-fed (2.2-fold) animals, however, the differences were not significant. After 
Triton injection, the plasma concentration of all VLDL components increased in all 
animals (Figure 4.3). However, the increase was greater for VLDL-triacylglycerol 
(VLDL-TG), VLDL-cholesteryl ester (VLDL-CE), VLDL-phospholipid (VLDL-PL) 
and VLDL-protein (VLDL-PRO) (2-fold) compared with VLDL-free cholesterol  
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TABLE 4.1 
Biochemical marker analyses of subcellular fractions from hamster liver1 
Markers3   Homogenate2 Rough ER2 Fold Change 
G-6-Pase (ug/mg protein) 0.85 ± 0.17 3.10 ± 0.32 3.6↑ 
RNA (ug/mg protein)  32.32 ± 7.61 95.63 ± 19.20 3.0↑ 
DGAT (pmoL/mg/min)  82 ± 15 22 ± 7 3.7↑ 
HMG-CoA red 
(nmoL/mg/min) 
25.30 ± 0.32 0.17 ± 0.01 149↓ 
succ INT red (pmoL/mg/min) 401 ± 8 10 ± 3 40↓ 
5’ nuc (ug Pi/mg protein/min) 0.78 ± 0.23 0.06 ± 0.01 13↓ 
acid phosph (nmoL/mg/min) 0.05 ± 0.002 0.01 ± 0.004 5↓ 
GM130 (ug/mg protein)  6.73 ± 0.35 0.50± 0.24 13↓ 
1 Values are expressed as means ± SEM, n = 10.  
2 Homogenate, whole hamster liver homogenate; Rough ER, rough ER membrane from hamster 
liver. 
3 G-6-Pase, Glucose-6-phosphatase; DGAT, acyl coenzyme A: diacylglycerol acyltransferase; 
HMG-CoA red, HMG-CoA reductase; succ INT red, succinate-INT dehydrogenase; 5’ nuc, 5’ 
nucleotidase; acid phosph, acid phosphatase. The data are expressed as fold change over whole 
hamster liver homogenate. 
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Figure 4.2   Plasma VLDL mass from hamsters fed chow, fructose-enriched 
and starch-enriched diets 60 min after the administration of Triton WR-1339. 
Values are expressed as means ± SEM, n = 10 per treatment group. Values that do 
not share a letter differ (P < 0.05). 
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Figure 4.3   Concentration of components of plasma VLDL from hamsters fed chow, 
fructose-enriched and starch-enriched diets after intracardial injection of Triton. Values 
are expressed as means ± SEM, n = 10 per treatment group. Abbreviations: TG, 
triacylglycerol; Fch, free cholesterol; CE, cholesterol ester; PL, phospholipid; PRO, 
apolipoprotein. Values that do not share a letter differ (P < 0.05). 
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(VLDL-Fch) (1-fold) for the chow- and fructose-fed hamsters. Calculation of hepatic 
VLDL secretion rate based on an individual VLDL fraction showed higher hepatic 
secretion rates for fructose-fed compared with chow- and starch-fed animals (Figure 
4.4). The difference in hepatic secretion rate between fructose fed and hamsters fed 
either chow or starch diet was statistically significant for VLDL-TG, VLDL-CE, VLDL-
PL and VLDL-PRO.  
Composition and concentration of nascent VLDL and apoB-containing lipoprotein 
assembly intermediate particles 
The contents of the rough ER were fractioned by ultracentrifugation into two 
fractions, those separating at d < 1.006 g/mL and those separating at 1.006 < d < 1.053 
g/mL. The chemical composition of these two fractions and VLDL isolated from plasma 
before and after Triton injection is shown in Table 4.2 for chow-fed hamsters, Table 4.3 
for fructose-fed hamsters and Table 4.4 for starch-fed hamsters. For animals in all 
dietary groups, the fraction isolated at d < 1.006 g/mL (second-step particle) was TG-
rich; compared with VLDL isolated from plasma before or after Triton injection. This 
fraction from animals in all dietary groups had an increased percentage of TG, and a 
decreased percentage of Fch and PRO compared with VLDL isolated from plasma 
before and after Triton injection. However, these second-step particles had an increased 
percentage of CE in chow- and starch-fed animals, but not in fructose-fed animals. The 
particles from fructose-fed hamsters were richer in TG than that from either chow- or 
starch-fed animals (P < 0.05). Fructose and starch feeding caused a higher Fch and a 
lower PRO in this VLDL fraction compared with chow feeding. These differences were  
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TABLE 4.2 
Composition of VLDL and lipoprotein assembly particles isolated from 
hamsters fed chow diet1 
  d < 1.006 g/mL3   1.006 < d < 1.053 g/mL3 
 Plasma Plasma after 
triton injection 
Rough ER  Rough ER 
   %   
TG2 70.5 ± 1.4 65.0 ± 1.3 72.2 ± 2.7  35.7 ± 3.7 
CE 6.5 ± 0.5 6.8 ± 0.6 8.0 ± 0.3  3.4 ± 0.2 
Fch 3.6 ± 0.6 2.4 ± 0.3 1.1 ± 0.3  3.8 ± 0.3 
PL 14.3 ± 1.2 14.8 ± 0.3 14.1 ± 1.4  29.4 ± 3.7 
PRO 7.9 ± 0.8 10.9 ± 1.9 4.6 ± 0.1  27.7 ± 2.6 
1 Values are means ± SEM, n = 15 per treatment group. 
2 See Figure 4.3 for abbreviations. 
3 Rough ER d < 1.006 d/mL particle NEFA 0.024 mmol/L; 1.006 < d <1.053 g/mL 
particle NEFA 0.0086 mmol/L 
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TABLE 4.3 
Composition of VLDL and lipoprotein assembly particles isolated from hamsters fed 
fructose-enriched diet1 
  d < 1.006 g/mL   1.006 < d < 1.053 g/mL 
 Plasma Plasma after 
triton injection 
Rough ER  Rough ER 
   %   
TG2 70.5 ± 1.6 68.6 ± 0.9 73.4 ± 3.6  29.6 ± 2.1 
CE 6.8 ± 0.7 8.1 ± 0.7 3.5 ± 0.3  10.3 ± 0.3 
Fch 4.8 ± 0.5 2.3 ± 0.3 5.4 ± 0.1  8.7 ± 0.3 
PL 11.8 ± 0.6 14.1 ± 0.3 13.9 ± 2.9  29.6 ± 0.9 
PRO 5.9 ± 0.6 6.9 ± 0.8 4.0 ± 0.1  22.3 ± 2.6 
1 Values are means ± SEM, n = 15 per treatment group. 
2 See Figure 4.3 for abbreviations 
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TABLE 4.4 
Composition of VLDL and lipoprotein assembly particles isolated from hamsters fed 
starch-enriched diet1 
  d < 1.006 g/mL   1.006 < d < 1.053 g/mL 
 Plasma Plasma after 
triton injection 
Rough ER  Rough ER 
   %   
TG2 65.4 ± 6.0 64.1 ± 1.3 69.7 ± 0.9  24.9 ± 0.8 
CE 9.3 ± 0.7 8.6 ± 0.4 8.5 ± 0.5  10.5 ± 0.4 
Fch 4.8 ± 0.5 3.7 ± 0.4 3.6 ± 0.5  5.4 ± 0.5 
PL 11.3 ± 4.0 14.8 ± 0.4 13.9 ± 2.1  33.95 ± 0.8 
PRO 9.2 ± 1.5 8.8 ± 0.7 4.3 ± 0.1  25.21 ± 3.7 
1 Values are means ± SEM, n = 15. 
2 See Figure 4.3 for abbreviations. 
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Figure 4.4   Secretion rates of VLDL components in hamsters fed chow, fructose-
enriched and starch-enriched diets. Values are means ± SEM, n = 10 per treatment 
group. See Figure 4.3 for abbreviations. Values that do not share a letter differ (P < 
0.05). 
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significant in fructose feeding, but not in starch feeding. Comparing the mass of 
lipoprotein assembly intermediate particles in the three groups, the increase was 
significantly greater (80%) in the fructose-fed than that in chow- or starch-fed animals. 
The fraction isolated at 1.006 < d < 1.053 g/mL (first-step particle) of lipoproteins 
had little core material-TG and CE-but was rich in Fch, PL and PRO compared with the 
core material in the second-step particle. These first-step particles from fructose-and 
starch-fed hamsters were richer in CE (P < 0.01) and Fch (P < 0.05), but poorer in PRO 
(P < 0.05) compared with those from chow-fed hamsters. These particles from starch-fed 
group were richer in PL, but poorer in TG (P < 0.05) compared with the first-step 
particles in the other two groups. However, comparing the lipoprotein mass of particles 
in the three groups, the increase was significantly greater for all core material 
components in the fructose-fed than for the chow- or starch-fed animals (Figure 4.5). 
The increase in mass of first-step particles from rough ER was consistent with that in 
plasma before and after Triton injection (Figure 4.3, Figure 4.5) By 3-10% SDS-PAGE, 
the second-step particles from the rough ER contained apoE but not apoB100, These 
first-step particles contained apoB100 and apoE. Some protein bands were consistently 
observed, but these proteins were not identified (Figure 4.6). The Western blot analysis 
of apoB in the fractions released from liver rough ER are shown in Figure 4.7. An 
apoB100 band was found in blots of the first-step particle, but not the second-step 
particle. The quantification of apoB from the first-step particle recovered from rough ER 
and plasma VLDL before and after Triton injection is shown in Figure 4.8 and Figure 
4.9, respectively. The apoB concentration of the first-step particles from fructose-fed  
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Figure 4.5   Comparison of the concentration of components of particles from 
liver rough ER from hamsters fed chow, fructose-enriched and starch-enriched diets. 
Values are means ± SEM, n = 6 per treatment group. Abbreviations were given in 
Figure 4.3. Values that do not share a letter differ (P < 0.05). 
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1 2 3 4 5 6 7 8 9
Figure 4.7   In-gel Western blot identification of apoB in lipoprotein 
assembly intermediate particles from hamster liver rough ER. Lane: 1, first-step 
particle (1 µg), chow-fed hamsters; 2, first-step particle (1.3 µg), fructose-fed 
hamsters; 3, first-step particle (1.3 µg), starch-fed hamsters; 4, apoB100 standard 
(1 µg); 5, second-step particle (2 µg), chow-fed hamsters; 6, second-step particle 
(2 µg), fructose-fed hamsters; 7, second-step particle (2 µg), starch-fed hamsters; 
8, plasma VLDL (1 µg), chow-fed hamsters; 9, apoB100 standard (0.3 µg). 
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Figure 4.8   Comparison of the concentration of apoB in first-step particles 
isolated from hamsters fed chow, fructose-enriched and starch-enriched diets. 
Values are means ± SEM, n = 6 per treatment group. Values that do not share a 
letter differ (P < 0.05). 
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Figure 4.9   Quantification of apoB from plasma VLDL isolated from hamsters 
before and 60 min after Triton injection. Values are means ± SEM, n = 15 per 
treatment group. Comparisons are made among chow, fructose-enriched and starch-
enriched diets. Values that do not share a letter differ (P < 0.05). 
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hamsters was significantly greater than their concentration in particles from the other 
groups. The increase in VLDL-apoB for fructose-fed (2.4-fold) was greater compared 
with chow- (2.1-fold) or starch-fed (1.9-fold) animals. 
Particle size distribution of nascent VLDL and apoB-containing lipoprotein 
assembly intermediate particles 
After Triton injection, the diameter of nascent VLDL isolated from plasma was 
significantly smaller in all hamsters compared with the size of VLDL from plasma 
before Triton injection (Figure 4.10). Fructose-fed hamsters had average diameters of 49 
nm, slightly larger than the diameters of chow- (47 nm) or starch-fed (48 nm) hamsters, 
however, there was no significant difference among the three groups. The second-step 
particles from chow-fed hamsters averaged 53 nm in diameter, with particle sizes 
ranging from 38 to 238 nm (Figure 4.10). Fructose feeding was associated with a larger 
second-step particle (63 nm) compared with chow or starch (51 nm) feeding (Figure 
4.11). There was no significant difference in second-step particle diameters between 
chow and starch feeding. For chow- and starch-fed hamsters, the diameter of second-step 
particles was larger than that of nascent VLDL, but smaller than that of circulating 
VLDL (Figure 4.10). However, the size of second-step particles from fructose-fed 
animals was not larger than that of nascent VLDL. Consistent with their density and 
composition, the first-step particles from chow-fed hamsters were smaller than second-
step particles. Their diameters ranged from 11 to 22 nm, and averaged 13.4 nm, while 
the diameters of these particles from the fructose-fed group were significantly larger (16 
nm) than those of either chow- or starch-fed (12.6 nm) group (Figure 4.11). 
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Figure 4.10   Dynamic light scattering-determined diameter distribution of 
VLDL, d < 1.006 g/mL, isolated from hamsters before and 60 min after Triton 
injection, and particles d < 1.006 g/mL and 1.006 < d > 1.053 isolated from rough 
ER. 2nd, second-step particles; 1st, first –step particles; a, VLDL after Triton 
injection; b, VLDL before injection. C, F and S: hamsters fed from chow, fructose-
enriched and starch-enriched diets. 
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Figure 4.11   Dynamic light scattering-determined diameter distribution of 
particles d < 1.006 g/mL (second-step particle) and 1.006 < d > 1.053 g/mL (first-step 
particle) isolated from hamster liver rough ER. 2nd, second-step particles; 1st, first –
step particles. C, F and S: hamsters fed chow, fructose-enriched and starch-enriched 
diets. 
 158
Discussion 
The purpose of the present study was to investigate nutrient effects on the assembly 
and secretion of apoB-containing lipoproteins in hamster liver by isolating and 
characterizing intermediates in the assembly pathway and nascent VLDL after Triton 
WR-1339 injection. The results from chapter III showed that fructose feeding could 
induce insulin resistance, elevated plasma TG concentration, apoB overproduction and 
small dense LDL in hamsters. Elevated plasma TG concentration, apoB overproduction 
and small dense LDL are collectively termed atherogenic lipoprotein profile (ALP). Do 
assembly particle physical properties change with diet? Are manifestations of ALP 
solely the result of metabolic differences post secretion or are nascent particles different? 
Extensive research relative to apoB-LP assembly and secretion in vitro has been carried 
out in primary rat hepatocytes (Boren et al., 1992; Boren et al., 1994; Hamilton et al., 
1998; Rusinol et al., 1993). However, few studies have been performed in vivo because 
of technical difficulties. Liver rough ER is the major organelle for lipoprotein synthesis 
and assembly. Recently, Hamilton et al. (1999) introduced a novel technique for 
isolating rough ER membrane from liver. The rapid and non-ultracentrifugal method can 
recover large amounts of highly pure hepatocyte rough ER, which is a valuable method 
that can be used to study in vivo the assembly of apoB-LP, as well as secretion and 
membrane protein translation, translocation and folding. The hamster is a good model 
for the study of lipoprotein metabolism because its lipoprotein metabolism appears to 
resemble that of humans. Hamster liver secretes VLDL containing only apoB100 with a 
density close to that of human apoB100 (Arbeeny et al., 1992). As in humans, hamster 
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LDL receptor plays a key role in LDL metabolism (Spady and Dietschy, 1985). The 
hamster develops insulin resistance in association with a marked hyper-
triacyglycerolmia when fed a fructose-enriched diet (Kasim-Karakas et al., 1996). 
However, unlike the human, the hamster is a HDL-cholesterol-rich animal. Hamster 
lipoproteins are primarily distinguished by their lipoprotein core lipid content compared 
with their human counterparts. Both hamster plasma VLDL and LDL are CE-deficient 
and TG-rich, whereas HDL are CE-rich and TG-poor (Goulinet and Chapman, 1993). 
Recently, Taghibiglou et al. (2000a) introduced a fructose-fed hamster model to 
investigate the mechanisms mediating the overproduction of VLDL in the 
insulin-resistant state. These investigators demonstrated that hepatic VLDL-apoB 
overproduction in fructose-fed hamsters resulted from intracellular stability of nascent 
apoB and enhanced expression of MTP. However, whether core lipid availability 
determines the efficiency of the VLDL assembly process is currently unknown. In the 
present study, employing the fructose-fed hamster model and the calcium precipitation 
method of recovering rough ER membrane, the author investigated dietary effects on the 
physical properties of apoB-LP particles during the assembly and secretion pathway. 
The author also suggested the value of establishing the effect of high fructose on the 
assembly and secretion of apoB-LP in the fructose-fed hamster model so as to 
systemically characterize hepatic apoB-LP.  
Two lipoprotein fractions were isolated from the contents of rough ER by 
ultracentrifugation. The second-step particles (d < 1.006 g/mL) were TG-rich, PRO-
poor, they were slightly larger than nascent VLDL recovered 1 h post Triton WR-1339 
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injection, but smaller than plasma VLDL. They contained proportionately less protein 
and no apoB, indicating that these particles were lipid-rich, apoB-deficient apoB-LP 
precursors. Fructose-fed hamsters had 80% more particle mass compared with those fed 
a chow diet or a starch diet. The results in this study revealed particles with a greater 
mass of large lipid-rich, apoB-deficient apoB-LP precursors synthesized by liver when 
fed a fructose-containing diet.  
The first-step particles recovered between the densities 1.006 and 1.053 g/mL were 
rich in PL and protein, and contained apoB, but a lower percentage of TG and CE than 
that of second-step particles. These particles were small, consistent with their chemical 
composition, indicating that they were apoB-containing lipid-poor lipoprotein 
precursors. Like second-step particles, the lipoprotein mass of first-step particles from 
fructose-fed hamsters was much greater than that of particles from hamsters fed a chow 
diet or starch diet, however, the particles from fructose-fed animals contained 
proportionately less protein. These results indicate that liver produced larger, lipid-rich, 
first-step apoB-LP precursors under the fructose feeding condition. The composition and 
size of second-step particles and first-step particles were different among the three 
groups, which suggested that diet did affect the formation of liver lipoprotein precursors 
and assembly of apoB-LP. 
It has been suggested that in the first step, apoB might be associated with lipid as it is 
translated and translocated across the membrane of the rough ER (Boren et al., 1992). 
The primary lipid involved in the apoB-containing particles is PL, TG and cholesterol. 
Newly synthesized apoB may have two fates: assembly and secretion, or degradation 
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depending on the lipid availability (Davis, 1999). Fructose feeding increased the 
concentrations of TG, PL and cholesterol, which provided more available lipid to apoB 
to assemble and decreased the chance of apoB degradation. Thus, hamsters fed fructose 
have more apoB-containing apoB-LP precursors. In the second step, at the smooth 
surface ends of the rough ER, the apoB-containing particle and TG-rich apoB-deficient 
particle could join and convert to nascent VLDL, Golgi VLDL and eventually to plasma 
VLDL (Hamilton et al., 1998). More apoB-containing apoB-LP precursors fuse with 
TG-rich apoB-deficient particles, leading to more mature apoB-LP formation in 
fructose-fed animals.  
In order to further investigate the changes in physical properties of VLDL particles 
that occur during the secretion pathway, hamsters were injected via cardiac puncture 
with Triton WR-1339 to block not only the removal of VLDL from plasma but also the 
intravascular conversions that occur as a result of lipase-mediated events (Steiner et al., 
1984). This indirect method has been used successfully to study the rate of secretion of 
VLDL from liver (Holt and Dominguez, 1980; Taghibiglou et al., 2000a). Comparing 
the chemical composition and size among nascent VLDL, second-step particles and first-
step particles from animals in all dietary groups, the chemical composition of nascent 
VLDL was between that of second-step particles and that of first-step particles, and the 
size of nascent VLDL was slightly smaller than that of second-step particles, but 
significantly larger than that of first-step particles. The present study, for the first time, 
reported the plasma VLDL particle diameter after Triton injection. Feeding a fructose 
diet resulted in a higher percentage of TG in nascent VLDL compared with feeding a 
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starch or chow diet. These results suggest that a lipid-rich, second-step particle might be 
added to an apoB-containing first-step particle to form a VLDL particle. Different 
assembly precursors led to production of different nascent VLDL. The interaction of 
lipid and protein during the assembly of the two particles assembly may result in the 
changes in composition and size. Such an interaction could explain why there was no 
significant difference in the size of nascent VLDL isolated from animals in the three 
dietary groups.  
The study on VLDL secretion rate based on individual VLDL components clearly 
indicates that hepatic secretion of VLDL-TG, VLDL-CE and VLDL-PL were 
significantly elevated in fructose-fed hamsters as compared with chow- or starch-fed 
hamsters. Fructose feeding caused greater secretion rates of VLDL-Fch and VLDL-PRO 
compared with chow feeding, however, the differences were not statistically significant. 
This indicates that fructose feeding induces the increase in secretion rate for all VLDL 
components, but that the increase in secretion rate for individual components differs. 
Fructose feeding induces insulin resistance in hamster (see Chapter III). Hepatic 
overproduction of VLDL in the metabolic state may result from direct hepatic effects of 
insulin and the effects of the increased availability of free fatty acids for certain lipid 
synthesis (Lewis et al., 1995). The increased concentration of plasma free fatty acids in 
fructose-fed animals suggests that the increased flux of free fatty acids into the liver may 
contribute to overproduction of VLDL-TG, VLDL-CE and VLDL-PL (see Chapter III). 
Regulation of apoB-LP assembly and secretion mainly depends on the availability of 
lipid (Dixon and Ginsberg, 1993). Overproduction of hepatic lipid may result in reduced 
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the degradation of apoB (Zhou et al., 1995) and an increased expression of MTP 
(Taghibiglou et al., 2000a), which can in turn facilitate the assembly and secretion of 
apoB-LP. 
Interestingly, in hamster, the size of nascent VLDL was smaller than that of 
circulating VLDL although the concentration of VLDL-TG in nascent VLDL was 2-fold 
greater than that in circulating VLDL, which also occurs in hens from immature to 
laying (Griffin et al., 1982). However, this did not occur in overfed laying hens (Walzem 
et al., 1994). In hamsters, the concentrations of both VLDL-TG and VLDL-PL in 
nascent VLDL were significantly higher than that in circulating VLDL, and the 
increased rate of VLDL-PL was greater than that of VLDL-TG. Overfeeding of laying 
hens led to accumulation of TG (concentration and composition) but not PL (Walzem et 
al., 1994), thus overfeeding can increase hen VLDL particle size. VLDL metabolism 
appears to respond differently in the metabolic state of overproduction of TG and may 
be due to species differences. The species difference may also explain why hens do not 
have insulin resistance in spite of having a high concentration of TG.  
The present study provides the first characterization of nascent apoB-LP and apoB-
LP precursors from rough ER in hamster. The data indicate that apoB-containing apoB-
LP precursor and lipid-rich apoB-deficient apoB-LP precursor are synthesized 
independently by liver. At the smooth surface ends of the rough ER, these two 
precursors join and convert to nascent apoB-LP. The nascent apoB-LP modified by 
further addition of lipid during the secretion process, but the source of lipid and the 
mechanism by which the lipid is added to the particles are not clear. This study also 
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showed that diets affected apoB-LP precursor formation and assembly, and apoB-LP 
secretion. Further work is necessary to delineate the steps in apoB-LP secretion and to 
define the interaction of nascent apoB-LP and lipid in the secretion process. 
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CHAPTER V 
SUMMARY AND CONCLUSIONS 
Summary of Research Findings 
Understanding of the pathobiological mechanisms of atherosclerotic cardiovascular 
disease is necessary to effectively prevent and treat ASCVD. Elevated concentrations of 
circulating apoB-LP are strongly associated with the risk of ASCVD. In this dissertation 
research, the author investigated three aspects in pathobiological mechanisms of 
ASCVD related to apoB-LP: 1). the role of several genetic components that impinge on 
ASCVD through use of a statistical model; 2). the role of certain dietary components as 
metabolic modifiers of the concentrations and physical properties (i.e., mass, particle 
diameter and composition) of circulating apoB-LP in hamsters; and 3). the role of apoB-
LP assembly and secretion in nutritionally induced changes to the physical properties of 
circulating apoB-LP. 
Selective delays in apolipoprotein B-containing lipoprotein clearance affect 
circulating particle diameter distribution and plaque formation 
In humans, lipoprotein profiles differ with regards to concentrations of individual 
particle type that vary in pro-atherogenicity. Such variation is the result of differences in 
genotype and environment. Lipoprotein phenotypes produce a number of different pro-
athergenicities and antiatherogenicity due to genetic drivers. Numerous investigators 
have studied the relationship among apoB-LP physical properties and atherogenesis in 
transgenic and knockout mouse models. In these models, tests have been designated to 
isolate single factors whereas observed variables have numerous factors for which risk 
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must be assayed. The uniqueness of the approach is the availability and use of numerous 
transgenic models simultaneously to verify the mechanistic drivers of phenotypes 
observed in free populations. Little is known whether complex mixtures of apoB-LP 
types found in humans occur systemically in these same mouse models. Results of the 
studies described in Chapter II demonstrate for the first time the associations of apoB 
concentration, genotype, apoB-LP particle diameter, and plasma cholesterol 
concentration with arterial plaque formation in transgenic mice. The major findings are 
summarized as follows: 
1. Plasma total apoB concentration explained 30.8% of arterial lesions when 
adjusted for delayed particle clearance, while only 15.3% of arterial lesions 
without the adjustment. Moreover, in each model that included apoB, failure to 
adjust for delay in particle clearance reduced the ability of themodel to account 
for plaque formation. These results indicate that delayed clearance is a significant 
driver in the formation of atherogenic lipoprotein species. 
2. In the mouse population, apoB-LP particle diameter became smaller when 
particle clearance was delayed. Correlation analysis identified diameter-specific 
apoB-LP subpopulations that were significantly related to plaque formation in 
either a positive or negative fashion.. This is the first time a subpopulation of 
apoB-LP particles has been identified that negatively associated with plaque 
formation.. 
3. Genotype alone can explain 87% of the arterial lesions that developed. Adding 
plasma cholesterol concentration, apoB concentration, and particle diameter did 
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not significantly change the explanation for arterial lesions. Plasma total 
cholesterol alone explained 18% of arterial plaque formation, while genotype 
explained 74% of the variation in total plasma cholesterol that had little 
relationship to apoB-LP diameter. These results clearly indicate that genotype 
probably dictated the metabolic conditions under which apoB-LP accumulation 
occurs critically influences arterial lesion formation in this transgenic model.  
Effects of high-carbohydrate diets on physical properties of plasma lipoproteins 
in hamsters  
High-carbohydrate diets can affect lipoprotein metabolism, and induce an 
atherogenic lipoprotein profile (ALP) and insulin resistance that are associated with 
atherosclerosis in humans and animals. The hamster fed a fructose-enriched diet is a 
widely used model in studies of ALP, insulin resistance. However, little is known 
about the changes in physical properties of lipoprotein that occur under these 
metabolic conditions in hamster. Results of the studies described in Chapter III show 
for the first time features of the physical properties of plasma lipoprotein in hamsters 
fed high-carbohydrate diets. The major findings from this study are summarized as 
follows: 
1. Fructose feeding significantly increased hamster VLDL lipoprotein mass and 
decreased the percentage of VLDL-PRO. VLDL particle diameter increased in 
the 20-60th population percentiles in hamsters fed a fructose-enriched diet. This 
is the first report of large, TG-rich plasma VLDL in hamsters fed this type of 
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diet. The large, TG-rich plasma VLDL may be the result of limited lipolysis prior 
to the conversion from VLDL to LDL and/or altered assembly of VLDL. 
2. Fructose feeding significantly increased plasma LDL lipoprotein mass and the 
concentrations of LDL-Fch and LDL-PL. The fructose-fed group of hamsters had 
a significant increase in LDL-TG at the expense of a reduction in LDL-CE, while 
the starch-fed group had a significant increase in LDL-CE. LDL particle 
diameter was smaller in fructose-fed hamsters than in starch-fed hamsters. These 
results demonstrate for the first time that fructose feeding induces small, TG-rich 
LDL, while starch feeding produces large, CE-rich LDL in hamsters. 
3. ApoB-containing lipoproteins exhibit similar physical properties in fructose-fed 
hamsters and in humans with an atherogenic lipoprotein phenotype. 
4. Increased plasma HDL lipoprotein mass and HDL-cholesterol during fructose 
and starch feeding indicate that hamsters have a different response to simple 
carbohydrates than that of other animal species. It may be possible to develop an 
intervention to increase HDL in insulin resistant humans with ALP. 
Dietary effects on the assembly and secretion of apoB-containing lipoproteins in 
hamsters  
The profiles of circulating lipoproteins result from the interactions of several factors, 
including the physical properties of nascent lipoproteins. Dietary effects on the physical 
properties of circulating lipoproteins were presented in Chapter III. Chapter IV presented 
a study of whether the changes in the physical properties of circulating lipoproteins arise 
from changes in the physical properties of nascent lipoprotein assembly intermediates 
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during apoB-LP assembly and/or during their secretion. This study was pursued via 
isolating lipoprotein assembly intermediate particles from rough ER and measurement of 
plasma VLDL secretion rates and particle physical properties after Triton injection. The 
major findings from this study are summarized as follows: 
1. Two types of lipoprotein assembly intermediate particles were isolated from 
rough ER. One set of particles was TG-rich, apoB-deficient and VLDL-sized, 
putative second-step, The other type of particle was small, lipid-poor, and apoB-
containing, putative first-step. The composition of nascent VLDL was between 
that of second-step particle and that of first-step particle. These results suggest 
that two sets of particles are independently synthesized in liver then and 
assemble to produce a nascent VLDL particle. The odds further support the "two-
step" theory of apoB-LP assembly. 
2. This is first report that the diameter of first-step particles in fructose-fed hamsters 
is larger than that of either chow-fed or starch-fed animals. Increased diameter in 
first-step particles suggests there is decreased chance for apoB degradation, 
which is physical basis for apoB oversecretion. 
3.  The concentrations of the lipoprotein mass and individual components of both 
second-step particles and first-step particles recovered from liver were higher in 
fructose-fed than in either chow-fed or starch-fed hamsters. The composition and 
size of the two particle types were different among the three dietary groups. 
Changes observed in lipoprotein assembly intermediate particles are consistent 
with those in plasma VLDL. These data demonstrate for the first time that diets 
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do affect the formation of lipoprotein assembly precursors and that changes in 
the physical properties of circulating lipoproteins can stem from the changes in 
the physical properties of lipoprotein assembly precursors. 
4.  VLDL from post-Triton plasma differed in both circulating VLDL composition 
(low TG and high PRO) and diameter. The fructose-fed group of hamsters had a 
greater secretion rate of VLDL components in comparison with the other groups. 
These findings suggest that lipid is added to the nascent VLDL and the nascent 
VLDL is further modified during the secretory pathway. For the first time, 
fructose feeding of hamsters was shown to increase the secretion rates not only of 
VLDL-TG, and VLDL-apoB but also of VLDL-CE, VLDL-Fch, and VLDL-PL. 
Conclusions 
The metabolism and physical properties of apoB-containing lipoproteins play an 
important role in the atherogenicity of apoB-LP. The results of this research show that 
both genetic factors and dietary factors can affect the metabolism and physical properties 
of apoB-LP. Genetic factors are a major determinant of metabolism in such a complex 
transgenic model. Metabolic conditions under which apoB-LP accumulate critically 
influence the physical properties of apoB-LP and further enhance arterial lesion 
formation. Diet is the other important factor that determines the metabolism and physical 
properties of lipoproteins. Diet can change the physical properties of apoB-LP during the 
processes of assembly and secretion, and subsequently alter the physical properties and 
further metabolism of circulating apoB-LP. The completion of the dissertation research 
may have important implications for explaining the mechanism of atherosclerosis and 
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identifying the targets of intervention against which food and food ingredients could 
regulate lipid and lipoprotein metabolism to improve health. 
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APPENDIX 
 
Model Variables in Model Adjusted  
R-Square 
Unadjusted  
R-Square 
1 HDL cholesterol (HDLc) 0.392 0.392 
1 apoB 0.308 0.153 
1 Cholesterol (Chol) 0.180 0.180 
1 Moderate Diameter Particle (PV2) 0.038 0.038 
1 Body wight (BW) 0.038 0.038 
1 Small Diameter Particles (PV1) -0.008 -0.008 
1 Triacylglycerols (TG) -0.014 -0.014 
2 apoB + HDLc 0.522 0.473 
2 PV2 + Chol 0.458 0.458 
2 Chol + HDLc 0.437 0.437 
2 PV2 + HDLc 0.433 0.433 
2 BW + HDLc 0.412 0.412 
2 PV1 + HDLc 0.408 0.408 
2 TG + HDLc 0.389 0.389 
2 apoB + PV2 0.349 0.189 
2 apoB + BW 0.309 0.166 
2 apoB + Chol 0.308 0.212 
2 apoB + TG 0.302 0.145 
2 apoB +PV1 0.297 0.139 
2 PV1 +Chol 0.252 0.252 
2 BW + Chol 0.176 0.176 
2 TG + Chol 0.169 0.169 
2 PV2 + BW 0.113 0.113 
2 PV1 + PV2 0.086 0.086 
2 PV1 + BW 0.040 0.040 
2 PV2 + TG 0.038 0.038 
2 BW + TG 0.022 0.022 
2 PV1 + TG -0.015 -0.015 
3 PV2+ Chol + HDLc 0.612 0.612 
3 PV1+ PV2+ Chol 0.577 0.577 
3 apoB+ PV2 + HDLc 0.566 0.512 
3 apoB+ PV1 + HDLc 0.525 0.475 
3 apoB+ BW + HDLc 0.525 0.481 
3 apoB+ TG + HDLc 0.523 0.474 
3 apoB+ Chol + HDLc 0.515 0.473 
3 PV1+ Chol + HDLc 0.502 0.502 
3 apoB+ PV1 + PV2 0.490 0.335 
3 PV2+ BW + HDLc 0.482 0.482 
3 PV2+ Chol + Chol 0.474 0.474 
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(Continued)    
Model Variables in Model Adjusted  
R-Square 
Unadjusted  
R-Square 
3 apoB+ PV2 + Chol 0.464 0.448 
3 PV2+ TG + Chol 0.454 0.454 
3 PV2+ TG + HDLc 0.450 0.450 
3 PV1+ BW + HDLc 0.441 0.441 
3 BW + Chol + HDLc 0.439 0.439 
3 PV1+ PV2+ HDLc 0.432 0.432 
3 PV1+ TG + HDLc 0.423 0.423 
3 TG + Chol + HDLc 0.423 0.423 
3 BW+ TG + HDLc 0.404 0.404 
3 apoB+ PV2 + BW 0.369 0.229 
3 apoB+ PV2 + TG 0.361 0.198 
3 apoB+ PV1 + Chol 0.311 0.246 
3 apoB+ BW + Chol 0.304 0.208 
3 apoB+ PV1 + BW 0.300 0.156 
3 apoB+ BW + TG 0.299 0.153 
3 apoB+ PV1 + TG 0.295 0.134 
3 PV1+ BW + Chol 0.253 0.253 
3 PV1+ TG + Chol 0.243 0.243 
3 PV1 + PV2 + BW 0.177 0.177 
3 BW+ TG + Chol 0.168 0.168 
3 PV2 + BW + TG 0.103 0.103 
3 PV1 + PV2 + TG 0.072 0.072 
3 PV1+ BW + TG 0.026 0.026 
4 PV1 + PV2 + Chol + HDLc 0.659 0.659 
4 PV2 + BW+ Chol + HDLc 0.630 0.630 
4 PV2 + TG + Chol + HDLc 0.618 0.618 
4 apoB + PV2 + Chol + HDLc 0.616 0.607 
4 apoB + PV1 +PV2 + HDLc 0.613 0.552 
4 apoB + PV1 +PV2 + Chol 0.605 0.580 
4 PV1 + PV2 + BW + Chol 0.603 0.603 
4 apoB+ PV2 + TG + HDLc 0.588 0.535 
4 apoB+ PV2 + BW + HDLc 0.586 0.542 
4 PV1 + PV2 + TG + Chol 0.574 0.574 
4 apoB+ PV1 + TG + HDLc 0.542 0.493 
4 apoB+ PV1 + BW + HDLc 0.534 0.491 
4 apoB+ PV1 + Chol + HDLc 0.528 0.503 
4 apoB+ BW + TG + HDLc 0.521 0.476 
4 apoB+ PV1 +PV2 + BW 0.517 0.384 
4 apoB + BW + Chol + HDLc 0.516 0.476 
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(Continued)    
Model Variables in Model Adjusted  
R-Square 
Unadjusted  
R-Square 
4 apoB + TG + Chol + HDLc 0.515 0.469 
4 PV1 + TG + Chol + HDLc 0.513 0.513 
4 PV1 + PV2 +BW + HDLc 0.487 0.487 
4 PV2 + BW + TG +HDLc 0.486 0.486 
4 apoB + PV1 + PV2 + TG 0.481 0.324 
4 apoB + PV2 + BW + Chol 0.477 0.465 
4 PV2 + BW + TG + Chol 0.467 0.467 
4 apoB + PV2 + TG + Chol 0.464 0.444 
4 PV1 + BW+ TG + HDLc 0.449 0.449 
4 PV1 + PV2 + TG + HDLc 0.441 0.441 
4 BW + TG + Chol + HDLc 0.429 0.429 
4 apoB + PV1 + BW + Chol 0.309 0.247 
4 apoB + PV1 + TG + Chol 0.306 0.238 
4 apoB + PV1 + BW + TG 0.293 0.145 
4 aPoB + BW + TG + Chol 0.293 0.195 
4 PV1 + BW+ TG + Chol 0.242 0.242 
4 PV1 + PV2 +BW + TG 0.165 0.165 
5 PV1 + PV2 +BW + Chol + HDLc 0.683 0.683 
5 apoB + PV1 + PV2 + Chol + HDLc 0.676 0.664 
5 PV1 + PV2 +TG +Chol + HDLc 0.653 0.653 
5 apoB + PV1 + PV2 + BW + HDLc 0.638 0.588 
5 apoB + PV2 + BW + Chol + HDLc 0.632 0.625 
5 PV2 + BW + TG + Chol + HDLc 0.631 0.631 
5 apoB + PV2 + TG + Chol + HDLc 0.626 0.625 
5 apoB + PV1 + PV2 + BW + Chol 0.625 0.604 
5 apoB + PV1 + PV2 + TG + HDLc 0.614 0.554 
5 PV1 + PV2 +BW + TG + Chol 0.608 0.608 
5 apoB + PV1 + PV2 + TG + Chol 0.600 0.577 
5 apoB + PV2 + BW + TG + HDLc 0.598 0.553 
5 apoB + PV1 + BW + TG + HDLc 0.543 0.483 
5 apoB + PV1 + TG + Chol + HDLc 0.541 0.515 
5 apoB + PV1 + BW + Chol + HDLc 0.533 0.511 
5 PV1 + BW+ TG + Chol + HDLc 0.515 0.515 
5 apoB + BW + TG + Chol + HDLc 0.513 0469 
5 apoB + PV1 + PV2 + BW + TG 0.510 0.376 
5 PV1 + PV2 +BW + TG + HDLc 0.483 0.483 
5 apoB + PV2 + BW + TG + Chol 0.472 0.457 
5 apoB + PV1 + BW + TG + Chol 0.301 0.236 
6 apoB + PV1 + PV2 + BW + Chol + HDLc 0.696 0.687 
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(Continued)    
Model Variables in Model Adjusted  
R-Square 
Unadjusted  
R-Square 
6 PV1 + PV2 +BW + TG + Chol + HDLc 0.678 0.678 
6 apoB + PV1 + PV2 + TG + Chol + HDLc 0.671 0.658 
6 apoB + PV1 + PV2 + BW + TG + HDLc 0.633 0.582 
6 apoB + PV1 + PV2 + BW + TG + Chol 0.626 0.608 
6 apoB + PV1 + BW + TG + Chol + HDLc 0.541 0.516 
7 apoB + PV1 + PV2 + BW + TG + Chol + 
HDLc 
0.691 0.682 
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